Sources

This is the source-first view of the evidence map. The linked papers, labels, reviews, and regulatory documents are the durable object; entry notes are incomplete curation context, not clinical guidance.

case report

  1. Acute liver failure associated with anabolic-androgenic steroid use
    pubmed_stanozolol_liver_failure_2014
    Safety signal source involving anabolic steroid misuse; useful for hepatic-risk framing around stanozolol and oral AAS.
    Used by: Stanozolol
  2. Adverse events from clenbuterol misuse
    pubmed_clenbuterol_adverse_events_2013
    Poison-center/case-series style safety source for clenbuterol misuse presentations.
    Used by: Clenbuterol
  3. Clonidine for sleep disturbances associated with attention-deficit hyperactivity disorder: a systematic chart review of 62 cases
    pubmed_clonidine_sleep_adhd_chart_1996
    Retrospective pediatric ADHD sleep-disturbance chart review; useful for off-label sleep signal but not adult insomnia proof.
    Used by: Clonidine
  4. Drug-Induced Liver Injury Associated With Alpha Bolic (RAD-140) and Alpha Elite (RAD-140 and LGD-4033)
    pubmed_rad_lgd_dili_case_2020
    Case report involving RAD-140 and RAD-140/LGD-4033 product exposure; useful for SARM liver-risk context.
    Used by: Ligandrol, RAD140
  5. LGD-4033 and a Case of Drug-Induced Liver Injury: Exploring the Clinical Implications of Off-Label Selective Androgen Receptor Modulator Use in Healthy Adults
    pubmed_ligandrol_dili_case_2024
    Healthy-adult LGD-4033 DILI case report; supports liver-risk caution in off-label SARM use.
    Used by: Ligandrol
  6. LGD-4033 and MK-677 use impacts body composition and circulating biomarkers
    pubmed_lgd_mk677_case_report_2022
    Self-administration case report with body composition, lipid, liver enzyme, and hormone changes.
    Used by: Ibutamoren, Ligandrol
  7. RAD-140 Drug-Induced Liver Injury
    pubmed_rad140_dili_case_2022
    RAD-140 DILI case report; risk anchor for off-label/research-chemical use.
    Used by: RAD140

clinical trial registry

  1. BELIEVE: Safety and Efficacy of Bimagrumab and Semaglutide in Adults Who Are Overweight or Obese
    clinicaltrials_believe_bimagrumab_semaglutide
    ClinicalTrials.gov registry for BELIEVE; confirms 507 enrollment, completed status, IV bimagrumab plus open-label SC semaglutide design, and body-composition rationale.
    Used by: Bimagrumab
  2. COURAGE: Trevogrumab or Trevogrumab With Garetosmab in Addition to Semaglutide in Patients With Obesity
    clinicaltrials_courage_trevogrumab_garetosmab_semaglutide
    ClinicalTrials.gov registry for COURAGE; useful for design, enrollment, active-not-recruiting status, endpoints, and route details: trevogrumab SC in Parts B/C, garetosmab IV in Part B, semaglutide SC.
    Used by: Garetosmab, Trevogrumab
  3. Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly
    clinicaltrials_rtb101_protector1
    ClinicalTrials.gov registry for the PROTECTOR1 phase 3 RTB101 study in adults aged 65 and older.
    Used by: RTB101
  4. EMBRAZE: Efficacy and Safety of Apitegromab for the Treatment of Adults Who Are Overweight or Obese
    clinicaltrials_embraze_apitegromab_tirzepatide
    ClinicalTrials.gov registry for EMBRAZE; completed phase 2 study with IV apitegromab every 4 weeks plus weekly SC tirzepatide.
    Used by: Apitegromab
  5. NCT06633016 - Study of ABX-002 for adjunctive treatment of major depressive disorder
    ctgov_abx002_mdd_2026
    Phase 2 trial record; no posted efficacy results at curation time.
    Used by: Elunetirom
  6. Saskatoon Berry on Metabolism and Gut Microbiota in Prediabetes
    clinicaltrials_saskatoon_berry_nct04809688
    Trial registry context for Saskatoon berry powder, metabolism, and gut-microbiota outcomes.
    Used by: Saskatoon Berry

company

  1. Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
    regeneron_courage_easd_2025
    Sponsor-reported 26-week COURAGE phase 2 obesity results: semaglutide 2.4 mg plus trevogrumab with or without garetosmab shifted weight-loss composition toward fat mass; not a peer-reviewed paper at this curation point.
    Used by: Garetosmab, Semaglutide, Trevogrumab
  2. Scholar Rock Reports Positive Phase 2 EMBRAZE Trial Results Demonstrating Statistically Significant Preservation of Lean Mass with Apitegromab During Tirzepatide-Induced Weight Loss
    businesswire_apitegromab_embraze_2025
    Sponsor-reported 24-week EMBRAZE phase 2 obesity results: apitegromab plus tirzepatide preserved more lean mass and shifted loss composition toward fat; not a peer-reviewed obesity paper at this curation point.
    Used by: Apitegromab, Tirzepatide

company regulatory

  1. Regeneron Announces Positive Phase 3 Trial in Adults with Fibrodysplasia Ossificans Progressiva, Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
    regeneron_garetosmab_optima_phase3_2025
    Sponsor/regulatory context for garetosmab in FOP, including investigational status and planned submissions; useful safety and development context, not a body-composition source.
    Used by: Garetosmab
  2. Scholar Rock Reports First Quarter 2026 Financial Results and Recent Business Highlights
    scholarrock_apitegromab_bla_accepted_2026
    Current regulatory context as of May 2026: FDA accepted the apitegromab BLA for SMA with a September 30, 2026 PDUFA date; this does not mean obesity approval.
    Used by: Apitegromab

database

  1. IUPHAR/BPS Guide to Pharmacology ligand page for elunetirom
    guidetopharmacology_elunetirom
    Identity, synonym, prodrug, active-metabolite, and TR-beta pharmacology reference.
    Used by: Elunetirom
  2. PubChem: Clorgyline
    pubchem_clorgyline
    Chemical identity and literature links.
    Used by: Clorgyline

early human

  1. A phase 1/2a follistatin gene therapy trial for Becker muscular dystrophy
    pubmed_follistatin_bmd_phase12a_2015
    Open-label AAV1-FS344 intramuscular gene-transfer study in Becker muscular dystrophy; useful human disease-context anchor for follistatin gene therapy, not healthy-user hypertrophy evidence.
    Used by: Follistatin / FS344
  2. A Phase I, First-in-Human, Healthy Volunteer Study of CVN424
    pubmed_cvn424_phase1_2022
    First-in-human safety, tolerability, and pharmacokinetics source for oral CVN424.
    Used by: CVN424
  3. A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
    pubmed_rapamycin_older_feasibility_2018
    Small randomized older-adult rapamycin feasibility/safety trial; useful human context but not proof of lifespan extension.
    Used by: Rapamycin / Sirolimus
  4. A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
    springer_apitegromab_phase1_2021
    Randomized placebo-controlled phase 1 study in healthy adults; IV apitegromab showed dose-dependent latent-myostatin target engagement and tolerability up to 30 mg/kg.
    Used by: Apitegromab
  5. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in type 2 diabetes
    pmc_ara290_innate_repair_receptor_2014
    Small human diabetes/neuropathy study plus innate repair receptor rationale.
    Used by: ARA-290 / Cibinetide
  6. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission
    pubmed_pinealon_polymorbidity_2015
    Older regional human source; interpret cautiously due limited accessibility/generalizability.
    Used by: Pinealon
  7. Effectiveness and Safety of rhIGF-1 Therapy in Children: The European Increlex Growth Forum Database Experience
    pubmed_mecasermin_increlex_database_2015
    Large registry-style mecasermin safety/effectiveness source in severe IGF-1 deficiency contexts; useful label-adjacent human anchor.
    Used by: Mecasermin / Recombinant Human IGF-1
  8. Effectiveness of Semax in the acute period of hemispheric ischemic stroke
    pubmed_semax_stroke_1997
    Citation anchor for the 1997 Russian clinical/electrophysiological ischemic-stroke Semax study; not an easily accessible PubMed abstract in this pass.
    Used by: No public entries linked.
  9. Effects of Daily Saskatoon Berry Supplementation on Cardiometabolic Health, Gut Microbiota, and Short-Chain Fatty Acids in Healthy Adults
    mdpi_saskatoon_berry_human_microbiota_2026
    Recent healthy-adult supplementation study linking Saskatoon berry intake to cardiometabolic markers, gut microbiota, and SCFA readouts.
    Used by: Saskatoon Berry
  10. First-in-human phase 1 study of RAD140 in ER+/HER2- metastatic breast cancer
    pubmed_rad140_phase1_breast_cancer_2022
    Oncology phase 1 study of oral RAD140/vosilasarm.
    Used by: RAD140
  11. Follistatin Gene Therapy Improves Ambulation in Becker Muscular Dystrophy
    pubmed_follistatin_bmd_ambulation_2015
    Becker muscular dystrophy follistatin gene-therapy follow-up/clinical interpretation paper; relevant to ambulation and FS344 rationale.
    Used by: Follistatin / FS344
  12. GRK-biased adrenergic agonists for the treatment of type 2 diabetes and obesity
    sciencedirect_atr258_cell_2025
    Cell paper for ATR-258/compound 15 GRK2-biased beta-2 adrenergic mechanism, preclinical metabolic data, and first-in-human context; cardiovascular and tolerability scrutiny remain central because of the beta-2 mechanism.
    Used by: ATR-258
  13. Intravenous infusion of nicotinamide adenine dinucleotide (NAD+) versus nicotinamide riboside (NR): a retrospective tolerability pilot study in a real-world setting
    pubmed_nad_iv_nr_retrospective_2026
    Recent real-world tolerability pilot of commercial IV NAD+ and IV NR; observational and not proof of anti-aging, addiction, or performance benefit.
    Used by: NAD+ / Intravenous NAD
  14. Oral SSTR5 antagonist SCO-240 for growth hormone stimulation: phase I single-dose study
    pubmed_sstr5_sco240_phase1_2024
    Human phase 1 SSTR5 antagonist anchor.
    Used by: No public entries linked.
  15. Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype
    pubmed_danavorexton_2022
    Human and mouse evidence for OX2R agonism.
    Used by: Declozindol
  16. Peptides of pineal gland and thymus prolong human life
    pubmed_thymalin_longevity_2003
    Older regional longevity report; hypothesis-generating, not definitive geroprotection evidence.
    Used by: Thymalin
  17. Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers
    pubmed_ipamorelin_human_pkpd
    Human volunteer PK/PD modeling.
    Used by: Ipamorelin
  18. Phase 1 safety, PK, and pharmacodynamics study of ABX-002 in healthy adult participants
    oxford_abx002_phase1_2025
    Endocrine Society abstract for ABX-002/elunetirom SAD/MAD human phase 1 data.
    Used by: Elunetirom
  19. Pilot trial of clenbuterol in spinal and bulbar muscular atrophy
    pubmed_clenbuterol_sbma_pilot_2013
    Small disease-context human trial; relevant to beta2-muscle rationale but not healthy fat-loss or bodybuilding evidence.
    Used by: Clenbuterol
  20. Preclinical and clinical pharmacology of TPA023B, a GABAA receptor alpha2/alpha3 subtype-selective partial agonist
    pubmed_tpa023b_alpha2_alpha3_2010
    Alpha2/alpha3 GABA-A PAM program source with preclinical and human PET/pharmacology context.
    Used by: No public entries linked.
  21. Prolonged stimulation of GH and IGF-I secretion by CJC-1295
    pubmed_cjc1295_2006
    Healthy adult pharmacokinetic/pharmacodynamic study.
    Used by: CJC-1295
  22. Safety, pharmacokinetics and pharmacological effects of GSK2881078
    pubmed_gsk2881078_phase1_2017
    Phase 1 study in healthy men and postmenopausal women.
    Used by: GSK2881078
  23. Safety, pharmacokinetics, and effects of LGD-4033 in healthy young men
    pubmed_lgd4033_healthy_men_2013
    Placebo-controlled 21-day ascending-dose study in healthy men.
    Used by: Ligandrol
  24. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant cagrilintide with semaglutide 2.4 mg
    pubmed_cagrilintide_semaglutide_phase1b
    Randomized phase 1b coadministration study; early human bridge for cagrilintide plus semaglutide before later phase 2/3 trials.
    Used by: Cagrilintide, Cagrilintide + Semaglutide / CagriSema
  25. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fosgonimeton in healthy volunteers and subjects with Alzheimer's disease
    pubmed_fosgonimeton_phase1_2022
    Phase 1 HGF/MET positive-modulator context; fosgonimeton is related pathway context, not Dihexa itself.
    Used by: Dihexa
  26. Topical rapamycin reduces markers of senescence and aging in human skin: an exploratory, prospective, randomized trial
    pmc_topical_rapamycin_skin_2019
    Exploratory human topical rapamycin trial with skin-aging/senescence endpoints; route-specific and not evidence for systemic longevity use.
    Used by: Rapamycin / Sirolimus
  27. Treatment of chronic nonhealing neurotrophic corneal epithelial defects with thymosin beta4
    pubmed_tb4_neurotrophic_corneal_defects_2010
    Uncontrolled human topical eye-drop case series for full-length Tbeta4 in chronic corneal epithelial defects.
    Used by: TB-500 / thymosin beta-4-related products

evidence report

  1. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults
    pubmed_ags_beers_criteria_2023
    Geriatric prescribing criteria covering strongly anticholinergic drugs, including first-generation antihistamines and selected antidepressants; useful for older-adult delirium, falls, cumulative anticholinergic burden, and dementia-risk framing.
    Used by: Clomipramine, Diphenhydramine, Hydroxyzine
  2. Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults
    pubmed_aasm_insomnia_guideline_2017
    American Academy of Sleep Medicine pharmacologic insomnia guideline; includes recommendations against trazodone and diphenhydramine for chronic adult insomnia.
    Used by: Diphenhydramine, Trazodone
  3. Ephedra and ephedrine for weight loss and athletic performance enhancement
    ahrq_ephedrine_weight_loss_2003
    AHRQ evidence report summary covering efficacy and adverse events, including cardiovascular/autonomic safety concerns.
    Used by: Ephedrine
  4. Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis
    pmc_follistatin_sibm_critique_2017
    Published critique arguing the IBM trial design and outcome handling do not support strong efficacy conclusions; important skepticism source for this entry.
    Used by: Follistatin / FS344

forensic toxicology

  1. First multifaceted ADME profile of ACP-105
    pubmed_acp105_adme_2025
    ADME and in silico toxicology work for ACP-105 in a doping/toxicology context.
    Used by: ACP-105

government fact sheet

  1. NIH ODS: Dietary supplements for weight loss - yohimbe/yohimbine section
    nih_ods_yohimbe_weight_loss
    Summarizes weak weight-loss evidence and cardiovascular/anxiety toxicity reports.
    Used by: Yohimbine

government review

  1. Clinical Review - Mecasermin (Increlex)
    ncbi_mecasermin_clinical_review_2024
    NCBI Bookshelf clinical review summarizing mecasermin efficacy and harms, including hypoglycemia, lipohypertrophy, and tonsillar hypertrophy.
    Used by: Mecasermin / Recombinant Human IGF-1
  2. FDA: Dermal fillers, including hyaluronic acid fillers
    fda_dermal_fillers_hyaluronic_acid
    Regulatory and safety context for injectable hyaluronic acid dermal fillers.
    Used by: Hyaluronic Acid / Sodium Hyaluronate
  3. Growth Hormone, IGF-1, and Insulin for Performance Enhancement
    ncbi_hgh_athletic_performance_review
    NCBI review of GH/IGF-1/insulin performance-enhancement claims and evidence limits.
    Used by: Human Growth Hormone / Somatropin
  4. Istradefylline - LiverTox
    ncbi_istradefylline_livertox
    Approved A2A antagonist context and hepatic safety summary.
    Used by: No public entries linked.
  5. Microorganisms & Microbial-Derived Ingredients Used in Food
    fda_microorganisms_food_yogurt_cultures
    FDA context page noting mandatory yogurt cultures and optional lactic-acid-producing bacteria in standardized foods.
    Used by: Astaxanthin-fortified yogurt
  6. NIH Office of Dietary Supplements: Carnitine Health Professional Fact Sheet
    ods_carnitine_factsheet
    NIH ODS review of carnitine biology, supplement forms, proposed weight-loss rationale, evidence limits, and safety.
    Used by: L-carnitine
  7. NIH Office of Dietary Supplements: Choline fact sheet for health professionals
    ods_choline_factsheet
    Component evidence for lipotropic injection blends; not direct evidence for Lipo C formulations.
    Used by: No public entries linked.
  8. NIH Office of Dietary Supplements: Niacin fact sheet for health professionals
    ods_niacin_factsheet
    Component evidence for some lipotropic or NAD-related blend claims.
    Used by: No public entries linked.
  9. NIH Office of Dietary Supplements: Vitamin B12 fact sheet for health professionals
    ods_vitamin_b12_factsheet
    Nutrient status, deficiency, dosing forms, safety, and clinical context.
    Used by: Vitamin B12 / Cobalamin
  10. Vitamin C - Health Professional Fact Sheet
    ods_vitamin_c_factsheet
    NIH Office of Dietary Supplements reference for vitamin C physiology, deficiency, intake ranges, tolerable upper intake, and interaction/safety context.
    Used by: Vitamin C / Ascorbic Acid
  11. Vitamin D - Health Professional Fact Sheet
    ods_vitamin_d_factsheet
    NIH Office of Dietary Supplements reference for vitamin D physiology, 25(OH)D status, intake ranges, toxicity, calcium interactions, and safety context.
    Used by: Vitamin D / D3

human association and preclinical

  1. Anticholinergic Drug Exposure and the Risk of Dementia: A Nested Case-Control Study
    pubmed_anticholinergic_dementia_coupland_2019
    Large nested case-control study; supports cumulative anticholinergic burden as a dementia-risk signal while requiring class-specific and confounding-aware interpretation.
    Used by: Clomipramine, Diphenhydramine, Hydroxyzine
  2. Association of NNMT mRNA expression in human adipose tissue and plasma 1-methylnicotinamide with insulin resistance
    pubmed_nnmt_human_adipose_ir_2015
    Human association anchor showing NNMT/1-MNA relevance to insulin resistance; not an intervention trial.
    Used by: 5-Amino-1MQ
  3. Cardiovascular Safety of Amphetamine/Dextroamphetamine versus Methylphenidate in Older Adults
    pubmed_stimulant_cv_older_adults_2024
    Retrospective older-adult veteran study comparing composite cardiovascular events between amphetamine/dextroamphetamine and methylphenidate.
    Used by: Dextroamphetamine, Methylphenidate
  4. Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study
    pubmed_anticholinergic_dementia_gray_2015
    Older-adult prospective cohort; higher 10-year cumulative strong anticholinergic exposure was associated with incident dementia, with first-generation antihistamines among common exposure classes.
    Used by: Diphenhydramine
  5. Gilbert's syndrome and the risk of death: a population-based cohort study
    pubmed_gilbert_mortality_2013
    Large observational cohort associating Gilbert syndrome/mild hyperbilirubinemia with lower all-cause mortality; association, not intervention.
    Used by: Bilirubin / Biliverdin axis
  6. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis
    nature_lcarnitine_tmao_atherosclerosis_2013
    Human association plus animal mechanism linking carnitine-derived TMAO biology to atherosclerosis; risk-context source, not a supplement RCT.
    Used by: L-carnitine
  7. Life extension factor klotho enhances cognition
    pubmed_klotho_cognition_2014
    Human KL-VS association plus mouse cognition work.
    Used by: No public entries linked.
  8. Plasma MOTS-c levels are associated with insulin sensitivity in lean but not in obese individuals
    pubmed_motsc_insulin_sensitivity_2018
    Human association study; helps separate endogenous MOTS-c physiology from intervention claims.
    Used by: MOTS-c
  9. Trigonelline is an NAD+ precursor that improves muscle function during ageing
    pmc_trigonelline_nad_sarcopenia_2024
    Human sarcopenia association plus mouse NAD+/muscle function data.
    Used by: Trigonelline

human physiology

  1. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+
    pubmed_nad_iv_metabolome_2019
    Small human IV NAD+ pharmacokinetic/metabolome pilot; supports route/metabolite handling, not clinical efficacy.
    Used by: NAD+ / Intravenous NAD
  2. Activation of human brown adipose tissue by a beta3-adrenergic receptor agonist
    pubmed_mirabegron_bat_2015
    Acute human mirabegron BAT activation and resting-energy-expenditure study; direct physiology anchor, not a weight-loss outcome trial.
    Used by: Mirabegron
  3. Activation of the GH/IGF-1 axis by CJC-1295 results in serum protein profile changes in normal adult subjects
    pubmed_cjc1295_proteomic_2009
    Healthy young adult men; direct human biomarker study after CJC-1295 exposure, useful for GH/IGF-1-axis mechanism rather than outcome claims.
    Used by: CJC-1295
  4. Age-related growth hormone-releasing activity of growth hormone secretagogues in humans
    pubmed_hexarelin_age_response_1997
    Human GH secretagogue response by age; relevant to extrapolation limits.
    Used by: Hexarelin
  5. Alpha 2-antagonist compounds and lipid mobilization: evidence for a lipid mobilizing effect of oral yohimbine in healthy male volunteers
    pubmed_yohimbine_lipid_mobilization_1988
    Direct human lipolysis physiology anchor for alpha-2 antagonism; not an obesity-outcome trial.
    Used by: Yohimbine
  6. Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals
    pubmed_bimagrumab_insulin_resistance_2017
    Small randomized human study using insulin-sensitivity and body-composition endpoints after bimagrumab exposure.
    Used by: Bimagrumab
  7. Changes in the responsiveness of the hypothalamic-pituitary-gonadal axis to kisspeptin-10 administration during pubertal transition in boys
    pubmed_kisspeptin_puberty_boys_2018
    Human kisspeptin-10 bolus physiology across pubertal stages and adult men; supports axis-state dependence.
    Used by: Kisspeptin-10
  8. Chronic mirabegron treatment increases human brown fat, HDL cholesterol, and insulin sensitivity
    jci_mirabegron_chronic_2020
    Four-week open-label human study using 100 mg mirabegron; supports BAT/metabolic physiology and also highlights dose/safety extrapolation issues.
    Used by: Mirabegron
  9. Delineating tesamorelin response pathways in HIV-associated NAFLD using targeted proteomic and transcriptomic approaches
    pubmed_tesamorelin_response_pathways_2021
    Human response-pathway analysis; helps explain why visceral/liver-fat effects may not generalize to every GH-secretagogue use case.
    Used by: Tesamorelin
  10. Determination of thymosin beta4 and protein in human wound fluid after abdominal surgery
    pubmed_tb4_human_wound_fluid_2007
    Human physiology source showing endogenous Tbeta4 in wound fluid after surgery; supports biological plausibility, not treatment efficacy.
    Used by: TB-500 / thymosin beta-4-related products
  11. Does growth hormone releasing factor desensitize the somatotrophbeta Responses during and after 10-hour infusion of GRF 1-29 amide in man
    pubmed_grf129_infusion_men_1986
    Human GRF(1-29) amide infusion study showing sustained GH release during infusion.
    Used by: CJC-1295 No DAC / Modified GRF(1-29)
  12. Effects of kisspeptin-10 on reproductive hormone release in men with type 2 diabetes and mild biochemical hypogonadism
    pubmed_kisspeptin10_t2d_hypogonadism_2013
    Direct human endocrine-challenge study; supports LH/testosterone stimulation mechanism, not a mature therapeutic protocol.
    Used by: Kisspeptin-10
  13. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
    pubmed_semaglutide_appetite_energy_2017
    Human appetite and energy-intake physiology study; helps explain why semaglutide works beyond a generic GLP-1 label.
    Used by: Semaglutide
  14. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD
    pubmed_tesamorelin_hepatic_transcriptomic_2020
    Human liver transcriptomic analysis from tesamorelin-treated HIV-associated NAFLD context; mechanism-adjacent to the liver-fat signal.
    Used by: Tesamorelin
  15. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine
    pubmed_ephedrine_caffeine_2004
    Randomized crossover human physiology study of combined ephedrine and caffeine stimulant/metabolic effects.
    Used by: Ephedrine
  16. Growth hormone releasing hexapeptide-6 test in the diagnosis of GH-deficiency
    pubmed_ghrp6_gh_deficiency_test_1996
    Older human diagnostic physiology source for GHRP-6.
    Used by: GHRP-6
  17. Growth hormone releasing peptide-2, like ghrelin, increases food intake in healthy men
    pubmed_ghrp2_food_intake_men_2005
    Human GH/ghrelin physiology and appetite context for GHRP-2/pralmorelin.
    Used by: GHRP-2 / Pralmorelin
  18. Growth hormone-releasing activity of hexarelin in humans: a dose-response study
    pubmed_hexarelin_human_dose_response_1994
    Human GH response dose-ranging for hexarelin.
    Used by: Hexarelin
  19. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial
    pubmed_elamipretide_older_muscle_atp_2021
    Randomized older-adult physiology study using 31P MRS ATPmax; supports a mitochondrial energetics signal, not a clinical performance protocol.
    Used by: SS-31 / Elamipretide
  20. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men
    pubmed_kisspeptin10_lh_men_2011
    Healthy male volunteer study of kisspeptin-10 effects on LH, FSH, testosterone, and LH pulsatility.
    Used by: Kisspeptin-10
  21. Lipids and insulin regulate mitochondrial-derived peptide MOTS-c in PCOS and healthy subjects
    pubmed_motsc_human_pcos_lipid_insulin_2019
    Human clamp/intralipid physiology study; circulating MOTS-c responds to lipid and insulin exposure but this is not exogenous MOTS-c treatment.
    Used by: MOTS-c
  22. Metabolic modulation of the growth hormone-releasing activity of hexarelin in man
    pubmed_hexarelin_metabolic_modulation_1995
    Human physiology paper showing nutritional/metabolic state can alter hexarelin GH response.
    Used by: Hexarelin
  23. Metformin suppresses the mitochondrial and transcriptional response to exercise, revealing a conserved BCL6B-associated angiogenic program
    pubmed_metformin_exercise_mito_transcriptome_2025
    Human/mouse mechanistic exercise-adaptation source; supports caution that metformin can alter mitochondrial and transcriptional responses to aerobic training.
    Used by: Metformin
  24. Modulation of growth hormone-releasing activity of hexarelin in man
    pubmed_hexarelin_modulation_1995
    Human volunteer physiology study mapping hexarelin interaction with GHRH and somatostatin tone.
    Used by: Hexarelin
  25. Nebivolol, but not metoprolol, lowers blood pressure in nitric oxide-sensitive human hypertension
    pubmed_nebivolol_no_hypertension_2014
    Human hypertension physiology study supporting the nebivolol-specific nitric oxide distinction from older beta blockers.
    Used by: Nebivolol
  26. Pulsatile secretion of growth hormone persists during continuous stimulation by CJC-1295
    pubmed_cjc1295_pulsatile_2006
    Healthy-adult CJC-1295 physiology paper showing GH pulsatility can persist despite long-acting GHRH analog exposure.
    Used by: CJC-1295
  27. Robust growth hormone responses to GH-releasing peptide 2 in adolescents
    pubmed_ghrp2_adolescent_gh_response_2024
    Human diagnostic GH response context.
    Used by: GHRP-2 / Pralmorelin
  28. Sildenafil improves cardiac output and exercise performance during acute hypoxia, but not normoxia
    pubmed_sildenafil_hypoxia_performance_2006
    Healthy-human physiology study supporting the narrow altitude/hypoxia performance rationale and the lack of normoxia performance effect.
    Used by: PDE5 inhibitors / Cialis / Viagra, Sildenafil / Viagra
  29. Testing with growth hormone-releasing factor (GRF(1-29)NH2) and somatomedin C measurements for the evaluation of growth hormone deficiency
    pubmed_grf129_ghd_testing_1986
    GRF(1-29)NH2 GH-stimulation testing in young adult volunteers and children/adolescents.
    Used by: CJC-1295 No DAC / Modified GRF(1-29)
  30. Tirzepatide reduces appetite, energy intake, and fat mass in people with type 2 diabetes
    pubmed_tirzepatide_appetite_fatmass_2023
    Human mechanistic study connecting tirzepatide to reduced appetite/energy intake and fat mass.
    Used by: Tirzepatide

human rct

  1. A double-blind study of the efficacy and safety of sertraline and clomipramine in severe major depression
    pubmed_sertraline_clomipramine_depression_2000
    Head-to-head tolerability/efficacy comparison useful for explaining why clomipramine potency comes with a heavier adverse-effect burden.
    Used by: Clomipramine, Sertraline
  2. A phase 2 randomized controlled trial of mazdutide in Chinese overweight adults or adults with obesity
    pubmed_mazdutide_phase2_obesity_2023
    Human obesity trial for GLP-1/glucagon dual agonist mazdutide.
    Used by: Mazdutide
  3. A phase 2 randomized trial of survodutide in MASH and fibrosis
    pubmed_survodutide_mash_phase2_2024
    Human liver-disease trial; supports a MASLD/MASH rationale beyond simple scale weight for GLP-1/glucagon dual agonism.
    Used by: Survodutide
  4. A Phase 3 Trial of l-Glutamine in Sickle Cell Disease
    pubmed_lglutamine_scd_phase3_2018
    Randomized phase 3 sickle-cell disease trial behind the label context; does not establish general recovery or muscle-performance effects.
    Used by: Glutamine / L-Glutamine
  5. A Phase 3 Trial of Seladelpar in Primary Biliary Cholangitis
    pubmed_seladelpar_response_2024
    RESPONSE phase 3 RCT in PBC; direct clinical efficacy source for seladelpar's approved disease context.
    Used by: Seladelpar
  6. A Randomized Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Study of the Novel Myostatin Inhibitor Apitegromab (SRK-015): A Potential Treatment for Spinal Muscular Atrophy
    pubmed_apitegromab_phase1_2021
    Randomized phase 1 apitegromab/SRK-015 study in healthy adults; supports IV exposure, latent-myostatin target engagement, PK/PD, safety, and immunogenicity context.
    Used by: Apitegromab
  7. A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects
    pubmed_nr_obese_men_2018
    Direct human NR trial in obese insulin-resistant men; useful negative/limited-effect context for insulin sensitivity and fat-loss claims.
    Used by: Nicotinamide Riboside
  8. A randomized, double-blind, placebo-controlled trial of human growth hormone for the treatment of wasting in AIDS
    pubmed_somatropin_hiv_wasting_1996
    Direct recombinant human GH trial in AIDS wasting; supports lean-mass/wasting context, not healthy hypertrophy use.
    Used by: Human Growth Hormone / Somatropin
  9. Activity and safety of enobosarm in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer: a randomised phase 2 trial
    pubmed_enobosarm_breast_cancer_phase2_2024
    Oncology phase 2 trial source; shows clinical SARM development outside gym contexts and reinforces endpoint-specific interpretation.
    Used by: Enobosarm
  10. Anabolic effects of nandrolone decanoate in patients receiving dialysis: a randomized controlled trial
    jama_nandrolone_dialysis_rct_1999
    Direct human RCT in dialysis patients; supports disease-associated wasting/anabolic effects, not nonmedical cycling.
    Used by: Nandrolone Decanoate
  11. ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density
    pubmed_ara290_sarcoidosis_sfn_2013
    Randomized human sarcoidosis-associated small-fiber neuropathy study; supports symptom and corneal nerve-fiber-density signal in a narrow disease context.
    Used by: ARA-290 / Cibinetide
  12. Bergamot phytosome improved visceral fat and plasma lipid profiles
    pubmed_bergamot_phytosome_2021
    Randomized placebo-controlled trial in overweight/obese class I subjects with mild hypercholesterolemia.
    Used by: Bergamot Phytosome
  13. Bimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial
    pmc_bimagrumab_semaglutide_phase2_2026
    Peer-reviewed BELIEVE phase 2 obesity trial testing IV bimagrumab, SC semaglutide, and combinations; relevant to fat-share of weight loss, lean-mass preservation, muscle-spasm tolerability, and combination-therapy questions.
    Used by: Bimagrumab, Semaglutide
  14. Bimagrumab vs Optimized Standard of Care for Treatment of Sarcopenia in Community-Dwelling Older Adults: A Randomized Clinical Trial
    pubmed_bimagrumab_sarcopenia_2020
    Larger sarcopenia RCT with optimized standard care; important functional-outcome counterweight to simple lean-mass enthusiasm.
    Used by: Bimagrumab
  15. Blood pressure changes with cagrilintide plus semaglutide treatment
    pubmed_cagrisema_blood_pressure_2025
    CagriSema human cardiometabolic endpoint analysis from obesity trial data.
    Used by: Cagrilintide, Cagrilintide + Semaglutide / CagriSema
  16. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study
    pubmed_tirzepatide_surmount1_body_comp_2025
    DXA/body-composition substudy from SURMOUNT-1; relevant to fat-mass versus lean-mass interpretation.
    Used by: Tirzepatide
  17. Bremelanotide for female sexual dysfunctions in premenopausal women: a randomized, placebo-controlled dose-finding trial
    pubmed_bremelanotide_dose_finding_2016
    Phase 2b dose-finding trial with subcutaneous bremelanotide.
    Used by: Bremelanotide
  18. Bremelanotide for the treatment of hypoactive sexual desire disorder: two randomized phase 3 trials
    pubmed_bremelanotide_reconnect_phase3_2019
    RECONNECT phase 3 randomized trials in premenopausal women with HSDD.
    Used by: Bremelanotide
  19. Cagrilintide-semaglutide in adults with overweight or obesity and type 2 diabetes
    pubmed_cagrisema_redefine2_2025
    REDEFINE 2 phase 3 trial in obesity/overweight with type 2 diabetes.
    Used by: Cagrilintide, Cagrilintide + Semaglutide / CagriSema
  20. Cardiovascular Safety of Testosterone-Replacement Therapy
    pubmed_testosterone_traverse_cv_2023
    TRAVERSE cardiovascular-safety trial in symptomatic hypogonadal men with pre-existing or high cardiovascular risk; replacement-therapy context, not supraphysiologic cycling.
    Used by: Testosterone
  21. Cerebrolysin and Recovery After Stroke (CARS): a randomized, placebo-controlled, double-blind, multicenter trial
    pubmed_cerebrolysin_cars_2016
    Human stroke recovery RCT; disease-specific neurorehabilitation context.
    Used by: Cerebrolysin
  22. Cerebrolysin and repetitive transcranial magnetic stimulation in patients with traumatic brain injury: a randomized three-arm trial
    pubmed_cerebrolysin_tbi_2023
    Human TBI trial; keep separate from generalized nootropic claims.
    Used by: Cerebrolysin
  23. Cetoleic acid concentrate decreased serum LDL-cholesterol in adults with overweight or obesity
    lifescience_cetoleic_acid_ldl_2026
    British Journal of Nutrition randomized double-blind controlled clinical trial listing.
    Used by: Cetoleic Acid Concentrate
  24. Characterization of flare-ups and impact of garetosmab in adults with fibrodysplasia ossificans progressiva: a post hoc analysis of the randomized, double-blind, placebo-controlled LUMINA-1 trial
    pubmed_garetosmab_lumina_flareups_2024
    Post hoc phase 2 LUMINA-1 FOP analysis; disease-specific context for garetosmab effects on flare-ups and heterotopic ossification biology.
    Used by: Garetosmab
  25. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults
    pubmed_nr_healthy_older_2018
    Randomized crossover human NR study; supports oral NAD+ metabolome elevation and tolerability, with exploratory cardiovascular/metabolic endpoints.
    Used by: Nicotinamide Riboside
  26. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk
    pubmed_tadalafil_endothelial_cvrisk_2005
    Randomized trial of tadalafil and endothelial function in men with increased cardiovascular risk; useful vascular-function context beyond ED symptom scores.
    Used by: Tadalafil / Cialis
  27. Clenbuterol induces lean mass and muscle protein accretion, but attenuates cardiorespiratory fitness and desensitizes muscle beta2-adrenergic signalling
    pubmed_clenbuterol_lean_mass_protein_2025
    Healthy-men trial with oral clenbuterol cycles; supports lean-mass/protein-accretion signal while documenting fitness and beta2-desensitization tradeoffs.
    Used by: Clenbuterol
  28. Clomiphene citrate and hCG are both effective in restoring testosterone in hypogonadism
    pubmed_clomiphene_male_hypogonadism_rct_2018
    Short-course randomized male hypogonadism study.
    Used by: Clomiphene, Human chorionic gonadotropin
  29. Co-administered once-weekly cagrilintide with semaglutide in type 2 diabetes
    pubmed_cagrisema_t2d_phase2_2023
    Phase 2 active-controlled trial; useful bridge between early coadministration physiology and phase 3 obesity results.
    Used by: Cagrilintide, Cagrilintide + Semaglutide / CagriSema
  30. Coadministered cagrilintide and semaglutide in adults with overweight or obesity
    pubmed_cagrisema_redefine1_2025
    REDEFINE 1 phase 3 obesity trial for cagrilintide plus semaglutide; combo evidence should be kept separate from standalone cagrilintide claims.
    Used by: Cagrilintide, Cagrilintide + Semaglutide / CagriSema
  31. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study
    pubmed_berberine_obesity_rct_2024
    Randomized obesity study with body-composition, adipokine, and metabolic endpoints; useful direct body-composition context.
    Used by: Berberine
  32. Comparative effects of telmisartan and eprosartan on insulin sensitivity in overweight hypertensive patients
    pubmed_telmisartan_insulin_overweight_2009
    Randomized active-comparator study reporting insulin-sensitivity and lipid-profile advantages for telmisartan in overweight hypertensive patients.
    Used by: Telmisartan
  33. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity
    pubmed_tirzepatide_surmount4_2024
    SURMOUNT-4 randomized withdrawal/maintenance trial; direct human evidence that continued treatment maintains more weight loss than placebo withdrawal.
    Used by: Tirzepatide
  34. CVN424, a GPR6 inverse agonist, for Parkinson's disease and motor fluctuations
    pubmed_cvn424_phase2_2024
    Double-blind randomized phase 2 trial in Parkinson's disease OFF-time.
    Used by: CVN424
  35. DHEA enhances effects of weight training on muscle mass and strength in elderly women and men
    pubmed_dhea_weight_training_elderly_2006
    Randomized trial reporting DHEA replacement enhanced resistance-training adaptations in elderly participants.
    Used by: Dehydroepiandrosterone
  36. Dose-dependent increase in intratesticular testosterone by very low-dose human chorionic gonadotropin in normal men with experimental gonadotropin deficiency
    pubmed_hcg_dose_dependent_itt_2010
    Controlled human model showing dose-dependent intratesticular testosterone response to very-low-dose hCG under experimental gonadotropin deficiency.
    Used by: Human chorionic gonadotropin
  37. Dose-response effects on HbA1c and bodyweight reduction of survodutide compared with placebo and open-label semaglutide in people with type 2 diabetes
    pubmed_survodutide_t2d_phase2_2024
    Human diabetes/weight phase 2 dose-response trial.
    Used by: Survodutide
  38. Double-blind, randomized, placebo-controlled phase III trial of oxymetholone for the treatment of HIV wasting
    pubmed_oxymetholone_hiv_wasting_phase3_2003
    Phase III HIV-wasting RCT source for oxymetholone; serious indication and toxicity context, not casual mass-gain evidence.
    Used by: Oxymetholone
  39. Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia
    pubmed_finasteride_psa_rct_2007
    Randomized trial supporting PSA interpretation caveat even at 1 mg/day male-pattern-hair-loss dose.
    Used by: Finasteride
  40. Effect of administering kefir on the changes in fecal microbiota and symptoms of inflammatory bowel disease: A randomized controlled trial
    pubmed_kefir_ibd_rct_2019
    Open-label randomized IBD trial reporting fecal Lactobacillus/L. kefiri changes and short-term symptom/inflammation signals.
    Used by: Milk Kefir
  41. Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial
    pubmed_bimagrumab_obesity_t2d_phase2_2021
    Direct obesity/T2D phase 2 RCT; ActRII blockade reduced fat mass, increased lean mass, and improved metabolic markers over 48 weeks.
    Used by: Bimagrumab
  42. Effect of coenzyme Q10 plus nicotinamide adenine dinucleotide supplementation on maximum heart rate after exercise testing in chronic fatigue syndrome
    pubmed_coq10_nadh_cfs_2015
    CoQ10 plus NADH randomized trial in CFS; combination evidence, so not cleanly attributable to NADH alone.
    Used by: NADH
  43. Effect of low-dose tadalafil once daily on glycemic control in patients with type 2 diabetes and erectile dysfunction: a randomized, double-blind, placebo-controlled pilot study
    pubmed_tadalafil_t2d_glycemic_pilot_2022
    Pilot RCT of tadalafil 5 mg daily in type 2 diabetes with ED; useful for NO/cGMP-metabolic hypothesis but too small for general metabolic-drug claims.
    Used by: Tadalafil / Cialis
  44. Effect of salbutamol on muscle strength and endurance performance in nonasthmatic men
    pubmed_salbutamol_strength_endurance_2000
    Double-blind placebo-controlled study in nonasthmatic men; direct source for oral salbutamol ergogenic discussion.
    Used by: Oral Salbutamol
  45. Effect of seaweed (Ecklonia cava extract) on blood glucose and insulin level on prediabetic patients
    pubmed_ecklonia_prediabetes_rct_2022
    Human Ecklonia cava extract RCT; adjacent extract-level metabolic data, not isolated dieckol cardiovascular proof.
    Used by: Dieckol
  46. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial
    pubmed_tirzepatide_surpass5_2022
    Phase 3 type 2 diabetes RCT with tirzepatide added to insulin glargine; supports glycemic and body-weight effects in insulin-treated T2D context.
    Used by: Tirzepatide
  47. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients
    pubmed_tesamorelin_liver_fat_2014
    Randomized clinical trial in HIV abdominal fat accumulation.
    Used by: Tesamorelin
  48. Effect of vasoactive intestinal polypeptide on development of migraine headaches: a randomized clinical trial
    pubmed_vip_migraine_rct_2021
    Human provocative physiology trial; demonstrates biologic activity and headache risk.
    Used by: VIP / Vasoactive Intestinal Peptide
  49. Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults
    pubmed_mk677_older_adults_2008
    Two-year randomized trial of MK-677/ibutamoren in older adults.
    Used by: Ibutamoren
  50. Effects of anabolic steroids on physical performance
    sciencedirect_methandienone_strength_1976
    Older double-blind athletic-performance study involving methandienone; historical direct human evidence with dated methods.
    Used by: Methandienone
  51. Effects of Beta-Hydroxy-Beta-Methylbutyrate Supplementation on Older Adults with Sarcopenia: A Randomized, Double-Blind, Placebo-Controlled Study
    pubmed_hmb_sarcopenia_rct_2023
    Randomized double-blind placebo-controlled study in older adults with sarcopenia; useful for frailty/catabolic-context HMB claims.
    Used by: HMB
  52. Effects of Carnosine Supplementation on Cognitive Outcomes in Prediabetes and Well-Controlled Type 2 Diabetes: A Randomised Placebo-Controlled Clinical Trial
    pubmed_carnosine_cognition_diabetes_rct_2025
    Recent randomized trial in prediabetes/well-controlled type 2 diabetes assessing cognitive outcomes; useful brain/metabolic context but not a gym-performance trial.
    Used by: Carnosine / Beta-Alanine
  53. Effects of clomiphene citrate on male obesity-associated hypogonadism
    pubmed_clomiphene_obesity_hypogonadism_2018
    Randomized, double-blind, placebo-controlled male obesity-associated hypogonadism study.
    Used by: Clomiphene
  54. Effects of enobosarm on muscle wasting and physical function in patients with cancer
    pubmed_enobosarm_cachexia_phase2_2013
    Double-blind randomized phase 2 cancer cachexia trial.
    Used by: Enobosarm
  55. Effects of phosphatidic acid supplementation on muscle thickness and strength in resistance-trained men
    pubmed_phosphatidic_acid_resistance_men_2017
    Human resistance-trained men trial; useful direct evidence for muscle thickness/strength outcomes with PA supplementation.
    Used by: Phosphatidic Acid
  56. Effects of retatrutide on body composition in people with type 2 diabetes
    pubmed_retatrutide_body_comp_t2d_2025
    Phase 2 substudy focused on body composition in type 2 diabetes; relevant to lean/fat mass interpretation of triple-agonist weight loss.
    Used by: Retatrutide
  57. Effects of short-term oral salbutamol administration on exercise endurance and metabolism
    pubmed_salbutamol_endurance_metabolism_2000
    Oral salbutamol exercise-endurance/metabolism trial; complements strength/endurance trial and reinforces route-specific beta2-agonist discussion.
    Used by: Oral Salbutamol
  58. Effects of subantimicrobial-dose doxycycline in moderate acne
    jama_subantimicrobial_doxy_acne_2003
    Moderate acne trial assessing lesions, skin flora, and resistant organisms.
    Used by: Doxycycline
  59. Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation
    pubmed_tesamorelin_2010
    Randomized placebo-controlled trial with safety extension.
    Used by: Tesamorelin
  60. Effects of Tesamorelin on Neurocognitive Impairment in Persons With HIV and Abdominal Obesity
    pubmed_tesamorelin_neurocognition_hiv_2025
    Phase 2 randomized open-label trial testing tesamorelin for neurocognitive impairment in virally suppressed people with HIV and abdominal obesity; narrow disease-context evidence.
    Used by: Tesamorelin
  61. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial
    pubmed_tesamorelin_hiv_nafld_2019
    Randomized multicenter trial in people with HIV and NAFLD; supports liver-fat and histology context for tesamorelin.
    Used by: Tesamorelin
  62. Effects of Testosterone Treatment in Older Men
    pubmed_testosterone_trials_older_men_2016
    Coordinated Testosterone Trials source for older hypogonadal men; supports indication-specific benefits and endpoint-specific limits.
    Used by: Testosterone
  63. Effects of TS-142, a novel dual orexin receptor antagonist, on sleep in patients with insomnia: a randomized, double-blind, placebo-controlled phase 2 study
    pubmed_vornorexant_phase2_insomnia_2022
    Phase 2 crossover insomnia study; single oral doses improved PSG sleep latency and wake after sleep onset versus placebo.
    Used by: Vornorexant
  64. Efficacy and possible mechanisms of action of a new peptide anxiolytic Selank in generalized anxiety disorders and neurasthenia
    pubmed_selank_gad_2008
    Russian comparative clinical study in GAD/neurasthenia; regional evidence and translation caveats apply.
    Used by: Selank
  65. Efficacy and safety of hydroxyzine in generalized anxiety disorder: a 3-month double-blind study
    pubmed_hydroxyzine_gad_2002
    Randomized double-blind placebo/active-comparator GAD trial; useful for anxiety claims distinct from sleep-stack anecdotes.
    Used by: Hydroxyzine
  66. Efficacy and safety of K-877 pemafibrate in European patients on statin therapy
    pubmed_pemafibrate_phase2_europe_2022
    Phase 2 randomized trial showing triglyceride lowering on top of statin therapy; contrasts with negative PROMINENT outcomes.
    Used by: Pemafibrate
  67. Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial
    pubmed_mazdutide_t2d_phase2_china_2023
    Phase 2 T2D trial of mazdutide versus placebo/open-label dulaglutide; adds glycemic, weight, and safety context.
    Used by: Mazdutide
  68. Efficacy and safety of ospemifene in postmenopausal women with moderate-to-severe vaginal dryness
    pubmed_ospemifene_vaginal_dryness_2019
    Phase 3 randomized placebo-controlled trial for vaginal dryness due to VVA; direct clinical source.
    Used by: Ospemifene
  69. Efficacy and safety of setmelanotide in patients with Bardet-Biedl syndrome and Alstrom syndrome: a phase 3 trial
    doi_setmelanotide_bbs_phase3_2022
    Randomized placebo-controlled phase 3 trial with open-label period for Bardet-Biedl/Alstrom syndrome obesity context.
    Used by: Setmelanotide
  70. Efficacy and safety of tesamorelin in people with HIV on integrase inhibitors
    pubmed_tesamorelin_instis_hiv_2024
    Randomized trial analysis in people with HIV on INSTI regimens; supports visceral/liver fat and safety context in modern ART background.
    Used by: Tesamorelin
  71. Efficacy and safety of ultrahigh-dose methylcobalamin in early-stage amyotrophic lateral sclerosis: a randomized clinical trial
    pubmed_methylcobalamin_als_rct_2022
    Human high-dose methylcobalamin disease-context evidence; not a general wellness injection proof.
    Used by: Vitamin B12 / Cobalamin
  72. Efficacy of sertraline in a 12-week trial for generalized anxiety disorder
    pubmed_sertraline_gad_2004
    Randomized adult GAD trial; direct psychiatric indication-adjacent evidence for anxiety symptom reduction, not acute panic-attack rescue.
    Used by: Sertraline
  73. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone
    pubmed_enclomiphene_phase2_sperm_2014
    Phase II trial comparing enclomiphene with topical testosterone; anchors endogenous testosterone plus sperm-preservation rationale.
    Used by: Enclomiphene
  74. Esmirtazapine for the Treatment of Chronic Primary Insomnia: A Randomized Long-Term Safety Study in Elderly Outpatients
    kci_esmirtazapine_elderly_safety_2020
    Long-term randomized elderly insomnia safety study; relevant to esmirtazapine tolerability and sleep endpoints, not current approved use.
    Used by: Esmirtazapine
  75. Esmirtazapine in non-elderly adult patients with primary insomnia
    pubmed_esmirtazapine_insomnia_2015
    Randomized outpatient insomnia trial.
    Used by: Esmirtazapine
  76. Feasibility of high-dose tadalafil and effects on insulin resistance in well-controlled patients with type 2 diabetes (MAKROTAD): a single-centre, double-blind, randomised, placebo-controlled, cross-over phase 2 trial
    pubmed_tadalafil_makrotad_2023
    Phase 2 crossover trial in type 2 diabetes; adds insulin-resistance/metabolic context at high-dose tadalafil with tolerability caveats.
    Used by: Tadalafil / Cialis
  77. Fenfluramine for treatment-resistant seizures in Dravet syndrome receiving stiripentol-inclusive regimens
    pubmed_fenfluramine_dravet_rct_2019
    Randomized clinical trial in Dravet syndrome; relevant to the restricted modern fenfluramine use case.
    Used by: Fenfluramine
  78. Fenfluramine in the treatment of Dravet syndrome: results of a third randomized, placebo-controlled clinical trial
    pubmed_fenfluramine_dravet_rct_2023
    Additional randomized placebo-controlled Dravet syndrome trial with echocardiographic safety monitoring.
    Used by: Fenfluramine
  79. Finasteride in the treatment of men with androgenetic alopecia
    pubmed_finasteride_aga_trials_1998
    Two one-year placebo-controlled trials plus extension data in men with male pattern hair loss.
    Used by: Finasteride
  80. Forget me not: the effect of doxycycline on human declarative memory
    sciencedirect_doxycycline_declarative_memory_2024
    Healthy-human declarative learning and memory study.
    Used by: Doxycycline
  81. Galacto-Oligosaccharide RP-G28 Improves Multiple Clinical Outcomes in Lactose-Intolerant Patients
    pubmed_rpg28_multiple_outcomes_2020
    Multicenter blinded placebo-controlled RP-G28 study reporting clinical outcomes and fecal microbiome changes including Bifidobacterium.
    Used by: Galactooligosaccharides / RP-G28
  82. Garetosmab in fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trial
    pubmed_garetosmab_fop_phase2_2023
    Peer-reviewed LUMINA-1 FOP trial of IV garetosmab 10 mg/kg every 4 weeks; relevant for activin A blockade and safety, but not an obesity or performance trial.
    Used by: Garetosmab
  83. Garetosmab in Fibrodysplasia Ossificans Progressiva: Clinical Pharmacology Results from the Phase 2 LUMINA-1 Trial
    pubmed_garetosmab_lumina_clinpharm_2023
    Clinical pharmacology from phase 2 LUMINA-1; supports IV dosing, PK/PD, BMP9, immunogenicity, and exposure-response context for activin A blockade.
    Used by: Garetosmab
  84. GDF8 and activin A are the key negative regulators of muscle mass in postmenopausal females: a randomized phase I trial
    nature_trevogrumab_garetosmab_phase1_2025
    Peer-reviewed randomized phase 1 human pharmacodynamic study of trevogrumab and garetosmab, alone and together, with MRI/DXA body-composition endpoints and safety signals including muscle spasms.
    Used by: Garetosmab, Trevogrumab
  85. Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomized double-blind placebo-controlled dose-finding phase 2 trial
    pubmed_survodutide_obesity_phase2_2024
    Human obesity phase 2 trial.
    Used by: Survodutide
  86. Gynostemma pentaphyllum increases exercise performance and alters mitochondrial respiration and AMPK
    mdpi_gynostemma_exercise_2023
    Randomized crossover trial in healthy untrained males.
    Used by: Gynostemma pentaphyllum Extract
  87. Gypenoside L-containing Gynostemma pentaphyllum extract improves fatigue and physical performance
    pubmed_gynostemma_gypenoside_l_2023
    Double-blind randomized trial in 100 healthy adults.
    Used by: Gynostemma pentaphyllum Extract
  88. Improving lactose digestion and symptoms of lactose intolerance with a novel galacto-oligosaccharide (RP-G28): a randomized, double-blind clinical trial
    pubmed_rpg28_lactose_rct_2013
    Randomized double-blind RP-G28 trial using hydrogen breath testing and lactose-intolerance symptom endpoints.
    Used by: Galactooligosaccharides / RP-G28
  89. L-Carnosine supplementation attenuated fasting glucose, triglycerides, advanced glycation end products, and tumor necrosis factor-alpha levels in patients with type 2 diabetes: a double-blind placebo-controlled randomized clinical trial
    pubmed_carnosine_t2d_rct_2018
    Direct oral L-carnosine RCT in type 2 diabetes with glycemic, triglyceride, AGE, and inflammatory endpoints.
    Used by: Carnosine / Beta-Alanine
  90. Low-dose hCG maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression
    pubmed_hcg_intratesticular_2005
    Mechanistically important for TRT-plus-hCG fertility discussions.
    Used by: Human chorionic gonadotropin
  91. Low-dose lemon myrtle supplementation enhances muscle hypertrophy in older adults undergoing low-load resistance training
    pubmed_lemon_myrtle_lowdose_rct_2026
    Older-adult resistance training plus lemon myrtle randomized controlled trial.
    Used by: Lemon Myrtle Extract
  92. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
    pubmed_retatrutide_phase1b_t2d_2022
    Phase 1b multiple-ascending-dose retatrutide/LY3437943 trial in T2D; adds early human PK/PD, glycemic, weight, and safety context before phase 2 obesity data.
    Used by: Retatrutide
  93. Major outcomes in high-risk hypertensive patients randomized to ACE inhibitor or calcium channel blocker vs diuretic: ALLHAT
    pubmed_amlodipine_allhat_2002
    Large randomized outcomes trial including an amlodipine arm; anchors benefits and comparator risks in hypertension rather than stack lore.
    Used by: Amlodipine
  94. Maslinic acid suppressed early onset muscle soreness and systemic fatigue after full marathon
    jstage_maslinic_marathon_2025
    Randomized double-blind placebo-controlled marathon trial.
    Used by: Maslinic Acid
  95. MK-677 reverses diet-induced catabolism
    pubmed_mk677_catabolism_1998
    Randomized human study of oral GH secretagogue MK-677 in diet-induced catabolism.
    Used by: Ibutamoren
  96. mTOR inhibition improves immune function in the elderly
    pubmed_mtor_inhibition_elderly_immune_2014
    Randomized elderly-volunteer trial using RAD001/everolimus before influenza vaccination; central human evidence for low-dose rapalog immunosenescence discussions.
    Used by: Everolimus, Rapamycin / Sirolimus
  97. Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: results of a randomized, placebo-controlled clinical trial
    pubmed_ace031_dmd_trial_2017
    Randomized DMD trial; stopped after second dosing regimen because of potential safety concerns including epistaxis and telangiectasias.
    Used by: ACE-031
  98. Nandrolone decanoate safely combats catabolism in burned patients: A new potential indication after recall
    pubmed_nandrolone_burns_rct_2021
    Human burn-catabolism trial context for nandrolone; disease/injury setting rather than healthy enhancement.
    Used by: Nandrolone Decanoate
  99. Nicotinamide adenine dinucleotide (NADH) in patients with chronic fatigue syndrome
    pubmed_nadh_cfs_2010
    Randomized oral NADH study in CFS; relevant to fatigue discussions, not a general energy enhancement claim.
    Used by: NADH
  100. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women
    pubmed_nmn_insulin_sensitivity_2021
    Science RCT in postmenopausal overweight/obese women with prediabetes; direct NMN insulin-sensitivity source with narrow population scope.
    Used by: Nicotinamide Mononucleotide
  101. Nicotinamide mononucleotide supplementation enhances aerobic capacity in amateur runners: a randomized, double-blind study
    pubmed_nmn_runners_2021
    Human exercise-training NMN trial in amateur runners; supports aerobic-capacity endpoints, not broad anti-aging claims.
    Used by: Nicotinamide Mononucleotide
  102. Once-weekly cagrilintide for weight management in people with overweight and obesity
    pubmed_cagrilintide_phase2_2021
    Dose-finding phase 2 trial.
    Used by: Cagrilintide
  103. Once-weekly mazdutide in Chinese adults with obesity or overweight
    pubmed_mazdutide_obesity_2025
    More recent human obesity trial record.
    Used by: Mazdutide
  104. Once-Weekly Semaglutide in Adults with Overweight or Obesity
    pubmed_semaglutide_step1_2021
    STEP 1 trial.
    Used by: Semaglutide
  105. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men
    pubmed_enclomiphene_phase3_2015
    Phase 3 studies compared with topical testosterone.
    Used by: Enclomiphene
  106. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel
    pubmed_enclomiphene_vs_testosterone_gel_2013
    Human comparison with testosterone gel; central source for why enclomiphene is discussed differently from exogenous testosterone.
    Used by: Enclomiphene
  107. Oral hyaluronan relieves wrinkles and improves dry skin: a 12-week double-blinded placebo-controlled study
    pubmed_oral_hyaluronic_acid_skin_2021
    Oral supplement context; product and molecular-weight specificity matter.
    Used by: Hyaluronic Acid / Sodium Hyaluronate
  108. Oxymetholone ameliorates insulin sensitivity in maintenance hemodialysis patients: a randomized controlled trial
    pubmed_oxymetholone_hemodialysis_insulin_2009
    Hemodialysis RCT source; demonstrates systemic metabolic/anabolic relevance but in high-medical-risk disease context.
    Used by: Oxymetholone
  109. Pharmacokinetics and Pharmacodynamics of Garetosmab (Anti-Activin A): Results From a First-in-Human Phase 1 Study
    pubmed_garetosmab_phase1_2020
    First-in-human garetosmab phase 1 study in healthy women; supports IV/SC exposure, total activin A target engagement, PK/PD, and early safety context.
    Used by: Garetosmab
  110. Phase 2/3 randomized clinical trial and open-label extension of elamipretide in Barth syndrome
    pubmed_elamipretide_barth_phase23_2020
    Randomized crossover Barth syndrome trial; primary endpoints were not met in the placebo-controlled part.
    Used by: SS-31 / Elamipretide
  111. Phosphatidic acid enhances mTOR signaling and resistance exercise induced hypertrophy
    pubmed_phosphatidic_acid_mtor_hypertrophy_2014
    Combines cell signaling and resistance-training supplementation data; direct anchor for phosphatidic acid as an mTOR-linked hypertrophy supplement claim.
    Used by: Phosphatidic Acid
  112. Prolonged oral treatment with MK-677 improves sleep quality in man
    pubmed_mk677_sleep_1997
    Human sleep/GH-axis study for MK-677; useful because ghrelin/GH effects can include sleep architecture and appetite/glucose tradeoffs.
    Used by: Ibutamoren
  113. Randomised placebo-controlled trial of dietary glutamine supplements for postinfectious irritable bowel syndrome
    pubmed_glutamine_postinfectious_ibs_2019
    Gut-specific randomized trial in postinfectious IBS-D with increased intestinal permeability; supports narrow gut-barrier context without generalizing to all GI claims.
    Used by: Glutamine / L-Glutamine
  114. Randomized controlled proof-of-concept trial of MK-7622 in Alzheimer's disease
    pmc_m1_mk7622_ad_2018
    Clinical translation anchor for M1 PAM target class.
    Used by: No public entries linked.
  115. Randomized dose-escalation trial of elamipretide in adults with primary mitochondrial myopathy
    pubmed_elamipretide_pmm_dose_2018
    MMPOWER phase 1/2 PMM trial; short IV dosing showed a dose-response signal on 6-minute walk distance while other endpoints were limited.
    Used by: SS-31 / Elamipretide
  116. Randomized trial of tamoxifen therapy vs prophylaxis in bicalutamide-induced gynecomastia
    pubmed_tamoxifen_gynecomastia_2012
    Male gynecomastia context; not a general PCT validation source.
    Used by: Tamoxifen
  117. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
    pubmed_metformin_dpp_2002
    Diabetes Prevention Program RCT; key human prevention/metabolic anchor for metformin versus lifestyle intervention.
    Used by: Metformin
  118. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes
    pubmed_retatrutide_t2d_2023
    Phase 2 type 2 diabetes trial for the GLP-1/GIP/glucagon triple agonist retatrutide.
    Used by: Retatrutide
  119. Safety and efficacy of apitegromab in nonambulatory type 2 or type 3 spinal muscular atrophy (SAPPHIRE): a phase 3, double-blind, randomised, placebo-controlled trial
    pubmed_apitegromab_sapphire_2026
    Phase 3 SAPPHIRE SMA trial; useful for longer clinical-development evidence, but disease context is not obesity or healthy performance.
    Used by: Apitegromab
  120. Safety and Efficacy of Apitegromab in Patients With Spinal Muscular Atrophy Types 2 and 3: The Phase 2 TOPAZ Study
    pubmed_apitegromab_topaz_2024
    Phase 2 TOPAZ SMA study; adds disease-context human safety/function evidence for latent-myostatin inhibition.
    Used by: Apitegromab
  121. Safety and efficacy of mazdutide 9 mg and 10 mg in Chinese adults with type 2 diabetes
    pubmed_mazdutide_t2d_highdose_2022
    Human diabetes/metabolic phase 1b/2 dose context.
    Used by: Mazdutide
  122. Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE
    pubmed_seladelpar_enhance_2023
    ENHANCE phase 3 randomized placebo-controlled PBC study; adds direct human clinical context beyond the label.
    Used by: Seladelpar
  123. Selective androgen receptor modulation for muscle weakness in chronic obstructive pulmonary disease: a randomised control trial
    pubmed_gsk2881078_copd_phase2_2022
    Phase 2A COPD muscle-weakness trial of oral GSK2881078 plus exercise; disease-context SARM signal with sex-specific endpoint interpretation.
    Used by: GSK2881078
  124. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    pubmed_semaglutide_select_2023
    SELECT cardiovascular outcomes trial; direct human evidence in obesity without diabetes, adding hard-outcome context beyond weight-loss trials.
    Used by: Semaglutide
  125. Single dose creatine improves cognitive performance and induces changes in cerebral high energy phosphates during sleep deprivation
    nature_creatine_sleep_deprivation_2024
    Scientific Reports crossover study using 0.35 g/kg oral creatine with 31P/1H MRS and cognitive testing during sleep deprivation.
    Used by: Creatine
  126. Single-Dose Creatine Reduces Sleep Deprivation-Induced Deterioration in Cognitive Performance
    mdpi_creatine_sleep_deprivation_2026
    Randomized controlled double-blind crossover study using a single 0.2 g/kg oral creatine dose during total sleep deprivation.
    Used by: Creatine
  127. Skeletal muscle adaptations to exercise are not influenced by metformin treatment in humans: secondary analyses of 2 randomized, clinical trials
    pubmed_metformin_exercise_secondary_2022
    Counterpoint human analysis finding skeletal-muscle exercise adaptations were not influenced by metformin in two randomized trials; keeps the exercise-blunting claim nuanced.
    Used by: Metformin
  128. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial
    pubmed_clomipramine_panic_1992
    Panic-disorder RCT; relevant to anxiety/panic discussions, while label risks and tolerability still dominate practical use.
    Used by: Clomipramine
  129. Testosterone dose-response relationships in healthy young men
    pubmed_testosterone_dose_response_2001
    Graded testosterone-enanthate dosing under GnRH-agonist suppression; dose-dependent fat-free mass, muscle size, strength/power, hemoglobin, HDL, and IGF-1 effects.
    Used by: Testosterone
  130. Testosterone Restoration by Enclomiphene Citrate in Men with Secondary Hypogonadism: Pharmacodynamics and Pharmacokinetics
    pubmed_enclomiphene_pkpd_2013
    Dose-ranging phase II pharmacodynamic/pharmacokinetic source for enclomiphene in secondary hypogonadism.
    Used by: Enclomiphene
  131. The clinical effectiveness of sertraline in primary care: the PANDA randomized trial
    pubmed_sertraline_panda_2019
    Pragmatic double-blind placebo-controlled trial; relevant because anxiety symptoms improved earlier than depressive symptoms.
    Used by: Sertraline
  132. The effect of piceatannol from passion fruit seeds on metabolic health in humans
    mdpi_piceatannol_metabolic_health_2017
    Overweight-men subgroup showed reduced insulin, HOMA-IR, BP, and HR; effects were not broad across all groups.
    Used by: Piceatannol
  133. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men
    pubmed_testosterone_supraphysiologic_muscle_1996
    Landmark randomized human trial showing dose/exposure-linked muscle-size and strength effects; not a safety endorsement.
    Used by: Testosterone
  134. The efficacy and safety of beta-nicotinamide mononucleotide supplementation in healthy middle-aged adults
    pmc_nmn_middle_aged_2022
    Randomized multicenter dose-ranging NMN trial in healthy middle-aged adults; supports blood NAD and short-term safety/functional endpoints.
    Used by: Nicotinamide Mononucleotide
  135. The Efficacy and Safety of Evekeo, Racemic Amphetamine Sulfate, for Treatment of Attention-Deficit/Hyperactivity Disorder Symptoms
    pubmed_evekeo_rct_2015
    Dose-optimized double-blind randomized placebo-controlled crossover laboratory-classroom study in pediatric ADHD.
    Used by: Racemic Amphetamine Sulfate
  136. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter randomized controlled trial
    pmc_thymosin_alpha1_sepsis_etass_2014
    Multicenter severe sepsis RCT; useful for immune-modulation evidence and limitations.
    Used by: Thymosin alpha-1
  137. Therapeutic effects of oral NADH on the symptoms of patients with chronic fatigue syndrome
    pubmed_nadh_cfs_pilot_1999
    Small randomized double-blind crossover NADH pilot in chronic fatigue syndrome; disease-specific and preliminary.
    Used by: NADH
  138. THN102 during 40-hour total sleep deprivation in healthy subjects
    pubmed_thn102_2019
    Modafinil plus low-dose flecainide combination.
    Used by: Flecainide, THN102
  139. Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients
    pubmed_thymosin_alpha1_pancreatitis_rct_2010
    Double-blind randomized pilot trial with immune parameters and infection outcomes.
    Used by: Thymosin alpha-1
  140. Thymosin beta 4 ophthalmic solution for dry eye: randomized phase II trial
    pmc_tb4_dry_eye_2015
    Full-length thymosin beta-4 topical/ophthalmic, not necessarily injected TB-500 fragment.
    Used by: TB-500 / thymosin beta-4-related products
  141. Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial
    pubmed_tirzepatide_surmount_cn_2024
    Phase 3 obesity trial in Chinese adults; adds population-specific tirzepatide weight-loss and safety evidence.
    Used by: Tirzepatide
  142. Tirzepatide Once Weekly for the Treatment of Obesity
    pubmed_tirzepatide_surmount1_2022
    SURMOUNT-1 trial.
    Used by: Tirzepatide
  143. Treatment of Sarcopenia with Bimagrumab: Results from a Phase II, Randomized, Controlled, Proof-of-Concept Study
    pubmed_bimagrumab_sarcopenia_poc_2017
    Phase 2 proof-of-concept sarcopenia trial; supports thigh muscle volume/lean-mass signals and helps test whether body-composition effects translate to function.
    Used by: Bimagrumab
  144. Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized placebo-controlled clinical trial
    pubmed_ll37_venous_ulcer_rct_2014
    First-in-man topical LL-37 venous leg ulcer trial.
    Used by: LL-37
  145. Tripeptide K(D)PT Is Well Tolerated in Mild-to-moderate Ulcerative Colitis: Results from a Randomized Multicenter Study
    pubmed_kpv_kdpt_uc_rct_2017
    Human randomized multicenter ulcerative-colitis study of K(D)PT, a related alpha-MSH-derived tripeptide analog; useful human tolerability/anti-inflammatory-pathway context but not direct proof for KPV products.
    Used by: KPV
  146. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial
    pubmed_retatrutide_masld_phase2a_2024
    Human MASLD substudy; retatrutide reduced liver fat, body weight, abdominal subcutaneous adipose tissue, and visceral adipose tissue over 24 weeks.
    Used by: Retatrutide
  147. Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial
    pubmed_retatrutide_obesity_2023
    Phase 2 obesity trial; PubMed record for NEJM paper.
    Used by: Retatrutide
  148. Vitamin C and E supplementation hampers cellular adaptation to endurance training in humans: a double-blind, randomised, controlled trial
    pubmed_vitamin_c_e_endurance_adaptation_2014
    Human endurance-training RCT showing antioxidant supplementation can blunt cellular adaptation markers, supporting caution around high-dose chronic antioxidant use near training.
    Used by: Vitamin C / Ascorbic Acid
  149. Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
    pubmed_vitamin_d_vital_2019
    Large VITAL randomized trial; useful negative/neutral context for broad disease-prevention claims in a general adult population.
    Used by: Vitamin D / D3
  150. Yohimbine: the effects on body composition and exercise performance in soccer players
    pubmed_yohimbine_soccer_players_2006
    Randomized controlled trial in elite soccer players; fat-mass endpoint with limited generalizability.
    Used by: Yohimbine

human rct negative

  1. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial
    pubmed_high_dose_vitamin_d_falls_fractures_2010
    Large annual bolus-dose vitamin D RCT reporting increased falls/fractures; key caution against megadose/bolus logic.
    Used by: Vitamin D / D3
  2. Effect of glutamine supplementation combined with resistance training in young adults
    pubmed_glutamine_resistance_training_2001
    Randomized resistance-training trial in young adults; useful as a direct caution against treating isolated glutamine as a reliable hypertrophy adjunct.
    Used by: Glutamine / L-Glutamine
  3. Effects of salbutamol on the contractile properties of human skeletal muscle before and after fatigue
    pubmed_salbutamol_contractile_properties_2011
    Randomized double-blind acute oral salbutamol study in nonasthmatic recreational male athletes; found no relevant ergogenic effect on muscle contractility/fatigability.
    Used by: Oral Salbutamol
  4. Effects of vitamin D supplementation on androgens in men with low testosterone levels: a randomized controlled trial
    pubmed_vitamin_d_low_testosterone_rct_2018
    Randomized trial in men with low testosterone; useful counterweight to older/smaller positive testosterone claims.
    Used by: Vitamin D / D3
  5. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial
    pubmed_elamipretide_pmm_mmpower3_2023
    Phase 3 PMM trial; subcutaneous elamipretide was tolerated but did not improve 6MWT or fatigue endpoints versus placebo at 24 weeks.
    Used by: SS-31 / Elamipretide
  6. FDA briefing document mentioning AOD-9604 clinical development
    fda_aod9604_briefing
    FDA regulatory review summarizing AOD-9604 obesity clinical development; Phase 2B/OPTIONS did not support commercial obesity development, and most identified studies failed to show weight-reduction benefit versus placebo.
    Used by: AOD9604
  7. Intranasal oxytocin in children and adolescents with autism spectrum disorder
    pubmed_oxytocin_autism_phase2_2021
    Large NEJM randomized trial in autism; important counterweight to broad social-cognition claims.
    Used by: Oxytocin
  8. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double-blind, placebo-controlled, multicenter trial: The MASTERS trial
    pubmed_metformin_masters_hypertrophy_2019
    MASTERS trial; central caution for performance users because metformin blunted resistance-training hypertrophy in older adults and trended against mTORC1 signaling.
    Used by: Metformin
  9. Recombinant human mechano growth factor does not improve muscle strength or performance in healthy men
    pubmed_pegmgf_athlete_trial_2014
    Human trial warning against assuming MGF/PEG-MGF has meaningful performance effects.
    Used by: PEG-MGF / Pegylated Mechano Growth Factor
  10. Safety and efficacy of intravenous bimagrumab in inclusion body myositis (RESILIENT): a randomised, double-blind, placebo-controlled phase 2b trial
    sciencedirect_bimagrumab_resilient_2019
    Large sIBM phase 2b trial; important negative functional-endpoint context despite muscle/lean-mass biology.
    Used by: Bimagrumab
  11. Seven days of piceatannol supplementation exerted no effect on fat metabolism
    pubmed_piceatannol_no_fat_metabolism_2025
    Short crossover trial found no effect on fat metabolism at rest or during/after exercise.
    Used by: Piceatannol
  12. Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
    pubmed_rtb101_phase2b_phase3_2021
    RTB101 older-adult phase 2b/phase 3 publication; important because early RTI/antiviral signals did not translate cleanly into the phase 3 primary endpoint.
    Used by: RTB101
  13. The Effects of Four Doses of Vitamin D Supplements on Falls in Older Adults: A Response-Adaptive, Randomized Clinical Trial
    pubmed_vitamin_d_falls_four_doses_2021
    Dose-ranging fall-risk RCT in older adults; helps mark higher-dose vitamin D as not automatically better.
    Used by: Vitamin D / D3
  14. The efficacy and safety of thymosin alpha 1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trial
    bmj_thymosin_alpha1_tests_sepsis_2025
    Large phase 3 sepsis RCT; found no clear evidence that thymosin alpha 1 decreased 28-day all-cause mortality in adults with sepsis.
    Used by: Thymosin alpha-1
  15. Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
    pubmed_pemafibrate_prominent_2022
    PROMINENT outcomes trial; important direct negative/neutral evidence separating triglyceride lowering from cardiovascular event reduction.
    Used by: Pemafibrate
  16. Ursolic acid has no additional effect on muscle strength and mass in active men
    pubmed_ursolic_human_null_2020
    Human resistance-training/high-protein trial tempering anabolic claims.
    Used by: Ursolic Acid
  17. Vitamin D and Testosterone in Healthy Men: A Randomized Controlled Trial
    pubmed_vitamin_d_testosterone_healthy_men_rct_2017
    Randomized trial testing testosterone effects in healthy men; important for separating deficiency correction from testosterone-booster marketing.
    Used by: Vitamin D / D3

human trial

  1. A clinical trial of intracavernous vasoactive intestinal peptide to induce penile erection
    pubmed_vip_erection_trial_1990
    Human erectile-function physiology/trial context for VIP.
    Used by: VIP / Vasoactive Intestinal Peptide
  2. A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema
    pubmed_cibinetide_dme_phase2_2020
    Phase 2 human diabetic macular edema trial; adds disease-specific clinical context for cibinetide beyond neuropathy, but not general recovery evidence.
    Used by: ARA-290 / Cibinetide
  3. A single ascending-dose study of muscle regulator ACE-031 in healthy volunteers
    pubmed_ace031_healthy_volunteers_2013
    Double-blind placebo-controlled single-dose ACE-031 study in healthy postmenopausal women; lean mass and thigh muscle volume signals at the highest dose.
    Used by: ACE-031
  4. Antiestrogenic properties of raloxifene
    pubmed_raloxifene_tamoxifen_male_antiestr_1995
    Healthy-male volunteer study comparing raloxifene/tamoxifen endocrine responses to estrogen challenge; useful SERM mechanism anchor.
    Used by: Raloxifene, Tamoxifen
  5. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins
    pubmed_berberine_ldlr_2004
    Early human plus mechanistic source showing LDL-cholesterol reduction and LDL receptor upregulation mechanisms distinct from statins.
    Used by: Berberine
  6. Cibinetide improves corneal nerve fiber abundance in patients with sarcoidosis-associated small nerve fiber loss and neuropathic pain
    pubmed_cibinetide_sarcoidosis_neuropathy_2017
    Human neuropathy anchor for ARA-290/cibinetide; disease-specific and not a general recovery peptide proof.
    Used by: ARA-290 / Cibinetide
  7. Clinical and biochemical effects of stanozolol therapy for hereditary angioedema
    pubmed_stanozolol_hae_1981
    Clinical hereditary-angioedema source for stanozolol; indication-specific and not physique evidence.
    Used by: Stanozolol
  8. Clinical and metabolic effects of methyl-androstenediol and methandienone
    pmc_methandienone_clinical_effects_1958
    Older clinical methandienone/metabolic source; historically relevant but not modern safety-quality evidence.
    Used by: Methandienone
  9. Colonic adaptation to daily lactose feeding in lactose maldigesters reduces lactose intolerance
    pubmed_colonic_adaptation_lactose_1996
    Blinded crossover human work supporting the concept of microbial/colonic adaptation to repeated lactose exposure.
    Used by: Galactooligosaccharides / RP-G28
  10. Danazol and stanozolol in long-term prophylactic treatment of hereditary angioedema
    pubmed_stanozolol_hae_danazol_1980
    Older HAE prophylaxis source comparing attenuated androgens; clinical route/context differs from PED use.
    Used by: Stanozolol
  11. DHEA in elderly women and DHEA or testosterone in elderly men
    pubmed_dhea_elderly_nejm_2006
    Two-year placebo-controlled trial; DHEA restored DHEA-S but did not improve VO2 peak, muscle strength, or insulin sensitivity.
    Used by: Dehydroepiandrosterone
  12. Does yohimbine act as a slimming drugbeta
    pubmed_yohimbine_obesity_trial_1991
    Small human obesity trial under low-energy diet conditions.
    Used by: Yohimbine
  13. Effectiveness of antiestrogens in infertile men
    pubmed_antiestrogens_infertile_men_1993
    Older male infertility antiestrogen follow-up; useful negative/mixed endpoint context for clomiphene/tamoxifen fertility claims.
    Used by: Clomiphene, Tamoxifen
  14. Effects of carnosine supplementation on glucose metabolism: Pilot clinical trial
    pubmed_carnosine_glucose_pilot_2016
    Small overweight/obesity pilot trial of oral carnosine for diabetes/cardiovascular risk markers; useful metabolic context with sample-size caveats.
    Used by: Carnosine / Beta-Alanine
  15. Effects of DSIP in man: multifunctional psychophysiological properties besides induction of natural sleep
    pubmed_dsip_insomnia_1987
    Older double-blind human DSIP psychophysiology/sleep studies; modern certainty is limited.
    Used by: Delta Sleep-Inducing Peptide
  16. Effects of GRF (1-29) NH2 on short-term memory: neuroendocrine and neuropsychological assessment in healthy young subjects
    pubmed_grf129_memory_1990
    Controlled healthy-young-subject GRF(1-29)NH2 study; useful for acute GH-response and CNS extrapolation caveats.
    Used by: No public entries linked.
  17. Effects of tadalafil administration on plasma markers of exercise-induced muscle damage, IL6 and antioxidant status capacity
    pubmed_tadalafil_exercise_muscle_damage_2014
    Double-blind crossover healthy-male trial around exhaustive exercise, oxidative status, IL-6, and muscle-damage markers; mechanistic recovery-adjacent but not hypertrophy proof.
    Used by: Tadalafil / Cialis
  18. Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT
    pubmed_bimagrumab_resilient_extension_2021
    Long-term extension of the sIBM program; reports IV dosing, safety, progressive functional decline, and limited durable functional signal.
    Used by: Bimagrumab
  19. Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency
    pubmed_setmelanotide_pomc_lepr_phase3_2020
    Open-label phase 3 POMC/PCSK1 and LEPR deficiency trials with placebo-withdrawal design; supports rare MC4R-pathway obesity use, not common obesity.
    Used by: SC19 MC4R agonist lead, Setmelanotide
  20. Efficacy of bioactive peptides loaded on hyaluronic acid microneedle patches: a monocentric clinical study
    pubmed_snap8_microneedle_2020
    Cosmetic peptide microneedle study including acetyl octapeptide-3/SNAP-8-style anti-wrinkle mechanism.
    Used by: SNAP-8 / Acetyl Octapeptide-3
  21. Fertility outcomes in men with prior history of anabolic steroid use
    pubmed_aas_prior_use_fertility_hcg_clomiphene_2023
    Human fertility-recovery cohort using discontinuation plus clomiphene/hCG regimen; relevant to AAS-induced suppression discussions, not proof of safe cycling.
    Used by: Clomiphene, Human chorionic gonadotropin
  22. Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes
    pubmed_follistatin_sibm_trial_2017
    Open-label sIBM AAV-FS344 gene-therapy report; relevant early human signal, but trial design and efficacy claims need the critique source alongside it.
    Used by: Follistatin / FS344
  23. Kefir improves lactose digestion and tolerance in adults with lactose maldigestion
    sciencedirect_kefir_lactose_digestion_2003
    Human lactose-maldigestion study comparing milk, yogurt, and kefir; useful anchor for the lactose-tolerance discussion.
    Used by: Milk Kefir
  24. Long-term administration of gonadotropin-releasing hormone in men with idiopathic hypogonadotropic hypogonadism
    pubmed_gonadorelin_hypogonadotropic_men_1986
    Pulsatile GnRH/gonadorelin physiology and treatment source in hypogonadotropic men.
    Used by: Gonadorelin
  25. Long-term efficacy, safety, and patient-reported outcomes of apitegromab in patients with spinal muscular atrophy: results from the 36-month TOPAZ study
    frontiers_apitegromab_topaz_36mo_2024
    Open-label extension in SMA, not obesity; useful for longer human exposure and function/safety context around selective pro/latent-myostatin inhibition.
    Used by: Apitegromab
  26. Nicotinamide Riboside Augments the Aged Human Skeletal Muscle NAD+ Metabolome and Induces Transcriptomic and Anti-inflammatory Signatures
    pubmed_nr_aged_muscle_2019
    Aged human skeletal-muscle NR study; supports tissue NAD metabolome and transcriptomic signals, not a demonstrated hypertrophy or performance protocol.
    Used by: Nicotinamide Riboside
  27. Optimal treatment for spermatogenesis in male patients with hypogonadotropic hypogonadism
    pmc_hmg_gnrh_spermatogenesis_hh_2019
    Human HH comparison of pulsatile GnRH and HCG/HMG injection protocols for spermatogenesis-oriented endpoints.
    Used by: Gonadorelin, HMG / Menotropins
  28. Oxandrolone in AIDS-wasting myopathy
    pubmed_oxandrolone_aids_wasting_1996
    Human AIDS-wasting source anchoring oxandrolone anabolic effects in disease catabolism.
    Used by: Oxandrolone
  29. Oxandrolone in trauma patients
    pubmed_oxandrolone_trauma_2000
    Trauma-patient source for clinical catabolic-stress context; not a healthy-user performance result.
    Used by: Oxandrolone
  30. Oxymetholone therapy in HIV-wasting syndrome
    pubmed_oxymetholone_hiv_wasting_1996
    Human HIV-wasting clinical source for oral oxymetholone anabolic effects; toxicity limits generalization.
    Used by: Oxymetholone
  31. Pharmacokinetics, pharmacodynamics and safety profile of the dual orexin receptor antagonist vornorexant/TS-142 in healthy Japanese participants
    pubmed_vornorexant_phase1_pk_2023
    Randomized double-blind placebo-controlled phase 1 single/multiple-dose PK/PD and safety studies in healthy Japanese participants.
    Used by: Vornorexant
  32. Phase II trial of the sigma-1 receptor agonist cutamesine (SA4503) for recovery enhancement after acute ischemic stroke
    ovid_cutamesine_stroke_phase2_2014
    Stroke phase 2 clinical trial; not evidence for general nootropic use.
    Used by: Cutamesine
  33. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency
    pubmed_rhigf1_laron_anabolic_2000
    Adult Laron syndrome/GH receptor deficiency study with body-composition changes under rhIGF-1 replacement.
    Used by: Mecasermin / Recombinant Human IGF-1
  34. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials
    pubmed_retatrutide_triumph_design_2026
    Design/rationale paper for phase 3 TRIUMPH obesity, OSA, and knee OA program; useful for current development direction and adiposity-related comorbidity framing.
    Used by: Retatrutide
  35. Skeletal muscle beta2-adrenoceptor density and muscle strength and hypertrophy response to beta2-agonist treatment with clenbuterol
    pubmed_clenbuterol_healthy_men_2019
    Human clenbuterol physiology/training source in healthy men; relevant to beta-2 anabolic/performance claims but still safety-limited.
    Used by: Clenbuterol
  36. Tadalafil improves lean mass and endothelial function in nonobese men with mild ED/LUTS: in vivo and in vitro characterization
    pubmed_tadalafil_lean_mass_endothelial_2017
    Human and in vitro tadalafil paper often cited in performance communities for lean mass/endothelial-function claims; population and endpoint limits should be preserved.
    Used by: Tadalafil / Cialis
  37. Tesamorelin improves fat quality independent of changes in fat quantity
    pubmed_tesamorelin_fat_quality_2021
    Secondary analysis of randomized tesamorelin trials in people with HIV; supports CT fat-density/fat-quality context beyond simple visceral-fat area.
    Used by: Tesamorelin
  38. The assessment of the clinical efficacy, vasoactive and metabolic effects of mexidol in elderly patients with discirculatory encephalopathy
    pubmed_mexidol_encephalopathy_rct_2012
    Small randomized clinical study in elderly patients with chronic cerebral ischemia/discirculatory encephalopathy; not evidence for healthy cognitive enhancement.
    Used by: Mexidol
  39. The beneficial effects of toremifene administration on the hypothalamic-pituitary-testicular axis and sperm parameters
    pubmed_toremifene_oligozoospermia_2007
    Male oligozoospermia study showing gonadotropin/testicular-axis effects; adjacent to PCT discussions but not a steroid-cycle recovery protocol.
    Used by: Toremifene
  40. The dietary effects of gellan gum in humans
    tandfonline_gellan_gum_human_dietary_effects_1988
    Older human dietary-effects/safety context for gellan gum exposure.
    Used by: Gellan Gum
  41. The effect of thymosin beta 4 treatment of venous ulcers
    pubmed_tb4_ulcers_2010
    Human wound-healing context for full-length Tbeta4.
    Used by: TB-500 / thymosin beta-4-related products
  42. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke
    pubmed_semax_rehab_2018
    Russian clinical trial in ischemic stroke/rehabilitation with BDNF-related endpoints.
    Used by: Semax
  43. The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep
    pubmed_dsip_human_sleep_1983
    Small older human chronic-insomnia study using intravenous synthetic DSIP.
    Used by: Delta Sleep-Inducing Peptide
  44. TORC1 Inhibition with RTB101 as a Potential Pan-Antiviral Immunotherapy to Decrease the Incidence of Respiratory Tract Infections Due to Multiple Respiratory Viruses in Older Adults
    pmc_rtb101_torc1_rti_2019
    Conference-abstract style human source for the phase 2 RTI signal; useful as context but weaker than the full phase 2b/phase 3 paper.
    Used by: RTB101
  45. Use of the synthetic superoxide dismutase/catalase mimetic EUK-134 to compensate for seasonal antioxidant deficiency by reducing pre-existing lipid peroxides at the human skin surface
    pubmed_euk134_skin_lipid_peroxides_2004
    Human topical skin-surface study; supports lipid-peroxide/photodamage mechanism, not systemic anti-aging efficacy.
    Used by: EUK-134
  46. Vitamin C-enriched gelatin supplementation before intermittent activity augments collagen synthesis
    pubmed_vitamin_c_gelatin_collagen_2017
    Small randomized crossover human study pairing vitamin C-enriched gelatin with loading activity; useful for tendon/collagen rationale but not proof of injury healing.
    Used by: Vitamin C / Ascorbic Acid

in vitro

  1. Anti-aromatase activity of constituents from damiana
    sciencedirect_damiana_aromatase_2009
    Damiana aromatase inhibition source.
    Used by: Damiana Extract
  2. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells
    pubmed_epitalon_telomerase_2003
    Human fetal fibroblast culture study reporting telomerase activity and telomere elongation after Epithalon exposure.
    Used by: Epitalon / Epithalon
  3. Flavonoid composition and sexual-enhancing mechanisms of Turnera diffusa extract
    mdpi_damiana_pde5_aromatase_2026
    PDE5 expression, aromatase activity, and nitric oxide mechanism source.
    Used by: Damiana Extract
  4. High-mesembrine Sceletium extract is a monoamine releasing agent
    pubmed_vmat2_sceletium_2016
    Reports VMAT2 upregulation after Sceletium extract treatment in cell models.
    Used by: No public entries linked.
  5. Investigating the impact of astaxanthin yogurt on gut microbiota and microbiota-mediated astaxanthin conversion using the SHIME model
    rsc_astaxanthin_yogurt_shime_2026
    Food & Function SHIME gut-simulator study reporting SCFA increases, microbiota shifts, and astaxanthin conversion signals.
    Used by: Astaxanthin-fortified yogurt
  6. Liposomes as Carriers of GHK-Cu Tripeptide for Cosmetic Application
    pubmed_ghkcu_cosmetic_liposomes_2024
    Formulation/in vitro cosmetic-delivery paper for GHK-Cu liposomes; useful for route/formulation specificity and topical claims.
    Used by: GHK, GHK-Cu
  7. Metabolic profiles of oligosaccharides derived from four microbial polysaccharides by faecal inocula from type 2 diabetes patients
    pubmed_gellan_gum_oligosaccharide_fermentation_2021
    In vitro human-faecal-inocula fermentation study including gellan gum oligosaccharides and microbiome metabolite profiling.
    Used by: Gellan Gum
  8. Prostaglandin EP2 receptor downstream of Notch signaling inhibits differentiation of human skeletal muscle progenitors
    pubmed_pge2_ep2_muscle_progenitors_2020
    Human skeletal muscle progenitor cell source for EP2/self-renewal biology; in vitro, not a muscle-growth protocol.
    Used by: No public entries linked.
  9. Protective effects of dieckol isolated from Ecklonia cava against high glucose-induced oxidative stress in HUVECs
    sciencedirect_dieckol_huvec_2009
    Direct dieckol endothelial-cell oxidative-stress source; mechanistic only.
    Used by: Dieckol
  10. Selective Androgen Receptor Modulator, YK11, Up-Regulates Osteoblastic Proliferation and Differentiation in MC3T3-E1 Cells
    pubmed_yk11_osteoblasts_2018
    Osteoblast cell source; supports broader AR/follistatin biology but remains non-human.
    Used by: YK11
  11. Senolytic peptide FOXO4-DRI selectively removes senescent cells from in vitro expanded human chondrocytes
    pubmed_foxo4dri_chondrocytes_2021
    Human-cell senolytic support; no direct anti-aging clinical evidence.
    Used by: FOXO4-DRI
  12. The effect of tripeptide-copper complex on human hair growth in vitro
    pubmed_ahkcu_hair_invitro_2007
    AHK-Cu increased proliferation and hair-shaft elongation in human follicle organ culture / dermal papilla cell models.
    Used by: AHK-Cu
  13. YK11 regulates myogenic differentiation by follistatin expression
    pubmed_yk11_follistatin_2013
    C2C12 myoblast work underlying YK11 follistatin/myostatin claims.
    Used by: YK11

institutional summary

  1. ATR-258 oral therapy for diabetes and obesity without loss of muscle mass
    monash_atr258_cell_2025
    Monash summary of Cell paper on pathway-selective beta-2 adrenergic agonism and glucose uptake.
    Used by: ATR-258

label

  1. DailyMed label: Acetic Acid Irrigation, USP
    dailymed_acetic_acid_irrigation_label
    Label context for acetic acid as an irrigation/pH product, not a general injectable peptide solvent.
    Used by: No public entries linked.
  2. DailyMed label: AFINITOR everolimus tablet and AFINITOR DISPERZ everolimus tablet for suspension
    dailymed_everolimus_label
    Official everolimus label; oral mTOR inhibitor with cancer/TSC indications and warnings including pneumonitis, infection, metabolic, renal, and stomatitis risks.
    Used by: Everolimus
  3. DailyMed label: Bacteriostatic Water for Injection, USP
    dailymed_bacteriostatic_water_label
    Support-material label context; bacteriostatic water is a diluent, not an efficacy compound.
    Used by: No public entries linked.
  4. DailyMed label: buspirone hydrochloride tablet
    dailymed_buspirone_label
    FDA label source for buspirone.
    Used by: No public entries linked.
  5. DailyMed label: clomiphene citrate tablets
    dailymed_clomiphene_label
    Approved ovulation-induction label; male endocrine use is off-label.
    Used by: Clomiphene
  6. DailyMed label: clonidine hydrochloride extended-release tablets
    dailymed_clonidine_er_label
    Clonidine ER label for ADHD with hypotension/bradycardia, somnolence/sedation, and discontinuation/rebound cautions.
    Used by: Clonidine
  7. DailyMed label: Cyanocobalamin injection
    dailymed_cyanocobalamin_label
    Approved injectable vitamin B12 label context.
    Used by: Vitamin B12 / Cobalamin
  8. DailyMed label: dexmedetomidine hydrochloride injection
    dailymed_dexmedetomidine_label
    Official IV sedation label; useful for route, indication, bradycardia/hypotension, and interaction framing.
    Used by: Dexmedetomidine
  9. DailyMed label: diphenhydramine hydrochloride OTC allergy-relief tablet
    dailymed_diphenhydramine_otc_label
    OTC diphenhydramine label warning about duplicate diphenhydramine products and marked drowsiness.
    Used by: Diphenhydramine
  10. DailyMed label: DUAVEE conjugated estrogens/bazedoxifene
    dailymed_bazedoxifene_duavee_label
    Approved tissue-selective estrogen complex containing bazedoxifene.
    Used by: Bazedoxifene
  11. DailyMed label: EGRIFTA WR tesamorelin kit
    dailymed_egrifta_label
    Official tesamorelin label context for HIV-associated lipodystrophy, subcutaneous route, IGF-1 monitoring, glucose, neoplasm, and hypersensitivity warnings.
    Used by: Tesamorelin
  12. DailyMed label: EMSAM selegiline transdermal system
    dailymed_emsam_label
    Official label for transdermal selegiline in major depressive disorder; useful for route-dependent MAOI risk.
    Used by: Selegiline
  13. DailyMed label: ENDARI (L-glutamine oral powder)
    dailymed_endari_label
    Official L-glutamine label for reducing acute complications of sickle cell disease in patients 5 years and older; anchors dosing, adverse reactions, population gaps, and disease-specific scope.
    Used by: Glutamine / L-Glutamine
  14. DailyMed label: EVEKEO (amphetamine sulfate) tablet
    dailymed_evekeo_label
    U.S. label for racemic amphetamine sulfate; notes d/l enantiomer differences, CNS stimulant status, boxed misuse/addiction warning, and cardiovascular cautions.
    Used by: Racemic Amphetamine Sulfate
  15. DailyMed label: EVISTA raloxifene hydrochloride tablet
    dailymed_raloxifene_label
    Approved SERM label for postmenopausal osteoporosis and invasive breast cancer risk reduction.
    Used by: Raloxifene
  16. DailyMed label: FARESTON toremifene citrate tablet
    dailymed_toremifene_label
    Approved SERM label for metastatic breast cancer in postmenopausal women.
    Used by: Toremifene
  17. DailyMed label: finasteride tablet
    dailymed_finasteride_label
    Finasteride label covering 5-alpha-reductase inhibition, DHT suppression, indications, warnings, and adverse reactions.
    Used by: Finasteride
  18. DailyMed label: FINTEPLA fenfluramine oral solution
    dailymed_fintepla_label
    Official US label for fenfluramine oral solution; boxed/cardiac monitoring and serotonergic warnings anchor safety context.
    Used by: Fenfluramine
  19. DailyMed label: flecainide acetate tablet
    dailymed_flecainide_label
    Official flecainide label; includes CAST/proarrhythmia context and conduction-risk warnings.
    Used by: Flecainide
  20. DailyMed label: FORZINITY (elamipretide) injection
    dailymed_forzinity_label
    U.S. accelerated-approval label for Barth syndrome in patients weighing at least 30 kg.
    Used by: SS-31 / Elamipretide
  21. DailyMed label: hydroxyzine hydrochloride tablet
    dailymed_hydroxyzine_label
    Hydroxyzine label for anxiety/sedation/allergy contexts; warns about CNS depressant potentiation and QT prolongation/TdP reports.
    Used by: Hydroxyzine
  22. DailyMed label: IMCIVREE (setmelanotide) injection
    dailymed_imcivree_label
    Current U.S. label for subcutaneous setmelanotide/IMCIVREE; anchors approved indications, warnings, and administration route.
    Used by: SC19 MC4R agonist lead, Setmelanotide
  23. DailyMed label: INCRELEX mecasermin injection
    dailymed_increlex_label
    Mecasermin/rhIGF-1 label for severe primary IGF-1 deficiency; includes subcutaneous route, hypoglycemia, neoplasia, intracranial hypertension, and lymphoid hypertrophy warnings.
    Used by: IGF-1 LR3 / DES(1-3)IGF-1, Mecasermin / Recombinant Human IGF-1
  24. DailyMed label: Menopur (menotropins for injection)
    dailymed_menopur_label
    Human menopausal gonadotropin label context.
    Used by: HMG / Menotropins
  25. DailyMed label: METFORMIN HYDROCHLORIDE tablet, film coated
    dailymed_metformin_label
    Official metformin label context: oral biguanide for type 2 diabetes, glycemic-control indication, dosing, contraindications, and lactic-acidosis/B12/renal precautions.
    Used by: Metformin
  26. DailyMed label: MYRBETRIQ mirabegron
    dailymed_myrbetriq_label
    Official overactive-bladder label context for oral route, dosing, blood-pressure warning, urinary-retention risk, and CYP2D6 interaction language.
    Used by: Mirabegron
  27. DailyMed label: Nandrolone decanoate injection
    dailymed_nandrolone_decanoate_label
    Official nandrolone decanoate label; anchors approved anemia context, IM route, androgen risks, and controlled-drug framing.
    Used by: Nandrolone Decanoate
  28. DailyMed label: nebivolol hydrochloride tablet
    dailymed_nebivolol_label
    Official nebivolol label for hypertension; anchors beta-blocker contraindications, abrupt-cessation warnings, bradycardia/hypotension context, and interaction cautions.
    Used by: Nebivolol
  29. DailyMed label: NORVASC amlodipine besylate tablet
    dailymed_norvasc_label
    Official US label for oral amlodipine hypertension and angina indications, dosing, contraindications, interactions, and adverse reactions.
    Used by: Amlodipine
  30. DailyMed label: Nutropin AQ NuSpin somatropin injection
    dailymed_somatropin_label
    Official somatropin label; anchors approved GH-deficiency and related indications, subcutaneous route, and safety warnings.
    Used by: Human Growth Hormone / Somatropin
  31. DailyMed label: OSPHENA ospemifene tablet
    dailymed_ospemifene_label
    Approved estrogen agonist/antagonist label for menopausal vulvar and vaginal atrophy symptoms.
    Used by: Ospemifene
  32. DailyMed label: Oxandrolone tablet
    dailymed_oxandrolone_label
    Official oral oxandrolone label for adjunctive weight gain/catabolic contexts and hepatic/lipid androgen warnings.
    Used by: Oxandrolone
  33. DailyMed label: PITOCIN oxytocin injection
    dailymed_oxytocin_label
    Oxytocin injection label for obstetric use; includes IV/IM route and water-intoxication/hyponatremia context.
    Used by: Oxytocin
  34. DailyMed label: Pregnyl chorionic gonadotropin for injection
    dailymed_pregnyl_label
    Official chorionic gonadotropin label; anchors indication, contraindication, ovarian hyperstimulation, thromboembolism, precocious puberty, and supervision cautions.
    Used by: Human chorionic gonadotropin
  35. DailyMed label: RITALIN (methylphenidate hydrochloride) tablet
    dailymed_ritalin_label
    Methylphenidate immediate-release label with ADHD/narcolepsy use, controlled-substance warning, and common stimulant adverse reactions.
    Used by: Methylphenidate
  36. DailyMed label: SIROLIMUS tablet, film coated
    dailymed_sirolimus_label
    Official label context for oral sirolimus, an mTOR inhibitor; includes approved indications, route, warnings, and adverse-effect monitoring.
    Used by: Rapamycin / Sirolimus
  37. DailyMed label: tamoxifen citrate tablet
    dailymed_tamoxifen_label
    Approved SERM label covering breast cancer treatment and risk-reduction contexts.
    Used by: Tamoxifen
  38. DailyMed label: telmisartan tablet
    dailymed_telmisartan_label
    Official telmisartan label for hypertension; anchors fetal-toxicity, hypotension, renal function, potassium, and interaction cautions.
    Used by: Telmisartan
  39. DailyMed label: Testosterone cypionate injection
    dailymed_testosterone_cypionate_label
    Official injectable testosterone label; anchors approved hypogonadism context, IM route, contraindications, and androgen adverse effects.
    Used by: Testosterone
  40. DailyMed label: trazodone hydrochloride tablet
    dailymed_trazodone_label
    Trazodone label covering serotonin syndrome, QT/cardiac arrhythmia risk, orthostatic hypotension/syncope, sedation, and priapism.
    Used by: Trazodone
  41. DailyMed label: VYLEESI bremelanotide injection
    dailymed_vyleesi_label
    Bremelanotide label context for acquired generalized HSDD in premenopausal women, subcutaneous route, nausea, blood-pressure, and hyperpigmentation warnings.
    Used by: Bremelanotide
  42. DailyMed label: VYVANSE (lisdexamfetamine dimesylate)
    dailymed_vyvanse_label
    Label for lisdexamfetamine capsules/chewables; ADHD and adult binge-eating-disorder indications plus stimulant misuse, cardiovascular, psychiatric, and appetite warnings.
    Used by: Lisdexamfetamine
  43. DailyMed label: WEGOVY semaglutide injection
    dailymed_wegovy_label
    Official semaglutide obesity-label context for subcutaneous route, titration, contraindications, and adverse-effect warnings.
    Used by: Semaglutide
  44. DailyMed label: ZENZEDI (dextroamphetamine sulfate) tablet
    dailymed_zenzedi_label
    Dextroamphetamine sulfate label with ADHD/narcolepsy use, controlled-substance warning, and cardiovascular/psychiatric cautions.
    Used by: Dextroamphetamine
  45. DailyMed label: ZEPBOUND tirzepatide injection
    dailymed_zepbound_label
    Official tirzepatide obesity-label context for subcutaneous route, dose escalation, contraindications, GI/gallbladder/pancreatitis warnings, and related precautions.
    Used by: Tirzepatide
  46. FDA label for selegiline hydrochloride orally disintegrating tablets
    fda_selegiline_label
    Official drug label.
    Used by: Selegiline
  47. FDA label: Anadrol-50 oxymetholone tablets
    fda_oxymetholone_label
    Official oxymetholone label for anemia context, oral route, and serious hepatic warnings.
    Used by: Oxymetholone
  48. FDA label: Anafranil clomipramine hydrochloride
    fda_clomipramine_label
    Official label.
    Used by: Clomipramine
  49. FDA label: Norvasc amlodipine besylate
    fda_amlodipine_label
    Official label.
    Used by: Amlodipine
  50. FDA label: seladelpar lysine
    fda_seladelpar_label_2026
    Official label identifies seladelpar as a PPAR-delta agonist.
    Used by: Seladelpar
  51. FDA label: Zoloft sertraline hydrochloride
    fda_sertraline_label
    Official label.
    Used by: Sertraline
  52. Tadalafil tablet, film coated - Prescribing Information
    dailymed_tadalafil_label
    DailyMed label for oral tadalafil, including ED/BPH dosing, nitrate/riociguat contraindications, alpha-blocker/antihypertensive cautions, and common adverse effects.
    Used by: PDE5 inhibitors / Cialis / Viagra, Tadalafil / Cialis
  53. VIAGRA (sildenafil citrate) tablets - Prescribing Information
    dailymed_viagra_label
    DailyMed label for oral sildenafil/Viagra, including ED dosing, nitrate/riociguat contraindications, CYP3A4 interaction cautions, and adverse-effect profile.
    Used by: PDE5 inhibitors / Cialis / Viagra, Sildenafil / Viagra

mechanistic

  1. Bioactivity and Compound Identification in Extracts from Three Australian Populations of Portulaca oleracea
    pubmed_portulaca_oleracein_characterization_2025
    Oleracein structural/antioxidant characterization source for purslane chemistry; not direct vascular-dementia efficacy.
    Used by: Oleracein E
  2. Biological activity of the E domain of the IGF-1Ec as addressed by synthetic peptides
    pubmed_mgf_review_2010
    Mechanistic IGF-1Ec/MGF peptide background; not equivalent to direct clinical hypertrophy evidence.
    Used by: PEG-MGF / Pegylated Mechano Growth Factor
  3. Development of Cagrilintide, a Long-Acting Amylin Analogue
    pubmed_cagrilintide_development_2021
    Drug-development paper covering structure/activity work that produced lipidated long-acting cagrilintide for obesity trials.
    Used by: Cagrilintide
  4. Differential DNA-binding and cofactor recruitment are possible determinants of the synthetic steroid YK11-dependent gene expression by androgen receptor
    pubmed_yk11_ar_cofactor_dna_binding_2022
    Mechanistic AR DNA-binding/cofactor-recruitment source; helps explain why YK11 is not interchangeable with nonsteroidal SARMs.
    Used by: YK11
  5. EDR peptide: possible mechanism of gene expression and protein synthesis regulation involved in the pathogenesis of Alzheimer disease
    pubmed_pinealon_edr_alz_2020
    Mechanistic EDR/Pinealon gene-expression paper.
    Used by: Pinealon
  6. Ethylmethylhydroxypyridine Succinate Is an Inhibitor but Not a Substrate of ABCB1 and SLCO1B1
    pubmed_mexidol_transporter_2023
    Transporter-interaction study; useful for mechanism and drug-interaction hypotheses, not efficacy.
    Used by: Mexidol
  7. Intracellular binding site for a D1 receptor positive allosteric modulator
    pubmed_d1_pam_2018
    DETQ/CID D1 PAM binding-site work.
    Used by: No public entries linked.
  8. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept
    pubmed_retatrutide_discovery_clinical_poc_2022
    Discovery and translational pharmacology paper: receptor activity, obese mouse effects, energy-expenditure contribution from glucagon receptor activity, and clinical proof-of-concept bridge.
    Used by: Retatrutide
  9. Mechanism of allosteric modulation of nicotinamide phosphoribosyltransferase to elevate cellular NAD
    pubmed_nampt_allosteric_2023
    NAMPT allosteric activator mechanism; includes P7C3-A20 context.
    Used by: No public entries linked.
  10. Mechanism of dopamine binding and allosteric modulation of the human D1 receptor
    pmc_d1_mechanism_2021
    Structural D1 allostery background.
    Used by: No public entries linked.
  11. New cardioactive steroid saponins and other glycosides from Mexican Tribulus cistoides
    pubmed_tribulus_cistoides_saponins_1996
    Species-specific chemistry source; supports that T. cistoides contains bioactive saponin/glycoside chemistry, not sexual-function efficacy.
    Used by: Tribulus cistoides Extract
  12. Paeonol attenuates inflammation by targeting HMGB1
    pmc_paeonol_hmgb1_2019
    HMGB1/miR-339-5p inflammatory signaling source.
    Used by: Paeonol
  13. Parameters for irreversible inactivation of monoamine oxidase
    pubmed_maoi_irreversible_2020
    MAOI mechanism background.
    Used by: Clorgyline
  14. PGE2 receptor EP2 is indispensable for maintenance of skeletal muscle stem cells
    oxford_pge2_ep2_muscle_stem_2026
    Muscle stem cell EP2/PGE2 mechanism paper.
    Used by: No public entries linked.
  15. Pharmacological inhibition of TRPV3 by natural forsythoside B attenuates pruritus and cytotoxicity of keratinocytes
    sciencedirect_forsythosideb_trpv3_2019
    Related TRPV3-inhibitor source for the same phenylethanoid-glycoside/TRPV3 hair-skin mechanism family; not direct forsythoside A hair-regrowth evidence.
    Used by: Forsythoside A
  16. Phosphatidic acid: a novel mechanical mechanism for how resistance exercise activates mTORC1 signalling
    pmc_phosphatidic_acid_mtor_mechanical_2009
    Mechanistic discussion of phosphatidic acid as part of mechanical activation of mTORC1 in skeletal muscle.
    Used by: Phosphatidic Acid
  17. Production and protein kinase C activation of diacylglycerols containing polymethylene-interrupted PUFA
    pubmed_sciadonic_dag_pkc_2005
    Mechanistic source showing sciadonic acid can be incorporated into signaling lipid species; indirect context for its unusual lipid biology.
    Used by: Sciadonic Acid
  18. Steroids interfere with human carbonic anhydrase activity by alternative binding mechanisms
    pmc_steroids_carbonic_anhydrase_2018
    Steroid derivative interactions with carbonic anhydrases.
    Used by: No public entries linked.
  19. Structural basis for telmisartan-mediated partial activation of PPAR gamma
    nature_telmisartan_ppargamma_structure
    Structural/mechanistic paper.
    Used by: Telmisartan
  20. Structural basis of positive allosteric modulation of metabotropic glutamate receptor activation
    pubmed_mglur_pam_structure_2024
    Structural/mechanistic group II/III mGluR PAM paper.
    Used by: No public entries linked.
  21. The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection
    pubmed_survodutide_candidate_selection_2024
    Biomarker and pharmacological profiling paper explaining candidate selection among dual GCGR/GLP-1R agonists; useful mechanism/translation context.
    Used by: Survodutide
  22. The mitochondria-targeted peptide SS-31 binds lipid bilayers and modulates surface electrostatics
    pubmed_ss31_bilayer_mechanism_2020
    Biophysical mechanism source for SS-31/elamipretide membrane and cardiolipin-linked activity.
    Used by: SS-31 / Elamipretide
  23. Transporter-mediated actions of R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane
    pubmed_bpap_transporter_2003
    Direct BPAP transporter/source pharmacology; helps separate older monoamine-enhancer framing from newer TAAR1 hypotheses.
    Used by: (-)-BPAP
  24. Tricyclic and tetracyclic antidepressants upregulate VMAT2 activity and rescue VMAT2 variants
    pubmed_vmat2_antidepressants_2023
    VMAT2 upregulation/rescue in cellular systems.
    Used by: No public entries linked.

medicinal chemistry

  1. Chemistry-led investigations into the mode of action of NAMPT activators
    pubmed_nampt_activator_discovery_2023
    Medicinal-chemistry source on NAMPT activator mode of action and non-pyridyl activators.
    Used by: No public entries linked.
  2. Discovery and Characterization of CEP-26401, Irdabisant: A Potent, Selective Histamine H3 Receptor Inverse Agonist
    acs_irdabisant_cep26401_2011
    Direct medicinal-chemistry characterization of irdabisant/CEP-26401; supports receptor identity and CNS-drug rationale, not clinical efficacy.
    Used by: Irdabisant
  3. Discovery of the first selective, nonpeptidic orexin 2 receptor agonists
    pubmed_orexin2_agonists_2015
    OX2R agonist field context.
    Used by: Declozindol
  4. Kinetically selective inhibitors of HDAC2 as cognition enhancers
    pubmed_hdac2_inhibitors_2015
    Selective HDAC2 inhibitor feasibility paper.
    Used by: No public entries linked.
  5. Melanocyte-Directed enzyme prodrug therapy: development of second generation prodrugs for targeted treatment of malignant melanoma
    pubmed_melanocyte_directed_prodrugs_2001
    Older tyrosinase-activated prodrug design source; useful as platform precedent only.
    Used by: No public entries linked.
  6. Neuroactive steroid NMDA receptor positive allosteric modulators
    pubmed_nmda_pam_sge301_2019
    SAR leading to SGE-301.
    Used by: No public entries linked.
  7. Novel inhibitors of nicotinamide N-methyltransferase for metabolic disorders
    pubmed_5amino1mq_nnmt_2021
    NNMT inhibitor chemistry; not a human weight-loss trial.
    Used by: 5-Amino-1MQ
  8. Salen-manganese complexes as catalytic scavengers of hydrogen peroxide and cytoprotective agents: structure-activity relationship studies
    pubmed_salen_manganese_sar_2002
    Chemistry/SAR source for salen-manganese SOD/catalase-mimetic properties including EUK-8 and EUK-134 context.
    Used by: EUK-134
  9. SAR investigation and synergistic optimization of setmelanotide yields a potent, selective, and soluble MC4R agonist
    pubmed_sc19_mc4r_sar_2026
    SC19 setmelanotide-analog SAR source; reports MC4R potency/selectivity, improved solubility, and diet-induced obesity mouse efficacy.
    Used by: SC19 MC4R agonist lead
  10. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500
    pubmed_tb500_fragment_characterization_2012
    Direct TB-500 chemistry source: identifies Ac-LKKTETQ, the N-acetylated 17-23 fragment of human thymosin beta-4; not an efficacy study.
    Used by: TB-500 / thymosin beta-4-related products
  11. Synthesis and pharmacological profiling of BQCA analogues as M1 muscarinic allosteric modulators
    pubmed_m1_bqca_2013
    M1 PAM medicinal chemistry and pharmacology.
    Used by: No public entries linked.
  12. Thyromimetics with improved selectivity for thyroid hormone receptor beta
    pubmed_thr_beta_thyromimetics_2004
    Background on TR-beta selective agonist design.
    Used by: Elunetirom

meta analysis

  1. A meta-analysis of randomized trials of telmisartan versus active controls for insulin resistance in hypertensive patients
    pubmed_telmisartan_insulin_meta_2014
    Meta-analysis of RCTs testing whether telmisartan improves insulin-resistance markers versus active antihypertensive comparators.
    Used by: Telmisartan
  2. A systematic review, meta-analysis and meta-regression of the effect of protein supplementation on resistance training-induced gains in muscle mass and strength in healthy adults
    pubmed_protein_resistance_training_meta_2018
    Meta-analysis/meta-regression of dietary protein supplementation during resistance exercise training.
    Used by: Protein Supplementation
  3. Acute Effect of Citrulline Malate on Repetition Performance During Strength Training: A Systematic Review and Meta-Analysis
    pubmed_lcitrulline_strength_meta_2021
    Human strength-training meta-analysis for citrulline malate repetition performance; useful for gym-performance claims.
    Used by: Citrulline / L-Citrulline
  4. Adverse sexual effects of treatment with finasteride or dutasteride for male androgenetic alopecia: a systematic review and meta-analysis
    pubmed_finasteride_sexual_adverse_meta_2018
    Meta-analysis of sexual adverse effects in male androgenetic alopecia treatment with finasteride or dutasteride.
    Used by: Finasteride
  5. Beneficial effects of l-carnitine supplementation for weight management in overweight and obese adults: An updated systematic review and dose-response meta-analysis of randomized controlled trials
    pubmed_lcarnitine_obesity_dose_meta_2020
    Updated RCT dose-response meta-analysis for overweight/obesity indices; supports modest weight-management discussion.
    Used by: L-carnitine
  6. Beta-alanine supplementation to improve exercise capacity and performance: a systematic review and meta-analysis
    pubmed_beta_alanine_performance_meta_2017
    Human exercise-performance meta-analysis for beta-alanine, the main supplement route used to raise skeletal-muscle carnosine.
    Used by: Carnosine / Beta-Alanine
  7. Clomiphene citrate for male infertility: A systematic review and meta-analysis
    pubmed_clomiphene_male_infertility_meta_2023
    Male infertility meta-analysis; anchors fertility-oriented clomiphene claims and endpoint limitations.
    Used by: Clomiphene
  8. Clomiphene citrate for men with hypogonadism: a systematic review and meta-analysis
    pubmed_clomiphene_hypogonadism_meta_2022
    Male hypogonadism systematic review/meta-analysis; supports testosterone/gonadotropin effects while preserving distinction from exogenous TRT.
    Used by: Clomiphene
  9. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials
    pubmed_enclomiphene_serm_hypogonadism_meta_2025
    RCT meta-analysis for clomiphene/enclomiphene in male hypogonadism; useful for HPTA-stimulation framing.
    Used by: Enclomiphene
  10. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis
    pubmed_tadalafil_sildenafil_meta_2017
    Head-to-head tadalafil versus sildenafil systematic review/meta-analysis; useful for duration/tolerability preference framing without implying one is universally superior.
    Used by: PDE5 inhibitors / Cialis / Viagra, Sildenafil / Viagra, Tadalafil / Cialis
  11. Dual orexin receptor antagonists for the treatment of insomnia: systematic review and network meta-analysis
    pubmed_dora_network_meta_2023
    Systematic review/network meta-analysis for DORAs in insomnia; provides class context for vornorexant comparisons.
    Used by: Vornorexant
  12. Effect of beta-hydroxy-beta-methylbutyrate supplementation on muscle loss in older adults
    pubmed_hmb_older_adults_meta_2015
    Older-adult muscle-loss meta-analysis; helps distinguish frailty/catabolic contexts from trained-young-lifter expectations.
    Used by: HMB
  13. Effect of Bimagrumab on body composition: a systematic review and meta-analysis
    pubmed_bimagrumab_bodycomp_meta_2024
    Meta-analysis across bimagrumab studies for body composition and physical-performance context; important for separating lean-mass changes from functional benefit.
    Used by: Bimagrumab
  14. Effect of Daily Vitamin D3 Supplementation on Muscle Health: An Individual Participant Meta-analysis
    pubmed_vitamin_d_muscle_health_ipd_meta_2022
    Individual-participant meta-analysis reporting no broad muscle-health benefit overall, including insufficient participants; useful against overclaiming.
    Used by: Vitamin D / D3
  15. Effect of food sources of nitrate, polyphenols, L-arginine and L-citrulline on endurance exercise performance
    pubmed_lcitrulline_exercise_meta_2021
    Systematic review/meta-analysis of randomized trials for nitric-oxide-related food compounds including L-citrulline and exercise performance.
    Used by: Citrulline / L-Citrulline
  16. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition
    pubmed_glp1_body_composition_network_meta_2025
    Network meta-analysis comparing body-composition effects across GLP-1 receptor agonists and co-agonists.
    Used by: Retatrutide, Semaglutide, Tirzepatide
  17. Effect of L-Arginine Supplementation on Blood Pressure in Adults: A Systematic Review and Dose-Response Meta-analysis
    pubmed_arginine_bp_meta_2022
    Human RCT meta-analysis for blood pressure; useful vascular endpoint context for arginine/NO claims.
    Used by: Arginine
  18. Effect of nebivolol on erectile function: a systematic review and meta-analysis of randomized controlled trials
    pubmed_nebivolol_ed_meta_2025
    Meta-analysis of RCTs comparing nebivolol and metoprolol for erectile-function outcomes.
    Used by: Nebivolol
  19. Effect of vitamin C on endothelial function in health and disease: a systematic review and meta-analysis of randomised controlled trials
    pubmed_vitamin_c_endothelial_meta_2014
    Human RCT meta-analysis for endothelial-function outcomes; anchors vascular claims to flow-mediated/vascular-function evidence rather than generic antioxidant language.
    Used by: Vitamin C / Ascorbic Acid
  20. Effects of carnosine and histidine-containing dipeptides on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis
    pmc_carnosine_hcd_inflammation_meta_2024
    Open-access systematic review/meta-analysis of carnosine and histidine-containing dipeptides for inflammatory and oxidative-stress biomarkers.
    Used by: Carnosine / Beta-Alanine
  21. Effects of exercise, metformin and their combination on glucose metabolism in individuals with abnormal glycaemic control: a systematic review and network meta-analysis
    pubmed_metformin_exercise_glucose_network_meta_2024
    Network meta-analysis comparing exercise, metformin, and combination treatment in prediabetes/T2D; useful for positioning metformin against lifestyle/exercise effects.
    Used by: Metformin
  22. Effects of HMB supplementation during resistance training on strength and body composition
    pubmed_hmb_training_meta_2009
    Found trivial effects in trained lifters and small effects in untrained men.
    Used by: HMB
  23. Effects of L-carnitine supplementation on weight loss and body composition
    pubmed_lcarnitine_weight_meta_2020
    Randomized clinical-trial meta-analysis; mostly oral supplementation, not injectable or non-trial use.
    Used by: L-carnitine
  24. Effects of L-citrulline supplementation on blood pressure: A systematic review and meta-analysis
    pubmed_lcitrulline_bp_meta_2019
    Human clinical-trial meta-analysis; supports modest oral citrulline blood-pressure signal with dose/population caveats.
    Used by: Citrulline / L-Citrulline
  25. Effects of leucine-rich protein supplements in older adults with sarcopenia: A systematic review and meta-analysis of randomized controlled trials
    pubmed_leucine_sarcopenia_meta_2022
    RCT meta-analysis in sarcopenic older adults; relevant to leucine-rich protein rather than isolated leucine as a drug-like anabolic.
    Used by: Leucine
  26. Effects of spirulina supplementation alone or with exercise on cardiometabolic health in overweight and obese adults
    pubmed_spirulina_cardiometabolic_meta_2025
    Human systematic review/meta-analysis of spirulina cardiometabolic endpoints; does not isolate purified phycocyanobilin.
    Used by: Phycocyanobilin / Spirulina
  27. Effects of vitamin C supplementation on blood pressure: a meta-analysis of randomized controlled trials
    pubmed_vitamin_c_bp_meta_2012
    RCT meta-analysis for oral vitamin C and blood-pressure outcomes; useful cardiovascular-adjacent context with short-trial limitations.
    Used by: Vitamin C / Ascorbic Acid
  28. Effects of vitamin D supplementation on maximal strength and power in athletes: a systematic review and meta-analysis of randomized controlled trials
    pubmed_vitamin_d_strength_power_athletes_meta_2023
    Athlete-focused RCT meta-analysis for strength and power outcomes; better fit for performance framing than generic deficiency sources alone.
    Used by: Vitamin D / D3
  29. Efficacy and Safety of Berberine Alone for Several Metabolic Disorders: A Systematic Review and Meta-Analysis of Randomized Clinical Trials
    pubmed_berberine_metabolic_disorders_meta_2021
    Meta-analysis of randomized trials across metabolic disorders; useful broad human anchor for glycemic, lipid, BMI, and safety signals.
    Used by: Berberine
  30. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis
    pubmed_cagrilintide_cagrisema_meta_2024
    Meta-analysis covering cagrilintide alone and CagriSema; useful synthesis but limited by few RCTs and combination attribution issues.
    Used by: Cagrilintide, Cagrilintide + Semaglutide / CagriSema
  31. Efficacy and safety of cagrilintide plus semaglutide for overweight and obesity: systematic review and meta-analysis
    pubmed_cagrisema_meta_2026
    Human evidence synthesis for CagriSema; useful for keeping combo claims separate from standalone semaglutide.
    Used by: Cagrilintide, Cagrilintide + Semaglutide / CagriSema
  32. Efficacy and safety of Mazdutide on weight loss among diabetic and non-diabetic patients: a systematic review and meta-analysis of randomized controlled trials
    pubmed_mazdutide_meta_2024
    RCT meta-analysis of mazdutide weight-loss efficacy and safety across diabetic and non-diabetic adults.
    Used by: Mazdutide
  33. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis
    pubmed_pde5_ed_network_meta_2020
    Network meta-analysis comparing PDE5 inhibitors for ED efficacy and adverse effects; useful class-level efficacy/safety context.
    Used by: PDE5 inhibitors / Cialis / Viagra, Sildenafil / Viagra
  34. Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis
    pubmed_semaglutide_obesity_meta_2023
    RCT meta-analysis in adults with obesity/overweight without diabetes; supports weight-loss efficacy and GI/discontinuation safety framing beyond a single STEP trial.
    Used by: Semaglutide
  35. Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis
    pubmed_survodutide_meta_2025
    Meta-analysis of RCTs evaluating survodutide glycemic, weight, waist, lipid, blood-pressure, and adverse-event outcomes.
    Used by: Survodutide
  36. Efficacy of Sildenafil on healthy humans in high-altitude hypoxia at rest and during exercise: A meta-analysis
    pubmed_sildenafil_hypoxia_meta_2024
    Recent meta-analysis on sildenafil in healthy humans exposed to high-altitude hypoxia; supports route-specific and environment-specific performance context.
    Used by: PDE5 inhibitors / Cialis / Viagra, Sildenafil / Viagra
  37. Efficacy, Acceptability, and Tolerability of Lisdexamfetamine, Mixed Amphetamine Salts, Methylphenidate, and Modafinil in Adult ADHD
    sage_adult_adhd_stimulants_meta_2019
    Systematic review/meta-analysis comparing adult ADHD stimulant and modafinil trial evidence.
    Used by: Dextroamphetamine, Lisdexamfetamine, Methylphenidate
  38. Glucose-lowering effect of berberine on type 2 diabetes: A systematic review and meta-analysis
    pubmed_berberine_t2d_glucose_meta_2022
    Type 2 diabetes-focused systematic review/meta-analysis; anchors berberine glucose-lowering claims to human RCT literature rather than ?natural Ozempic? marketing.
    Used by: Berberine
  39. Gonadotropins for pubertal induction in males with hypogonadotropic hypogonadism: systematic review and meta-analysis
    pubmed_hmg_puberty_induction_meta_2024
    Systematic review/meta-analysis relevant to FSH/LH-containing gonadotropin therapy and testicular development in male HH.
    Used by: HMG / Menotropins
  40. HMB does not improve resistance-exercise changes in young subjects
    pubmed_hmb_young_meta_2020
    Systematic review and meta-analysis in young subjects.
    Used by: HMB
  41. Impact of GH administration on athletic performance in healthy young adults: A systematic review and meta-analysis of placebo-controlled trials
    pubmed_hgh_athletic_performance_meta_2017
    Healthy-adult placebo-controlled GH evidence synthesis; useful for separating lean-mass/body-composition effects from actual athletic-performance outcomes.
    Used by: Human Growth Hormone / Somatropin
  42. Influence of study characteristics, methodological rigour and publication bias on efficacy of pharmacotherapy in obsessive-compulsive disorder
    pmc_ocd_pharmacotherapy_meta_2022
    Meta-analysis of randomized placebo-controlled OCD pharmacotherapy trials including clomipramine; useful indication-level context.
    Used by: Clomipramine
  43. Intranasal oxytocin administration but not peripheral oxytocin regulates behaviors of attachment insecurity: a meta-analysis
    pubmed_intranasal_oxytocin_social_cognition_meta_2021
    Human intranasal oxytocin meta-analysis for attachment/social-behavior context.
    Used by: Oxytocin
  44. Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis
    pubmed_pde5_cvd_outcomes_meta_2024
    Long-term cardiovascular-outcome meta-analysis; mostly observational/heterogeneous evidence, useful as hypothesis-generating rather than proof of mortality benefit.
    Used by: PDE5 inhibitors / Cialis / Viagra, Tadalafil / Cialis
  45. Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    pubmed_semaglutide_longterm_obesity_meta_2024
    Longer-duration RCT meta-analysis of semaglutide 2.4 mg in overweight/obesity without diabetes; useful for durability and safety synthesis.
    Used by: Semaglutide
  46. Meta-analysis of trials comparing toremifene with tamoxifen in postmenopausal women with breast cancer
    pubmed_toremifene_breast_cancer_meta_1999
    Clinical breast-cancer SERM evidence base; relevant to approved oncology context, not proof of PCT utility.
    Used by: Toremifene
  47. Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis
    pubmed_metformin_antipsychotic_weight_meta_2016
    Double-blind placebo-controlled trial meta-analysis for metformin in antipsychotic-associated weight gain; useful non-diabetes body-weight context.
    Used by: Metformin
  48. Nandrolone Decanoate for Postmenopausal Osteoporosis: A Systematic Review and Meta-Analysis of Randomized Trials
    pubmed_nandrolone_osteoporosis_meta_2025
    Randomized-trial evidence synthesis in postmenopausal osteoporosis; useful for bone/anabolic clinical context and adverse-effect framing.
    Used by: Nandrolone Decanoate
  49. Oral phosphodiesterase-5 inhibitors and hormonal treatments for erectile dysfunction: a systematic review and meta-analysis
    pubmed_pde5_ed_meta_2009
    Broad ED systematic review/meta-analysis covering sildenafil, tadalafil, vardenafil, and hormonal comparators.
    Used by: PDE5 inhibitors / Cialis / Viagra, Sildenafil / Viagra
  50. Ospemifene for the treatment of vulvar and vaginal atrophy: a meta-analysis of randomized trials
    pubmed_ospemifene_meta_2019
    Randomized-trial meta-analysis for vulvar/vaginal atrophy; direct clinical efficacy context for ospemifene.
    Used by: Ospemifene
  51. Oxandrolone use in adult burn patients. Systematic review and meta-analysis
    pubmed_oxandrolone_adult_burns_meta_2014
    Adult burn-patient evidence synthesis; supports catabolic-injury use, not general physique extrapolation.
    Used by: Oxandrolone
  52. The effect of (L-)carnitine on weight loss in adults: a systematic review and meta-analysis of randomized controlled trials
    pubmed_lcarnitine_weight_meta_2016
    Adult RCT meta-analysis for L-carnitine and weight loss; useful broad body-weight context with heterogeneity caveats.
    Used by: L-carnitine
  53. The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
    pubmed_berberine_t2d_profiles_meta_2022
    RCT meta-analysis of berberine in type 2 diabetes; supports glycemic and metabolic-profile claims with study-quality caveats.
    Used by: Berberine
  54. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials
    pubmed_berberine_obesity_inflammation_meta_2020
    RCT meta-analysis on berberine and anthropometrics, CRP, and liver enzymes; useful obesity/inflammation/liver-marker synthesis.
    Used by: Berberine
  55. The effect of glutamine supplementation on athletic performance, body composition, and immune function: A systematic review and a meta-analysis of clinical trials
    pubmed_glutamine_sports_meta_2019
    Clinical-trial meta-analysis for sport/body-composition/immune claims; useful for showing broad performance claims are limited and context dependent.
    Used by: Glutamine / L-Glutamine
  56. The effect of istradefylline for Parkinson's disease: a meta-analysis
    pmc_istradefylline_pd_meta_2017
    A2A antagonist human randomized-trial meta-analysis for Parkinson disease OFF-time context.
    Used by: No public entries linked.
  57. The effect of L-carnitine supplementation on exercise-induced muscle damage: systematic review and meta-analysis
    pubmed_lcarnitine_exercise_damage_meta_2020
    RCT meta-analysis for muscle soreness and muscle-damage markers; separate from fat-loss and injectable-use claims.
    Used by: L-carnitine
  58. The effectiveness of leucine on muscle protein synthesis, lean body mass and leg lean mass accretion in older people: a systematic review and meta-analysis
    pubmed_leucine_older_meta_2015
    Older-adult meta-analysis separating acute MPS effects from lean-mass accretion; useful for why leucine is plausible but bounded.
    Used by: Leucine
  59. The effectiveness of treatments for androgenetic alopecia: a systematic review and meta-analysis
    pubmed_minoxidil_aga_meta_2017
    Parent-drug human evidence for minoxidil in androgenetic alopecia; only indirectly relevant to tyrosinase-cleaved minoxidil prodrug ideas.
    Used by: Keraxidil
  60. The effects of creatine supplementation on cognitive function in adults: a systematic review and meta-analysis
    pubmed_creatine_cognition_meta_2024
    Adult cognitive-function meta-analysis for creatine supplementation; useful broad context beyond sleep deprivation.
    Used by: Creatine
  61. The Effects of L-Carnitine Supplementation on Weight Loss, Glycemic Control, and Cardiovascular Risk Factors in Patients With Type 2 Diabetes: A Systematic Review and Dose-response Meta-Analysis of Randomized Controlled Trials
    pubmed_lcarnitine_t2d_dose_meta_2024
    Dose-response RCT meta-analysis in type 2 diabetes; supports glycemic, weight, and cardiovascular-risk-marker context for oral L-carnitine.
    Used by: L-carnitine
  62. The effects of oxandrolone on severe burn injury: a systematic review and meta-analysis
    pubmed_oxandrolone_burns_meta_2019
    Human severe-burn evidence synthesis; supports catabolic-injury use, not general physique use.
    Used by: Oxandrolone
  63. The effects of vitamin C and E on exercise-induced physiological adaptations: a systematic review and meta-analysis of randomized controlled trials
    pubmed_vitamin_c_e_exercise_adaptation_meta_2019
    Human RCT meta-analysis across vitamin C/E and exercise adaptations; useful for keeping the antioxidant-blunting concern proportionate.
    Used by: Vitamin C / Ascorbic Acid
  64. The Muscle Carnosine Response to Beta-Alanine Supplementation: A Systematic Review With Bayesian Individual and Aggregate Data E-Max Model and Meta-Analysis
    frontiers_beta_alanine_muscle_carnosine_meta_2020
    Direct muscle-carnosine-loading source; supports the distinction between carnosine as the intramuscular target and beta-alanine as the limiting precursor used in studies.
    Used by: Carnosine / Beta-Alanine
  65. The Potential Role of Arginine Supplements on Erectile Dysfunction: A Systematic Review and Meta-Analysis
    pubmed_arginine_ed_meta_2019
    Human ED supplement meta-analysis; provides NO/endothelial clinical context separate from the Abeta animal model claim.
    Used by: Arginine
  66. Trazodone changed the polysomnographic sleep architecture in insomnia disorder: a systematic review and meta-analysis
    nature_trazodone_sleep_architecture_meta_2022
    Systematic review/meta-analysis of trazodone effects on PSG sleep-architecture parameters in insomnia.
    Used by: Trazodone
  67. Tribulus terrestris for management of patients with erectile dysfunction: a systematic review and meta-analysis of randomized trials
    pubmed_tribulus_terrestris_ed_meta_2025
    Genus-adjacent human ED evidence for T. terrestris, not T. cistoides; useful only as broader Tribulus context and should not be over-applied.
    Used by: Tribulus cistoides Extract

preclinical

  1. 14-3-3epsilon-VDAC1 interactions in androgen formation / TVS167 peptide
    pubmed_tvs167_2014
    Foundational TVS167/RdVTQ-lineage mechanism used to rationalize ACE-167-like claims; not a direct clinical source for named ACE-167 products.
    Used by: ACE-167
  2. 2-PMPA increases electroconvulsion threshold and enhances valproate antiseizure action in mice
    pubmed_2pmpa_seizure_2006
    GCPII inhibitor seizure-model paper.
    Used by: No public entries linked.
  3. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD decline
    pubmed_cd38_78c_2018
    78c mouse aging/metabolic dysfunction paper.
    Used by: No public entries linked.
  4. A selective and membrane-permeable NNMT inhibitor reverses high fat diet-induced obesity in mice
    pubmed_5amino1mq_dio_2018
    Direct 5-amino-1MQ/NNMT-inhibitor mouse obesity source; supports mechanism and animal signal, not human fat-loss efficacy.
    Used by: 5-Amino-1MQ
  5. A synthetic ERR agonist alleviates metabolic syndrome
    pubmed_slupp332_metabolic_syndrome_2024
    SLU-PP-332 preclinical metabolic-syndrome model; adjacent to exercise-mimetic and fat-oxidation rationale.
    Used by: SLU-PP-332
  6. ACE-031, a soluble activin type IIB receptor, increases muscle mass and strength in the common marmoset
    plos_ace031_marmoset_2026
    Common marmoset preclinical study reporting lean-mass and muscle-strength effects.
    Used by: ACE-031
  7. Activation of the EPOR-beta common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes
    pubmed_cibinetide_diabetic_wound_mouse_2017
    Genetic diabetic mouse wound-healing model; mechanistic bridge for EPOR-beta common receptor/innate repair receptor activation and tissue repair.
    Used by: ARA-290 / Cibinetide
  8. ADX71441, a novel, potent and selective positive allosteric modulator of the GABA(B) receptor, shows efficacy in rodent models of overactive bladder
    pubmed_gabab_adx71441_oab_2013
    Direct GABA-B PAM source in a separate rodent disease model, adding mechanism breadth beyond alcohol-seeking models.
    Used by: No public entries linked.
  9. Allosteric modulation of related ligand-gated ion channels enhances cognition
    pubmed_522054_ltp
    Mechanistic/preclinical 522-054 source.
    Used by: 522-054
  10. An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity
    pubmed_slupp915_exercise_2026
    Orally active pan-ERR agonist follow-on to SLU-PP-332; useful class/mechanism context, still non-human efficacy.
    Used by: SLU-PP-332
  11. An orally active SARM is efficacious on bone, muscle, and sex function with reduced impact on prostate
    pubmed_bms564929_preclinical_2006
    Preclinical tissue-selectivity work for orally active nonsteroidal SARMs including the BMS lineage.
    Used by: BMS-564929
  12. Anti-myostatin antibody increases muscle mass and strength and improves insulin sensitivity in old mice
    pubmed_antimyostatin_old_mice_insulin_2016
    Old-mouse anti-myostatin antibody study showing increased muscle mass/strength and improved insulin-stimulated glucose metabolism; mechanism-adjacent support for myostatin blockade.
    Used by: Trevogrumab
  13. Astaxanthin mitigates radiation-induced erectile dysfunction in a rat model
    nature_astaxanthin_ried_2025
    Rat radiation-induced erectile dysfunction and corpus cavernosum protection source.
    Used by: Astaxanthin
  14. Baicalin increases hair follicle development via Wnt/beta-catenin signaling
    pubmed_baicalin_hair_wnt_2018
    Mouse and dermal papilla cell hair-follicle mechanism source.
    Used by: Baicalin
  15. Baicalin, a flavonoid, affects the activity of human dermal papilla cells and promotes anagen induction in mice
    pubmed_baicalin_dermal_papilla_2015
    Human dermal papilla-cell and mouse anagen-induction study; supports baicalin hair-growth mechanism while remaining non-human outcome evidence.
    Used by: Baicalin
  16. Batatasin III alleviates slow transit constipation by regulating gut microbiota and inhibiting the NLRP3-IL-1beta pathway
    pubmed_batatasin_constipation_microbiota_2025
    Loperamide-induced slow-transit constipation mouse study using transit, fecal, inflammatory, neurotransmitter, and 16S microbiome endpoints.
    Used by: Batatasin III
  17. Batatasin III, a Constituent of Dendrobium scabrilingue, Improves Murine Pain-like Behaviors with a Favorable CNS Safety Profile
    pubmed_batatasin_pain_cns_mouse_2022
    Mouse Batatasin III pharmacology source; supports broader bioactivity and CNS/pain safety context, not constipation efficacy.
    Used by: Batatasin III
  18. Betulinic acid ameliorates cavernous nerve injury-induced erectile dysfunction through Nrf2/HO-1 pathway activation
    pubmed_betulinic_ed_nrf2_2026
    Direct rat cavernous-nerve-injury erectile-dysfunction paper; supports the specific Nrf2/HO-1 and mitochondrial-apoptosis claim but is not human ED evidence.
    Used by: Betulinic Acid
  19. BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
    pubmed_survodutide_discovery_preclinical_2022
    Discovery/preclinical pharmacology paper for survodutide/BI 456906; receptor agonism and rodent anti-obesity pharmacology support the dual GLP-1/glucagon mechanism.
    Used by: Survodutide
  20. BPC 157 accelerates healing of transected rat Achilles tendon
    pubmed_bpc157_achilles_2003
    Rat tendon model.
    Used by: BPC-157
  21. Brain-targeting bioprecursor prodrug of estradiol alleviates hot flushes without peripheral hormonal effects
    pubmed_dhed_hot_flush_2016
    DHED brain-selective estradiol prodrug animal work.
    Used by: No public entries linked.
  22. CD38 inhibitor 78c increases mice lifespan and healthspan in a model of chronological aging
    pmc_cd38_lifespan_2022
    Mouse lifespan/healthspan paper; not human anti-aging evidence.
    Used by: No public entries linked.
  23. Chemical optimization of the exercise mimetic SLU-PP-332
    sciencedirect_slupp332_sar_2026
    2026 SAR paper.
    Used by: SLU-PP-332
  24. Cibinetide dampens innate immune cell functions thus ameliorating the course of experimental colitis
    pubmed_cibinetide_colitis_mouse_2017
    Experimental colitis model supporting anti-inflammatory innate-immune effects of cibinetide; useful for mechanism breadth, not a wellness claim.
    Used by: ARA-290 / Cibinetide
  25. Citrulline regulates macrophage metabolism and inflammation to counter aging in mice
    pmc_citrulline_macrophage_aging_2025
    Science Advances mouse/mechanistic source linking citrulline to macrophage metabolism, inflammation, and aging phenotypes.
    Used by: Citrulline / L-Citrulline
  26. Comparison of morphine, oxycodone and SR-17018 for tolerance and efficacy in mouse pain models
    pubmed_sr17018_comparison_2020
    Preclinical comparative pain data.
    Used by: SR-17018
  27. Cortico-amygdala-striatal activation by modafinil/flecainide combination
    pubmed_modafinil_flecainide_2018
    Rodent FDG-PET support for THN102 mechanism.
    Used by: Flecainide, THN102
  28. Corylin Inhibits Vascular Cell Inflammation, Proliferation and Migration and Reduces Atherosclerosis in ApoE-Deficient Mice
    pubmed_corylin_atherosclerosis_mouse_2020
    Corylin vascular-inflammation/atherosclerosis mouse and cell source; useful related anti-inflammatory/metabolic-aging mechanism context.
    Used by: Corylin
  29. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model
    pubmed_kpv_inflammatory_bowel_2016
    Murine colitis-associated cancer model with therapeutic KPV/PepT1 context.
    Used by: KPV
  30. Critical role of PepT1 in promoting colitis-associated cancer and therapeutic benefits of the anti-inflammatory PepT1-mediated tripeptide KPV in a murine model
    pmc_kpv_colitis_cancer_2016
    Mouse colitis-associated cancer and human-biopsy mechanistic paper; supports PepT1-mediated KPV delivery, reduced inflammation/tumor burden in models, and gut-targeted rationale.
    Used by: KPV
  31. Dehydroevodiamine HCl enhances cognitive function in memory-impaired rat models
    pubmed_dehydroevodiamine_hcl_2017
    Scopolamine and Abeta-infused rat cognition models.
    Used by: Dehydroevodiamine HCl
  32. Dehydroevodiamine HCl Improves Stress-Induced Memory Impairments and Depression Like Behavior in Rats
    pmc_dehydroevodiamine_stress_2014
    Additional rat behavioral source; useful for stress-linked memory context, still non-human.
    Used by: Dehydroevodiamine HCl
  33. Dehydroevodiamine.HCl prevents impairment of learning and memory and neuronal loss in rat models of cognitive disturbance
    pubmed_dehydroevodiamine_memory_2000
    Earlier rat cognitive-disturbance source for DHED memory and neuronal-loss claims.
    Used by: Dehydroevodiamine HCl
  34. Design and in vivo activity of A3 adenosine receptor agonist prodrugs
    pmc_a3_agonist_prodrugs_2020
    A3 agonist prodrug medicinal chemistry and in vivo work.
    Used by: No public entries linked.
  35. Design, synthesis, and preclinical characterization of RAD140
    pubmed_rad140_preclinical_2010
    Discovery and preclinical characterization of RAD140 as a SARM.
    Used by: RAD140
  36. Design, Synthesis, anti-inflammatory activity Evaluation, preliminary exploration of the Mechanism, molecule Docking, and structure-activity relationship analysis of batatasin III analogs
    pubmed_batatasin_analogs_inflammation_2023
    Batatasin III analog anti-inflammatory pharmacology and SAR source for inflammatory-mechanism plausibility.
    Used by: Batatasin III
  37. Development of CVN424: A Selective and Novel GPR6 Inverse Agonist Effective in Models of Parkinson Disease
    pubmed_cvn424_development_2021
    Preclinical pharmacology and Parkinson disease model source for GPR6 inverse agonism.
    Used by: CVN424
  38. Dieckol attenuates endothelial dysfunction via Th17/Treg balance in spontaneously hypertensive rats
    pubmed_dieckol_endothelial_shr_2021
    Ecklonia cava/dieckol, peNOS/eNOS, nitrate/nitrite, NADPH oxidase, Treg/Th17 source.
    Used by: Dieckol
  39. Differential effects of des IGF-1 on Erks, AKT-1 and P70 S6K activation in mouse skeletal and cardiac muscle
    pubmed_des_igf1_skeletal_cardiac_muscle_2002
    Mouse skeletal/cardiac muscle signaling study; useful for both muscle rationale and cardiac-growth caution.
    Used by: IGF-1 LR3 / DES(1-3)IGF-1
  40. Discovery of piperlongumine as a potential novel lead for the development of senolytic agents
    pmc_piperlongumine_senolytic_2016
    Direct senolytic-discovery paper for piperlongumine; mostly cellular/preclinical and not human anti-aging evidence.
    Used by: Piperlongumine
  41. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease
    pubmed_p21_ad_model_2017
    P21/P021 preclinical Alzheimer-model anchor; no approved or mature human data.
    Used by: P21 / P021 Peptide
  42. Dose-Responses Relationship in Glucose Lowering and Gut Dysbiosis to Saskatoon Berry Powder Supplementation in High Fat-High Sucrose Diet-Induced Insulin Resistant Mice
    pmc_saskatoon_berry_dose_response_mouse_2021
    Mouse dose-response study for Saskatoon berry powder, glucose/lipid/inflammation markers, and gut dysbiosis.
    Used by: Saskatoon Berry
  43. Effect of pineal peptide on parameters of the biological age and life span in mice
    pubmed_epitalon_lifespan_mice_2001
    Mouse lifespan/aging-parameter study with subcutaneous synthetic tetrapeptide Epithalon.
    Used by: Epitalon / Epithalon
  44. Endogenous tyrosinase-catalyzed therapeutics
    pubmed_tyrosinase_therapeutics_2025
    Modern tyrosinase-catalyzed therapeutic/prodrug strategy source; general platform support, not an estradiol or RAR-gamma analog study.
    Used by: No public entries linked.
  45. Epithalon decelerates aging and suppresses development of breast adenocarcinomas in transgenic HER-2/neu mice
    pubmed_epithalon_her2_mice_2002
    Transgenic mouse study reporting lifespan and tumor-development effects; important for both longevity rationale and cancer-biology caveats.
    Used by: Epitalon / Epithalon
  46. Eucommia ulmoides leaf extract improves erectile dysfunction in diabetic rats
    pmc_eucommia_ed_2019
    STZ diabetic rat erectile function, Akt-eNOS, NO, oxidative stress, and HPG-axis source.
    Used by: Eucommia ulmoides Leaf Extract
  47. Exploring the beneficial effects of GHK-Cu on an experimental model of colitis and the underlying mechanisms
    pubmed_ghkcu_colitis_mouse_2025
    DSS mouse colitis model linking GHK-Cu to epithelial barrier, inflammatory cytokines, and SIRT1/STAT3 signaling; useful for anti-inflammatory mechanism breadth.
    Used by: GHK-Cu
  48. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank
    pubmed_selank_immune_gene_expression_2011
    Mouse spleen inflammatory-gene-expression study for Selank and fragments.
    Used by: Selank
  49. Fenfluramine modulates anti-amnesic effects induced by sigma-1 receptor agonists
    pubmed_fenfluramine_sigma1_2022
    Sigma-1 positive modulation context.
    Used by: Fenfluramine
  50. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates
    pubmed_follistatin_nhp_gene_delivery_2009
    AAV1-FS344 non-human-primate study reporting local muscle size and strength effects after intramuscular gene delivery; key translational mechanism source.
    Used by: Follistatin / FS344
  51. Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin
    pubmed_follistatin_activin_myostatin_muscle_2009
    Mouse/mechanistic study showing follistatin muscle effects involve both myostatin and activin inhibition plus satellite-cell proliferation, not a clean myostatin-only switch.
    Used by: Follistatin / FS344
  52. Food-derived inositol derivatives mitigate high-fat diet-induced adiposity
    sciencedirect_inositol_derivatives_adiposity_2026
    Mouse adiposity, inflammation, and adipocyte browning source.
    Used by: No public entries linked.
  53. Forsythoside A alleviates androgenetic alopecia by selectively inhibiting TRPV3 channels in mice
    pubmed_forsythosidea_trpv3_2025
    Mouse DHT-induced hair regrowth inhibition model and TRPV3 mechanism.
    Used by: Forsythoside A
  54. FOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
    pubmed_foxo4dri_leydig_2020
    Aged-mouse endocrine senolytic rationale for FOXO4-DRI.
    Used by: FOXO4-DRI
  55. From gains to gaps? How Selective Androgen Receptor Modulator (SARM) YK11 impact hippocampal function: In silico, in vivo, and ex vivo perspectives
    pubmed_yk11_hippocampal_function_2024
    Integrated preclinical/in silico hippocampal-function source for YK11 safety concerns.
    Used by: YK11
  56. G protein signaling-biased agonist at the mu-opioid receptor reverses morphine tolerance
    pubmed_sr17018_tolerance_2019
    Mouse data for SR-17018.
    Used by: SR-17018
  57. GABA-B PAM ADX71441 attenuates alcohol self-administration and relapse in rats
    pubmed_gabab_adx71441_alcohol_2017
    GABA-B PAM addiction-model paper.
    Used by: No public entries linked.
  58. GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates
    nature_gdf8_activin_glp1_animals_2025
    Mechanism-adjacent mouse and non-human-primate study supporting the COURAGE logic: GDF8 plus activin A blockade during semaglutide exposure preserved or increased lean mass while increasing fat loss.
    Used by: Garetosmab, Trevogrumab
  59. Gellan gum prevents non-alcoholic fatty liver disease by modulating the gut microbiota and metabolites
    pubmed_gellan_gum_nafld_microbiota_2022
    Mouse NAFLD and in vitro fermentation study reporting gellan-gum effects on gut microbiota, SCFAs/metabolites, liver inflammation, and lipid metabolism.
    Used by: Gellan Gum
  60. GHK-Cu-liposomes accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis
    pubmed_ghkcu_wound_liposomes_mouse_2017
    Mouse scald-wound and HUVEC study; GHK-Cu liposomes promoted endothelial-cell proliferation, VEGF/FGF-2/cell-cycle proteins, angiogenesis markers, and faster wound closure.
    Used by: GHK, GHK-Cu
  61. HDAC2 negatively regulates memory formation and synaptic plasticity
    pubmed_hdac2_memory_2009
    Foundational HDAC2 memory/plasticity paper.
    Used by: No public entries linked.
  62. Herring oil rich in long-chain monounsaturated fatty acid lowers plasma lipids and modulates fatty acid composition, oxidation, and inflammation in rats
    pubmed_cetoleic_herring_oil_lipids_2025
    Cetoleic-acid-rich herring-oil animal and in vitro source; supports lipid-metabolism plausibility adjacent to the human LDL trial.
    Used by: Cetoleic Acid Concentrate
  63. High-molecular weight hyaluronic acid protects against colitis by remodeling microbiota and restoring barrier function
    sciencedirect_hmw_ha_colitis_2026
    Molecular-weight-dependent hyaluronic acid colitis model.
    Used by: High-Molecular-Weight Hyaluronic Acid, Hyaluronic Acid / Sodium Hyaluronate
  64. Human growth hormone-releasing factor 1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats
    pubmed_cjc1295_albumin_bioconjugate_2005
    Preclinical medicinal-biology source identifying CJC-1295 as a long-lasting GHRH analog; route and human benefit cannot be inferred from this alone.
    Used by: CJC-1295, CJC-1295 No DAC / Modified GRF(1-29)
  65. Human skeletal muscle atrophy signatures identify ursolic acid as a compound that increases muscle mass
    pubmed_ursolic_mrna_muscle_2011
    Mouse muscle atrophy and hypertrophy source.
    Used by: Ursolic Acid
  66. Hyaluronan-induced alterations of the gut microbiome protects mice against Citrobacter rodentium infection and intestinal inflammation
    pubmed_hyaluronan_microbiota_colitis_2021
    Mouse microbiota-transfer and colitis/infection evidence for HA-gut-microbiome immune effects.
    Used by: High-Molecular-Weight Hyaluronic Acid
  67. Imidazenil: a new partial positive allosteric modulator of GABA action at GABAA receptors
    pubmed_imidazenil_gabaa_partial_pam_1993
    Foundational imidazenil GABA-A partial PAM and anticonflict/anticonvulsant pharmacology.
    Used by: Imidazenil
  68. Impact of anthocyanin component and metabolite of Saskatoon berry on gut microbiome and relationship with fecal short chain fatty acids in diet-induced insulin resistant mice
    sciencedirect_saskatoon_berry_scfa_mouse_2023
    Mouse study connecting Saskatoon berry anthocyanins/metabolites to gut microbiome and fecal SCFA patterns.
    Used by: Saskatoon Berry
  69. Improvement of Islet Allograft Function Using Cibinetide, an Innate Repair Receptor Ligand
    pubmed_cibinetide_islet_allograft_2020
    Islet allograft preclinical study linking cibinetide to innate repair receptor ligand activity and graft-function support.
    Used by: ARA-290 / Cibinetide
  70. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment
    pubmed_aod9604_obese_mice_2001
    Foundational obese-mouse source for hGH C-terminal fragment/AOD9604 fat-oxidation rationale; does not establish human efficacy.
    Used by: AOD9604
  71. Increased weight gain, nitrogen retention and muscle protein synthesis following treatment of diabetic rats with insulin-like growth factor-I and des(1-3)IGF-I
    pubmed_des13igf1_diabetic_rats_1991
    Diabetic-rat anabolic/protein-synthesis study for IGF-I and DES(1-3)IGF-I.
    Used by: IGF-1 LR3 / DES(1-3)IGF-1
  72. Influence of the 5-HT2C receptor antagonist, SB-242084, in tests of anxiety
    sciencedirect_sb242084_anxiety_2002
    Behavioral pharmacology source for selective 5-HT2C antagonism in anxiety models; non-human only.
    Used by: No public entries linked.
  73. Ipamorelin, the first selective growth hormone secretagogue
    pubmed_ipamorelin_1998
    Discovery and pharmacology paper.
    Used by: Ipamorelin
  74. KL1 domain of Klotho enhances cognition in young and aging mice
    pmc_kl1_cognition_2022
    Klotho fragment mouse cognition paper.
    Used by: No public entries linked.
  75. KY19382, a novel activator of Wnt/beta-catenin signalling, promotes hair regrowth and hair follicle neogenesis
    pmc_ky19382_hair_regrowth_2021
    Adjacent Wnt/CXXC5-Dvl hair-regrowth source; useful for hair biology context around competing-peptide approaches.
    Used by: No public entries linked.
  76. Lack of tolerance and dependence to repeated administration of the partial benzodiazepine receptor agonist imidazenil in rats
    pubmed_imidazenil_dependence_rat_1994
    Direct imidazenil rat tolerance/dependence source; relevant to liability hypotheses but not proof of human safety.
    Used by: Imidazenil
  77. Lemon myrtle extract and casuarinin activate skeletal muscle satellite cells
    pubmed_lemon_myrtle_satellite_cells_2022
    Mechanistic satellite-cell source for lemon myrtle.
    Used by: Lemon Myrtle Extract
  78. Leonurine Attenuates Obesity-Related Vascular Dysfunction and Inflammation
    pubmed_leonurine_vascular_dysfunction_2022
    Obesity-related vascular dysfunction model; supports inflammation/endothelial context adjacent to atherosclerosis claims.
    Used by: Leonurine
  79. Leonurine prevents atherosclerosis via ABCA1 and ABCG1 upregulation
    pubmed_leonurine_abca1_2017
    THP-1 foam cell and apoE knockout mouse atherogenesis source.
    Used by: Leonurine
  80. Ligandrol lowers endurance and negatively affects lipid and hormonal profile of male rats
    pubmed_ligandrol_endurance_lipids_hormones_rat_2025
    Male-rat study reporting endurance, lipid, and hormonal downsides; useful counterweight to lean-mass-only SARM claims.
    Used by: Ligandrol
  81. Limiting De Novo Lipogenesis Unlocks the Thermogenic Potential of Glucose in Brown Fat
    researchsquare_bat_dnl_thermogenesis_2026
    2026 preprint; not a mirabegron trial, but supports the related BAT idea that beta-adrenergic/glucose-driven thermogenesis depends on whether glucose is diverted into de novo lipogenesis.
    Used by: Mirabegron
  82. Long [R3] insulin-like growth factor-I reduces growth, plasma growth hormone, IGF binding protein-3 and endogenous IGF-I concentrations in pigs
    pubmed_long_r3_igf1_pigs_1997
    Long R3 IGF-I animal source showing systemic endocrine feedback and non-simple growth outcomes; useful caution against simplistic LR3 claims.
    Used by: IGF-1 LR3 / DES(1-3)IGF-1
  83. Long R3 insulin-like growth factor-I infusion stimulates organ growth but reduces plasma IGF-I, IGF-II and IGF binding protein concentrations in the guinea pig
    pubmed_long_r3_igf1_guinea_pig_1995
    Guinea-pig Long R3 IGF-I infusion study documenting systemic organ-growth biology.
    Used by: IGF-1 LR3 / DES(1-3)IGF-1
  84. M40401 SOD mimetic reduces cerulein-induced acute pancreatitis
    pubmed_m40401_pancreatitis_2004
    SOD mimetic source for adhesion molecule, nitrotyrosine, PARP, lipid peroxidation, and neutrophil-injury pathway claims.
    Used by: M40401
  85. Maslinic acid inhibits myocardial ischemia-reperfusion injury-induced apoptosis and necroptosis
    pubmed_maslinic_miri_2022
    Myocardial ischemia-reperfusion/autophagic flux source.
    Used by: Maslinic Acid
  86. Mazdutide ameliorates metabolic dysfunction-associated steatotic liver disease by modulating endoplasmic reticulum stress, improving lipid metabolism and alleviating inflammation
    pubmed_mazdutide_masld_preclinical_2026
    Direct preclinical MASLD mechanism source for mazdutide; useful adjacent rationale because current human data are mainly obesity/T2D.
    Used by: Mazdutide
  87. MOTS-c increases in skeletal muscle following long-term physical activity and improves acute exercise performance after a single dose
    pubmed_motsc_exercise_muscle_2022
    Rodent training and acute MOTS-c exercise-performance study with skeletal-muscle mechanism; not a controlled human performance trial.
    Used by: MOTS-c
  88. MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance
    pubmed_motsc_2015
    Foundational MOTS-c animal/metabolic paper.
    Used by: MOTS-c
  89. Multiomic profiling reveals that prostaglandin E2 reverses aged muscle stem cell dysfunction, leading to increased regeneration and strength
    sciencedirect_pge2_aged_muscle_stem_2025
    Aged muscle stem-cell regeneration source; related PGE2/MuSC biology, not proof for unsupervised prostaglandin manipulation.
    Used by: No public entries linked.
  90. Myo-inositol and D-chiro-inositol oral supplementation ameliorate cardiac dysfunction and remodeling in a mouse model of diet-induced obesity
    sciencedirect_inositol_dci_cardiac_obesity_2020
    Related inositol supplementation source in diet-induced obese mice; supports metabolic-disease plausibility, not the same phosphatidylinositol browning mechanism.
    Used by: No public entries linked.
  91. Myostatin blockade with a fully human monoclonal antibody induces muscle hypertrophy and reverses muscle atrophy in young and aged mice
    skeletalmuscle_regn1033_mice_2015
    Preclinical characterization of REGN1033/trevogrumab as a selective myostatin antibody with muscle-hypertrophy, atrophy-prevention, and functional endpoints in mice.
    Used by: Trevogrumab
  92. Neurotrophic peptides incorporating adamantane improve learning and memory, promote neurogenesis and synaptogenesis, and inhibit amyloid beta-associated neuronal death
    sciencedirect_p021_adamantane_2010
    Indirect mechanistic anchor for Adamax-style Semax/P021/adapted peptide claims; not direct Adamax efficacy evidence.
    Used by: Adamax, P21 / P021 Peptide
  93. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction
    pubmed_5amino1mq_obesity_metabolic_2024
    5A1MQ diet-induced-obesity mouse study assessing body composition, fatty liver pathology, metabolic variables, biomarkers, and pharmacokinetics.
    Used by: 5-Amino-1MQ
  94. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity
    nature_nnmt_knockdown_obesity_2014
    Foundational target-validation paper connecting adipose/liver NNMT to SAM, NAD+, polyamine flux, oxygen consumption, and diet-induced obesity in mice.
    Used by: 5-Amino-1MQ
  95. Novel pan-ERR agonists ameliorate heart failure through enhancing cardiac fatty acid metabolism and mitochondrial function
    pubmed_panerr_agonists_heart_failure_2024
    ERR agonist tissue-metabolism context; supports mitochondrial/fatty-acid oxidation mechanism but not human enhancement use.
    Used by: SLU-PP-332
  96. Oleracein E rejuvenates senescent hippocampal NSCs by inhibiting the ERK1/2-mTOR axis
    ovid_oleracein_e_2025
    Vascular dementia/cognitive dysfunction source; limited public abstract access.
    Used by: Oleracein E
  97. Optimization of preclinical metabolism for SSTR5-selective antagonists
    pmc_sstr5_antagonists_2018
    SSTR5 antagonist medicinal chemistry and metabolic stability.
    Used by: No public entries linked.
  98. Oral administration of arginine suppresses Abeta pathology in animal models of Alzheimer's disease
    pubmed_arginine_abeta_2025
    Mouse and Drosophila Alzheimer's disease model source.
    Used by: Arginine
  99. Oroxylin A enhances memory consolidation through BDNF in mice
    pubmed_oroxylina_bdnf_memory_2014
    Mouse memory consolidation and hippocampal BDNF source.
    Used by: Oroxylin A
  100. Oroxylin A stimulates adult neurogenesis in the hippocampal dentate gyrus region of mice
    khu_oroxylina_neurogenesis
    Institutional record for mouse hippocampal neurogenesis paper.
    Used by: Oroxylin A
  101. Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model
    pubmed_ostarine_ligandrol_ovx_rat_2020
    Ovariectomized-rat muscle source for ostarine and ligandrol; supports tissue effect biology but not healthy male cycle outcomes.
    Used by: Enobosarm, Ligandrol
  102. Ostarine-Induced Myogenic Differentiation in C2C12, L6, and Rat Muscles
    pubmed_ostarine_myogenic_differentiation_2022
    Cell/rat muscle source for enobosarm/ostarine myogenic signaling; mechanistic rather than human performance proof.
    Used by: Enobosarm
  103. Paeonol ameliorates diabetic erectile dysfunction by inhibiting HMGB1/RAGE/NF-kB pathway
    pubmed_paeonol_diabetic_ed_2023
    Direct diabetic-rat erectile-dysfunction source linking paeonol to HMGB1/RAGE/NF-kB, cGMP/NO, and corpus-cavernosum markers.
    Used by: Paeonol
  104. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
    pubmed_kpv_pept1_colitis_2008
    Cell and mouse colitis work supporting PepT1-mediated KPV intestinal anti-inflammatory rationale.
    Used by: KPV
  105. Peptides prevent the forming of secretory phenotype of chondrocytes associated with aging
    pubmed_cartalax_chondrocyte_2023
    Cartalax/AED-adjacent chondrocyte aging model source; translation to osteoarthritis outcomes is unproven.
    Used by: Cartalax
  106. Peripheral mu-opioid receptor activation by dermorphin analog alleviates behavioral and neurobiological alterations in a mouse model
    pubmed_dermorphin_peripheral_mu_2024
    Recent animal-mechanism anchor; not human safety/efficacy evidence.
    Used by: Dermorphin
  107. Pharmacokinetics and pharmacodynamics of LGD-3303
    sciencedirect_lgd3303_pkpd_2009
    Preclinical PK/PD study of LGD-3303 as an orally available nonsteroidal SARM.
    Used by: LGD-3303
  108. Pharmacokinetics of S-4, a non-steroidal selective androgen receptor modulator, in rats
    pmc_andarine_pk_rat_2007
    Rat pharmacokinetic and oral bioavailability study for S-4/andarine.
    Used by: Andarine
  109. Pharmacological characterization of AC-262536, a novel SARM
    pubmed_ac262536_characterization_2008
    Functional and pharmacological characterization of AC-262536.
    Used by: AC-262536
  110. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes
    pubmed_pinealon_cell_viability_2011
    Cell/organotypic model anchor for Pinealon claims.
    Used by: Pinealon
  111. PK/PD of the GCPII inhibitor 2-MPPA in neuropathic pain
    pmc_gcpii_2mppa_pain_2014
    GCPII/NAAG peptidase inhibitor pharmacology.
    Used by: No public entries linked.
  112. Polydatin targets ACADVL to combat obesity by promoting adipocyte browning and activating fatty acid oxidation
    jove_polydatin_acadvl_2026
    Diet-induced obesity mouse and adipocyte mechanism source.
    Used by: Polydatin
  113. Polydatin: a potential NAFLD therapeutic drug that regulates mitochondrial autophagy through SIRT3-FOXO3-BNIP3 and PINK1-PRKN mechanisms
    pubmed_polydatin_nafld_sirt3_2024
    Related metabolic-disease source for polydatin effects on mitochondrial/autophagy pathways in NAFLD models.
    Used by: Polydatin
  114. Preclinical characterization of S-23 for hormonal male contraception
    pubmed_s23_male_contraception_2009
    Rat male-contraception model using S-23 with estradiol benzoate.
    Used by: S-23
  115. Preclinical metabolism and the disposition of vornorexant/TS-142, a novel dual orexin 1/2 receptor antagonist for the treatment of insomnia
    pubmed_vornorexant_preclinical_metabolism_2024
    Preclinical metabolism/disposition paper; useful for half-life and PK rationale.
    Used by: Vornorexant
  116. Protective effect of a phenolic extract containing indoline amides from Portulaca oleracea against cognitive impairment
    pubmed_portulaca_indoline_cognition_2017
    Related Portulaca/indoline-amide mouse cognition source; adjacent to oleracein chemistry and cognition, not a pure oleracein E human study.
    Used by: Oleracein E
  117. Protective effects of a new stable, highly active SOD mimetic, M40401 in splanchnic artery occlusion and reperfusion
    pubmed_m40401_sao_2001
    Direct M40401 ischemia-reperfusion source for adhesion molecules, peroxynitrite-linked injury, and neutrophil-mediated tissue damage.
    Used by: M40401
  118. Protective effects of GHK-Cu in bleomycin-induced pulmonary fibrosis via anti-oxidative stress and anti-inflammation pathways
    pubmed_ghkcu_pulmonary_fibrosis_mouse_2020
    Bleomycin mouse pulmonary-fibrosis model; adds fibrosis/EMT, oxidative-stress, inflammation, NF-kappaB/Nrf2-adjacent mechanism context, not cosmetic or athletic proof.
    Used by: GHK-Cu
  119. RAD140 negatively impacts skeletal muscle adaptation, frailty status and mortality risk in female mice
    pubmed_rad140_muscle_adaptation_mouse_2023
    Preclinical RAD140 study reporting negative adaptation/frailty/mortality signals in female mice; important counter-signal for performance claims.
    Used by: RAD140
  120. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice
    pubmed_5amino1mq_microbiome_dio_2022
    Diet-induced-obesity mouse study combining 5A-1MQ with diet switch; mechanism-adjacent microbiome/body-composition context.
    Used by: 5-Amino-1MQ
  121. Regulation by TAAR1 of dopaminergic-GABAergic interaction in the striatum: effects of (-)-BPAP
    pubmed_bpap_taar1_2025
    BPAP and TAAR1-related mechanism.
    Used by: (-)-BPAP
  122. Retatrutide shows multiple metabolic benefits in diet-induced obese MASH mouse and hamster models
    pubmed_retatrutide_mash_models_2026
    Adjacent animal mechanism source for liver/metabolic effects; not a substitute for human MASLD outcome data.
    Used by: Retatrutide
  123. SA4503, a novel cognitive enhancer, with sigma 1 receptor agonistic properties
    pubmed_sa4503_cognitive_enhancer_1997
    Original SA4503 sigma-1 binding, acetylcholine, and anti-amnesic rat data.
    Used by: Cutamesine
  124. SARM treatment prevents bone loss and reduces body fat in ovariectomized rats
    pubmed_andarine_ovx_rat_2006
    S-4/andarine animal model of bone and body-composition effects.
    Used by: Andarine
  125. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist
    pubmed_5ht2c_sb242084_1997
    Classic selective 5-HT2C antagonist pharmacology.
    Used by: No public entries linked.
  126. Schisandrin B is a dual PAM of GABAA and glycine receptors and alleviates seizures in mouse models
    nature_schisandrinb_gabaa_glycine_2024
    Mouse seizure models and receptor PAM mechanism.
    Used by: Schisandrin B
  127. Sciadonic acid from pine nuts reduces plasma triglycerides by inhibiting rat hepatic delta-9 desaturase
    nature_sciadonic_acid_rat_2020
    Rat dietary fatty-acid study.
    Used by: Sciadonic Acid
  128. Semax, an analog of ACTH(4-7), regulates expression of immune response genes during ischemic brain injury in rats
    pubmed_semax_ischemia_genes_2017
    Rat focal-cerebral-ischemia transcriptome study supporting Semax neuroprotection/inflammation pathway rationale.
    Used by: Semax
  129. Semax, synthetic ACTH(4-10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats
    pubmed_semax_cns_review_2021
    Rat neurochemical/behavioral study providing additional Semax CNS mechanism context; not healthy-human nootropic evidence.
    Used by: Semax
  130. Shortened spadin analogs display better TREK-1 inhibition, in vivo stability and antidepressant activity
    pubmed_pe2228_spadin_2017
    PE 22-28 / shortened-spadin antidepressant mechanism anchor.
    Used by: PE-22-28
  131. Spadin, a sortilin-derived peptide, targeting rodent TREK-1 channels: a new concept in antidepressant drug design
    pubmed_spadin_trek1_2010
    Parent spadin/TREK-1 mechanistic background for PE-22-28.
    Used by: PE-22-28
  132. Spilanthes acmella ethanolic flower extract: alkylamide profiling and sexual behavior in male rats
    pubmed_spilanthes_acmella_2011
    In vitro and rat sexual-behavior source for N-alkylamide aphrodisiac claims.
    Used by: Spilanthes acmella Extract
  133. Synthetic ERR alpha/beta/gamma agonist induces an acute aerobic exercise response
    pubmed_slupp332_2023
    SLU-PP-332 mouse and cell work.
    Used by: SLU-PP-332
  134. TAK-861, an orally available OX2R agonist, produces wakefulness in monkeys and mouse models
    pubmed_tak861_2024
    Orexin agonist development context.
    Used by: No public entries linked.
  135. Testosterone and trenbolone enanthate increase mature myostatin protein expression despite increasing skeletal muscle hypertrophy and satellite cell number in rodent muscle
    pubmed_trenbolone_myostatin_satellite_cells_2017
    Rodent study linking androgen-induced hypertrophy with satellite-cell changes and mature myostatin protein; useful against simplistic myostatin narratives.
    Used by: Trenbolone
  136. The Dishevelled-binding protein CXXC5 negatively regulates cutaneous wound healing
    pubmed_cxxc5_wound_direct_2015
    Direct CXXC5-Dvl/PTD-DBM wound-healing source; supports the program mechanism but not human hair-regrowth efficacy.
    Used by: No public entries linked.
  137. The flavonoid corylin exhibits lifespan extension properties in mouse
    nature_corylin_lifespan_mouse_2022
    Mouse lifespan/metabolic-health source for corylin; high-fat-diet model, not human longevity evidence.
    Used by: Corylin
  138. The heptapeptide Semax stimulates BDNF expression in different areas of the rat brain in vivo
    pubmed_semax_bdnf_2003
    Rat BDNF-expression source for Semax neurotrophin rationale.
    Used by: Adamax, Semax
  139. The influence of peptides on the chondrogenic differentiation of human mesenchymal stem cells during replicative aging
    pubmed_cartalax_chondrogenic_differentiation_2023
    Human cell-culture differentiation context for cartilage bioregulator peptide claims.
    Used by: Cartalax
  140. The procognitive and synaptogenic effects of angiotensin IV-derived peptides are dependent on activation of the hepatocyte growth factor/c-Met system
    pubmed_dihexa_hgf_met_2014
    Key Dihexa mechanism paper linking HGF/c-Met modulation, synaptogenesis, and cognition models.
    Used by: Dihexa
  141. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration
    pubmed_bpc157_tendon_outgrowth_2010
    Rat Achilles tendon fibroblast/explant mechanism paper: BPC 157 increased tendon outgrowth, stress survival, migration, spreading, F-actin formation, and FAK/paxillin phosphorylation.
    Used by: BPC-157
  142. The protective effect of M40401, a superoxide dismutase mimetic, on post-ischemic brain damage in Mongolian gerbils
    pmc_m40401_brain_ischemia_2003
    Additional M40401 ischemia-reperfusion model; supports redox/neuroprotection context, not human anti-aging evidence.
    Used by: M40401
  143. The role of phospholipase D and phosphatidic acid in the mechanical activation of mTOR signaling in skeletal muscle
    pmc_pld_pa_mtor_skeletal_muscle_2006
    Foundational skeletal-muscle mechanistic work linking phospholipase D, phosphatidic acid, and mechanical mTOR signaling.
    Used by: Phosphatidic Acid
  144. The tri-peptide GHK-Cu complex ameliorates lipopolysaccharide-induced acute lung injury in mice
    pubmed_ghkcu_acute_lung_injury_mouse_2016
    Mouse LPS acute lung injury and macrophage study; supports anti-inflammatory/antioxidant mechanisms through ROS, SOD, TNF-alpha/IL-6, NF-kappaB p65, and p38 MAPK changes.
    Used by: GHK-Cu
  145. Therapeutic effect of an MRGPRX2/MRGPRB2 antagonist on LL-37-induced rosacea-like inflammation in mice
    pubmed_ll37_rosacea_mouse_2025
    Mouse and cell rosacea-like inflammation model where LL-37 acts as a pro-inflammatory trigger through mast-cell/MRGPR biology; important counterweight to only pro-healing framing.
    Used by: LL-37
  146. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice
    pubmed_tb4_dermal_repair_2003
    Important bridge source: full-length Tbeta4 and the LKKTETQ actin-binding peptide promoted dermal wound repair in animal models.
    Used by: TB-500 / thymosin beta-4-related products
  147. Thymosin beta 4 promotes corneal wound healing and modulates inflammatory mediators in vivo
    pubmed_tb4_corneal_wound_2001
    Rat corneal wound model; supports topical Tbeta4 repair and inflammatory-modulation biology.
    Used by: TB-500 / thymosin beta-4-related products
  148. Thymosin beta-4 enhances the healing of medial collateral ligament injury in rat
    pubmed_tb4_ligament_rat_2013
    Rat ligament-injury source; relevant to soft-tissue repair claims, but not direct human TB-500 evidence.
    Used by: TB-500 / thymosin beta-4-related products
  149. Thymosin beta4 accelerates wound healing
    pubmed_tb4_wound_healing_1999
    Early animal wound-healing source for full-length Tbeta4 repair biology.
    Used by: TB-500 / thymosin beta-4-related products
  150. Thymosin-beta4 modulates corneal matrix metalloproteinase levels and polymorphonuclear cell infiltration after alkali injury
    pubmed_tb4_alkali_injury_2005
    Mouse corneal alkali-injury model; supports MMP/TIMP and neutrophil-infiltration mechanisms in local injury repair.
    Used by: TB-500 / thymosin beta-4-related products
  151. Tissue selectivity of the anabolic steroid, 17beta-hydroxyestra-4,9,11-trien-3-one in male Sprague Dawley rats
    pubmed_trenbolone_tissue_selectivity_2010
    Direct trenbolone rat androgenic/anabolic tissue-selectivity source; non-human mechanism only.
    Used by: Trenbolone
  152. Transcriptional regulation of myotrophic actions by testosterone and trenbolone on androgen-responsive muscle
    pubmed_trenbolone_myotrophic_transcription_2014
    Rat androgen-responsive muscle transcription study comparing testosterone and trenbolone; supports mechanism without human safety inference.
    Used by: Trenbolone
  153. Transcriptome alteration in hippocampus under the treatment of tuftsin analog Selank
    pubmed_selank_transcriptome_2013
    Rat hippocampus transcriptome study after intranasal Selank exposure.
    Used by: Selank
  154. Trenbolone alters the responsiveness of skeletal muscle satellite cells to fibroblast growth factor and insulin-like growth factor I
    pubmed_trenbolone_satellite_cells_1989
    Rat satellite-cell/IGF-FGF responsiveness source; mechanistic support for muscle-growth claims, not a human performance trial.
    Used by: Trenbolone
  155. Trenbolone prevents fat accumulation and improves bone mineral density in orchidectomized rats
    pubmed_trenbolone_orchidectomized_rat_2012
    Direct trenbolone animal body-composition/bone source; does not establish human safety or dosing.
    Used by: Trenbolone
  156. Tribulus cistoides improves nicotine-induced sexual dysfunction in male Wistar rats
    pubmed_tribulus_cistoides_2025
    Nicotine-induced male sexual dysfunction, NO, gonadotropins, and hormone-level source.
    Used by: Tribulus cistoides Extract
  157. Trigonelline recovers memory function in Alzheimer's disease model mice
    pubmed_trigonelline_ad_model_2020
    5XFAD mouse memory recovery and brain-penetration source.
    Used by: Trigonelline
  158. Trigonelline restores BDNF levels in lipopolysaccharide-induced cognitive impairment
    pubmed_trigonelline_lps_bdnf_2018
    LPS cognitive impairment mouse source.
    Used by: Trigonelline
  159. Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction
    pubmed_ghkcu_acl_rat_2015
    Randomized rat ACL reconstruction model; intra-articular GHK-Cu transiently improved laxity and graft-bone healing endpoints, useful for orthopedic repair plausibility but not human ACL evidence.
    Used by: GHK, GHK-Cu
  160. YK11 induces oxidative stress and mitochondrial dysfunction in hippocampus: The interplay between a selective androgen receptor modulator (SARM) and exercise
    pubmed_yk11_hippocampus_oxidative_stress_2023
    Rat hippocampus oxidative-stress/mitochondrial source; important safety counterweight for YK11 forum claims.
    Used by: YK11

regulatory review

  1. DailyMed label: SYNOVEX PLUS trenbolone acetate and estradiol benzoate implant
    dailymed_synovex_trenbolone_label
    Veterinary cattle implant label; anchors trenbolone acetate as an approved animal growth-promoter context, not a human drug.
    Used by: Trenbolone
  2. FDA approves multiple generics of ADHD and BED treatment
    fda_vyvanse_generics_stimulant_warning_2023
    FDA context for lisdexamfetamine generics and standardized prescription-stimulant warnings on misuse, cardiovascular reactions, BP/HR, psychiatric adverse reactions, and serotonin syndrome.
    Used by: Lisdexamfetamine
  3. FDA Federal Register: sermorelin acetate was not withdrawn from sale for reasons of safety or effectiveness
    govinfo_sermorelin_not_withdrawn_2013
    Regulatory history for sermorelin/Geref.
    Used by: Sermorelin
  4. FDA grants accelerated approval to first treatment for Barth syndrome
    fda_forzinity_approval_2025
    FDA approval context and confirmatory-trial caveat for elamipretide.
    Used by: SS-31 / Elamipretide
  5. Japan approvals include Vorzzz (vornorexant) for insomnia
    pharmajapan_vornorexant_approval_2025
    Trade/regulatory news noting Japan MHLW approval of Taisho's vornorexant insomnia therapy in August 2025.
    Used by: Vornorexant
  6. Union list of novel foods: astaxanthin-rich oleoresin from Haematococcus pluvialis algae
    eurlex_astaxanthin_novel_food_spec
    EU novel-food specification context for astaxanthin-rich oleoresin products and labeling restrictions.
    Used by: Astaxanthin-fortified yogurt

regulatory safety

  1. Hydroxyzine: risk of QT interval prolongation and Torsade de Pointes
    govuk_hydroxyzine_qt_warning_2015
    UK drug-safety update summarizing European review and QT/TdP risk-minimization recommendations for hydroxyzine.
    Used by: Hydroxyzine
  2. Medsafe Medicines Classification Committee: classification of unscheduled peptides including Adamax and P21
    medsafe_unscheduled_peptides_2025
    Regulatory classification context for nootropic/research peptides with limited direct clinical evidence.
    Used by: Adamax, P21 / P021 Peptide
  3. Neonatal deaths associated with use of benzyl alcohol: United States
    pubmed_benzyl_alcohol_neonatal_toxicity_1983
    Safety context for benzyl alcohol preservative in bacteriostatic diluents.
    Used by: No public entries linked.
  4. Re-evaluation of gellan gum (E 418) as food additive
    efsa_gellan_gum_reevaluation_2018
    EFSA food-additive safety review; useful for additive status and human exposure context rather than efficacy.
    Used by: Gellan Gum

review

  1. A Comprehensive Review on Schisandrin B and Its Biological Properties
    pubmed_schisandrinb_review_2020
    Compound-level Schisandrin B review covering antioxidant, anti-inflammatory, neuroprotective, and cardioprotective mechanisms.
    Used by: Schisandrin B
  2. A novel prodrug approach for central nervous system-selective estrogen therapy
    pubmed_cns_estrogen_prodrug_2019
    NADPH-dependent short-chain dehydrogenase bioactivation of estrogen prodrugs.
    Used by: No public entries linked.
  3. A review of Psoralea corylifolia L.: a valuable plant with profound biological significance
    frontiers_psoralea_review_2025
    Botanical-source review covering Psoralea corylifolia phytochemistry, pharmacology, processing, and hepatotoxicity/safety context.
    Used by: Corylin
  4. Acetic acid treatment of pseudomonal wound infections--a review
    pubmed_acetic_acid_wound_antimicrobial_review_2022
    Clinical-use context for dilute acetic acid as an antimicrobial wound/irrigation lead; not a peptide efficacy mechanism.
    Used by: No public entries linked.
  5. Acetyl Hexapeptide-8 in cosmeceuticals: a review of skin permeability and efficacy
    pubmed_cosmetic_peptides_review_2023
    Mechanistic/cosmeceutical background for SNAP-25 mimic peptide claims; SNAP-8 itself has thinner independent literature than acetyl hexapeptide-8.
    Used by: SNAP-8 / Acetyl Octapeptide-3
  6. Adaptation to Lactose in Lactase Non Persistent People: Effects on Intolerance and the Relationship between Dairy Food Consumption and Evaluation of Diseases
    pubmed_lactose_adaptation_review_2015
    Review source for lactase non-persistence, dairy exposure, and colonic adaptation mechanisms.
    Used by: Galactooligosaccharides / RP-G28
  7. Adenosine A3 receptor: from molecular signaling to therapeutic strategies
    pubmed_a3ar_review_2024
    A3 receptor agonist target-class review.
    Used by: No public entries linked.
  8. Allosteric mGluR3 modulators for the treatment of psychiatric disorders
    pmc_mglur3_pam_review_2018
    mGluR3 PAM target-class review.
    Used by: No public entries linked.
  9. Allosteric modulators of sigma-1 receptor: a review
    pmc_sigma1_pam_review_2019
    Includes fenfluramine as a sigma-1 PAM.
    Used by: Fenfluramine
  10. Alpha-melanocyte-stimulating hormone and related tripeptides: antiinflammatory and protective effects
    pubmed_kpv_inflammation_review_2008
    Review of alpha-MSH-related tripeptides including KPV for anti-inflammatory and protective effects.
    Used by: KPV
  11. An update on water kefir: Microbiology, composition and production
    pubmed_water_kefir_microbiology_update_2021
    Review of water-kefir grain microbiology, substrates, composition, and production variables.
    Used by: Water Kefir
  12. Anabolic-androgenic steroids: How do they work and what are the risks?
    pubmed_aas_risks_2023
    General AAS mechanism and risk review; used as class-level caution for nonmedical androgen/anabolic steroid entries.
    Used by: Methandienone, Nandrolone Decanoate, Oxandrolone, Oxymetholone, Stanozolol, Testosterone, Trenbolone
  13. Angiotensin-receptor blocking agents and the PPAR-gamma system
    pubmed_telmisartan_ppargamma_2005
    Telmisartan partial PPAR-gamma agonism context.
    Used by: Telmisartan
  14. Anti-Inflammatory Activities of Betulinic Acid: A Review
    frontiers_betulinic_antiinflammatory_review_2022
    Broader betulinic-acid anti-inflammatory mechanism review; useful context, not direct erectile-function evidence.
    Used by: Betulinic Acid
  15. Antimicrobial Peptides of the Cathelicidin Family: Focus on LL-37 and Its Modifications
    pubmed_ll37_cathelicidin_modifications_review_2025
    Review of LL-37 and modified cathelicidin analogs; highlights broad antimicrobial/immunomodulatory promise but also proteolytic stability, cytotoxicity, production, and safety barriers.
    Used by: LL-37
  16. Antioxidant and anti-inflammatory properties of water kefir microbiota and its bioactive metabolites for health promoting bio-functional products and applications
    pubmed_water_kefir_antioxidant_review_2024
    Water-kefir review focused on microbial species, metabolites, antioxidant, antithrombotic, and anti-inflammatory biofunctional claims.
    Used by: Water Kefir
  17. AOD-9604 Metabolic
    pubmed_aod9604_metabolic_2004
    Investigational-drug profile from the obesity-development period; direct AOD-9604 context, not approval or strong efficacy evidence.
    Used by: AOD9604
  18. Bazedoxifene and the role of third-generation SERMs in postmenopausal osteoporosis
    pubmed_bazedoxifene_osteoporosis_review_2012
    Review of bazedoxifene osteoporosis data and SERM risks.
    Used by: Bazedoxifene
  19. Beta-hydroxy-beta-methylbutyrate supplementation and skeletal muscle in healthy and muscle-wasting conditions
    pubmed_hmb_muscle_review_2017
    Review of HMB effects on skeletal muscle in healthy, exercise, and muscle-wasting contexts; useful for differentiating trained-athlete claims from catabolic settings.
    Used by: HMB
  20. Biased versus partial agonism in the search for safer opioid analgesics
    pmc_biased_opioid_review_2020
    Important caution on interpreting biased MOR agonists.
    Used by: SR-17018
  21. Bilirubin - new insights into an old molecule
    pubmed_bilirubin_new_insights_2025
    Recent review of bilirubin as antioxidant, signaling, hormonal, and immunomodulatory molecule.
    Used by: Bilirubin / Biliverdin axis
  22. Bilirubin as a signaling molecule
    pubmed_bilirubin_signaling_2020
    Review of bilirubin antioxidant, immune, endocrine, PPAR, and metabolic signaling biology.
    Used by: Bilirubin / Biliverdin axis
  23. Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity
    pubmed_bimagrumab_obesity_review_2024
    Recent review summarizing bimagrumab mechanism, obesity/T2D trial evidence, and investigational status.
    Used by: Bimagrumab
  24. BPC 157 and Standard Angiogenic Growth Factors. Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing
    pubmed_bpc157_angiogenic_growth_factors_2018
    Mechanistic review linking BPC 157 to angiogenesis/growth-factor healing concepts across GI, tendon, ligament, muscle, and bone injury models.
    Used by: BPC-157
  25. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity
    pubmed_cagrilintide_obesity_review_2023
    Mechanistic review of cagrilintide as a long-acting amylin analog, including amylin satiety biology and pairing with semaglutide.
    Used by: Cagrilintide
  26. Carnosine and Beta-Alanine Supplementation in Human Medicine: Narrative Review and Critical Assessment
    pubmed_carnosine_beta_alanine_human_medicine_review_2023
    Narrative review and critical assessment across carnosine and beta-alanine human-medicine claims; useful for separating mechanistic enthusiasm from outcome-specific evidence.
    Used by: Carnosine / Beta-Alanine
  27. Cellular and Molecular Mechanisms of Metformin Action
    pmc_metformin_cellular_mechanisms_2021
    Mechanistic review of metformin, mitochondrial complex I, AMPK-dependent and independent mechanisms, lysosomal signaling, and nutrient-sensing pathways.
    Used by: Metformin
  28. Central and Peripheral Molecular Targets for Anti-Obesity Pharmacotherapy
    pmc_antiobesity_pharmacotherapy_aod9604_2011
    Anti-obesity pharmacotherapy review noting AOD9604 development history and that phase 2B results did not support commercial obesity development.
    Used by: AOD9604
  29. Challenges in water kefir production and limitations in human consumption: A comprehensive review of current knowledge
    pubmed_water_kefir_limitations_review_2024
    Review covering water-kefir microbial diversity, possible health-promoting properties, production challenges, and human-consumption limitations.
    Used by: Water Kefir
  30. Clenbuterol as a Substance of Abuse
    pubmed_clenbuterol_toxicity_review_2020
    Abuse/toxicity review; anchors tachycardia, hypokalemia, tremor, arrhythmia, and overdose-risk framing.
    Used by: Clenbuterol
  31. Clinical potential of Spirulina as a source of phycocyanobilin
    pubmed_spirulina_phycocyanobilin_2007
    Mechanistic review proposing spirulina/phycocyanin as a practical phycocyanobilin source with bilirubin-like NADPH oxidase/redox rationale.
    Used by: Phycocyanobilin / Spirulina
  32. Cognitive Vitality report: Cutamesine
    alzdiscovery_cutamesine_2020
    Secondary evidence summary.
    Used by: Cutamesine
  33. Delta-sleep-inducing peptide (DSIP): a review
    pubmed_dsip_review_1984
    Historical DSIP review across animal and human sleep/neuroendocrine literature.
    Used by: Delta Sleep-Inducing Peptide
  34. Des(1-3)IGF-I: a truncated form of insulin-like growth factor-I
    pubmed_des13igf1_review_1996
    Review describing DES(1-3)IGF-I structure, reduced binding-protein interaction, potency, and clinical uncertainty.
    Used by: IGF-1 LR3 / DES(1-3)IGF-1
  35. Do inhaled beta-2 agonists have an ergogenic potential in non-asthmatic competitive athletes?
    pubmed_beta2_agonists_ergogenic_2007
    Review contrasting mostly non-ergogenic inhaled beta-2 agonists with oral salbutamol signals.
    Used by: Oral Salbutamol
  36. Efficacy and safety of ethylmethylhydroxypyridine succinate in patients with chronic cerebral ischemia
    pubmed_mexidol_chronic_ischemia_2020
    Russian-language clinical review for Mexidol in chronic cerebral ischemia; clinical context differs from broad nootropic claims.
    Used by: Mexidol
  37. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
    pubmed_bpc157_orthopedic_systematic_review_2025
    Systematic review through June 2024; found 35 preclinical studies and 1 clinical study, so it supports broad musculoskeletal plausibility while emphasizing the thin human evidence base.
    Used by: BPC-157
  38. Enclomiphene citrate for the treatment of secondary male hypogonadism
    pubmed_enclomiphene_review_2016
    Review of enclomiphene in secondary hypogonadism.
    Used by: Enclomiphene
  39. Endotext: Hypogonadotropic hypogonadism and gonadotropin therapy
    ncbi_endotext_hh_gonadotropin_therapy
    Clinical review explaining pulsatile GnRH versus gonadotropin therapy and fertility endpoints.
    Used by: Gonadorelin, HMG / Menotropins, Human chorionic gonadotropin
  40. Fermented Beverage Benefits: A Comprehensive Review and Comparison of Kombucha and Kefir Microbiome
    pubmed_fermented_beverage_kombucha_kefir_review_2023
    Comparative fermented-beverage review describing microbial composition, gut-microbiota interaction, and product variability.
    Used by: Water Kefir
  41. From Rate-Limiting Enzyme to Therapeutic Target: The Promise of NAMPT in Neurodegenerative Diseases
    pmc_nampt_neurodegeneration_review_2022
    NAMPT/NAD salvage review discussing P7C3/P7C3-A20 activator context and neurodegeneration translation.
    Used by: No public entries linked.
  42. GABAergic inhibitory neurons as therapeutic targets for cognitive impairment in schizophrenia
    pubmed_522054_2018_review
    Includes 522-054 as alpha7 nicotinic PAM plus GABA-A alpha5 NAM.
    Used by: 522-054
  43. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing
    pubmed_bpc157_musculoskeletal_soft_tissue_review_2019
    Critical musculoskeletal soft-tissue review covering tendon, ligament, and skeletal muscle models; explicitly notes that most evidence is small-rodent work and human efficacy is unconfirmed.
    Used by: BPC-157
  44. Gene expression data suggest that the copper peptide GHK may have regenerative and protective actions
    pubmed_ghkcu_gene_data_2018
    Mechanistic/gene-expression review for GHK-Cu regenerative claims; useful context for skin/wound plausibility but not a direct cosmetic efficacy trial.
    Used by: AHK-Cu, GHK, GHK-Cu
  45. Geroprotective effect of thymalin and epithalamin
    pubmed_thymalin_geroprotective_2002
    Older thymic/pineal peptide bioregulator background.
    Used by: Thymalin
  46. GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
    pubmed_ghkcu_2015
    GHK-Cu skin regeneration review.
    Used by: GHK, GHK-Cu
  47. Growth hormone administration: is it safe and effective for athletic performance
    pubmed_hgh_athletic_performance_review_2010
    Sports-endocrinology review of GH performance claims, adverse effects, and evidence limits in healthy users.
    Used by: Human Growth Hormone / Somatropin
  48. Growth hormone-releasing peptides
    pubmed_ghrp_review_1997
    Class review for GHRP-2, GHRP-6, hexarelin, and related secretagogues.
    Used by: GHRP-2 / Pralmorelin, GHRP-6
  49. Histamine H3 receptor as a target for cognitive disorders
    pubmed_h3_cognition_review
    H3 antagonist cognition rationale.
    Used by: Irdabisant
  50. Hyaluronan: A Neuroimmune Modulator in the Microbiota-Gut Axis
    pmc_hyaluronan_gut_axis_review_2022
    Review of HA interactions with luminal bacteria and host gut neuroimmune responses; useful context for gut-barrier claims.
    Used by: High-Molecular-Weight Hyaluronic Acid
  51. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease
    pubmed_follistatin_myostatin_therapy_review_2009
    Review focused on follistatin/myostatin inhibition as muscle-disease therapy; useful for broad mechanism and development context.
    Used by: Follistatin / FS344
  52. INT131: a selective modulator of PPAR gamma
    pubmed_int131_review_2009
    Selective PPAR-gamma modulator overview.
    Used by: INT131
  53. International society of sports nutrition position stand: Beta-Alanine
    jissn_beta_alanine_position_stand_2015
    Sports-nutrition position stand summarizing beta-alanine, muscle carnosine, buffering, dose-response, and high-intensity exercise context.
    Used by: Carnosine / Beta-Alanine
  54. International Society of Sports Nutrition Position Stand: protein and exercise
    pubmed_issn_protein_position_2017
    ISSN position stand summarizing protein intake, timing, quality, and exercise-adaptation evidence.
    Used by: Leucine, Protein Supplementation
  55. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine
    pubmed_issn_creatine_position_2017
    ISSN position stand summarizing creatine safety, exercise, sport, and medical-use evidence.
    Used by: Creatine
  56. Kefir Consumption and Health Effects Based on Human Clinical Trials: An Overview of Literature
    pubmed_kefir_clinical_trials_review_2026
    Clinical-trial overview noting possible gut, metabolic, inflammatory, immune, and GI effects while emphasizing heterogeneity and limited certainty.
    Used by: Milk Kefir
  57. Known and new ideas about Mexidol mechanism of action
    pubmed_mexidol_review_2025
    Recent mechanism review; mostly regional literature.
    Used by: Mexidol
  58. Leonurine, a potential drug for the treatment of cardiovascular system and central nervous system diseases
    pubmed_leonurine_review_2020
    Review of leonurine cardiovascular and CNS mechanisms, bioavailability limitations, and translational gaps.
    Used by: Leonurine
  59. LL-37: Biological Mechanisms and Emerging Therapeutic Applications in Intestinal Disease
    pubmed_ll37_intestinal_review_2026
    Intestinal-immune axis review emphasizing context-dependent LL-37 biology, including antibacterial, immunomodulatory, tissue-repair, microbiome, IBD, and CRC considerations.
    Used by: LL-37
  60. LL-37: Cathelicidin-related antimicrobial peptide with pleiotropic activity
    pubmed_ll37_pleiotropic_review_2016
    Core LL-37 review covering antimicrobial, chemotactic, immunomodulatory, respiratory, GI, and skin biology; useful mechanism anchor beyond the venous-ulcer RCT.
    Used by: LL-37
  61. Long-term Prophylaxis with Androgens in the management of Hereditary Angioedema (HAE) in emerging countries
    pubmed_attenuated_androgens_hae_review_2022
    Review of attenuated androgen prophylaxis in HAE; useful for stanozolol/danazol benefit-risk context and long-term adverse effects.
    Used by: Stanozolol
  62. Mecasermin (recombinant human insulin-like growth factor I)
    pubmed_mecasermin_review_2009
    Drug review for rhIGF-1 pharmacology, clinical use, and safety; helps distinguish approved deficiency treatment from IGF-axis enhancement claims.
    Used by: Mecasermin / Recombinant Human IGF-1
  63. Mechanisms and inhibitors of nicotinamide N-methyltransferase
    pmc_nnmt_inhibitors_review_2021
    Review of NNMT biology and inhibitor classes, including 5-amino-1MQ context; useful for mechanism and translational caveats.
    Used by: 5-Amino-1MQ
  64. Medicinal plants of the genus Betula: traditional uses and phytochemical-pharmacological review
    pmc_betula_betulinic_review_2015
    Broad betulin/betulinic acid pharmacology; not a compound-specific erectile dysfunction source.
    Used by: Betulinic Acid
  65. Mitochondria-derived peptide MOTS-c: effects and mechanisms related to stress, metabolism and aging
    pubmed_motsc_mechanisms_2023
    Mechanistic review covering AMPK, stress-response, exercise, insulin-resistance, inflammation, and aging-related MOTS-c biology.
    Used by: MOTS-c
  66. Mitochondrial protein import and the genesis of steroidogenic mitochondria
    pubmed_steroidogenic_transduceosome_2011
    Background on mitochondrial cholesterol import in steroidogenesis.
    Used by: ACE-167
  67. Mitochondrial-derived peptide and metabolic states: systematic review and meta-analysis
    pubmed_motsc_meta_2024
    Human association literature, not interventional efficacy.
    Used by: MOTS-c
  68. Moclobemide. A review of its pharmacological properties and therapeutic use in depressive illness
    pubmed_moclobemide_review_1992
    Clinical and pharmacology review of moclobemide as a reversible selective MAO-A inhibitor; supports the reversible MAO-A program entry.
    Used by: No public entries linked.
  69. Molecular mechanisms, targets and clinical potential of berberine in regulating metabolism: a review focussing on databases and molecular docking studies
    pmc_berberine_metabolic_mechanisms_review_2024
    Mechanism review covering AMPK/mTOR, PCSK9/LDLR, SIRT/FOXO/SREBP, Nrf2, and other metabolic signaling pathways; useful but less direct than RCTs.
    Used by: Berberine
  70. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review
    pubmed_bpc157_literature_patent_review_2025
    Recent broad review of biological activities, mechanisms, probable toxicity, patent interest, online sale context, and lack of sufficient comprehensive clinical studies for standard medical approval.
    Used by: BPC-157
  71. N-alkylamides of Spilanthes (syn: Acmella): Structure, purification, characterization, biological activities and applications
    sciencedirect_spilanthes_alkylamide_review_2021
    Review of Spilanthes/Acmella N-alkylamide chemistry and biological activity claims, including aphrodisiac context.
    Used by: Spilanthes acmella Extract
  72. Nandrolone Decanoate: Use, Abuse and Side Effects
    pubmed_nandrolone_use_abuse_side_effects_2020
    Compound-specific nandrolone review covering therapeutic uses, abuse patterns, and adverse effects.
    Used by: Nandrolone Decanoate
  73. Nitric oxide mechanisms of nebivolol
    pubmed_nebivolol_no_2009
    Nebivolol beta1 blocker and NO-mediated vasodilation.
    Used by: Nebivolol
  74. Opioid peptide-derived analgesics
    pubmed_dermorphin_opioid_peptide_review_2005
    Mechanistic opioid peptide context including dermorphin-derived ligands.
    Used by: Dermorphin
  75. Paeonol for atherosclerotic cardiovascular disease: pharmacological and mechanistic overview
    pubmed_paeonol_atherosclerosis_review_2021
    Cardiovascular mechanism review including anti-inflammatory and lipid/vascular targets.
    Used by: Paeonol
  76. Pentadecapeptide BPC 157 and the central nervous system
    pubmed_bpc157_cns_review_2021
    CNS-focused review covering rat stroke, spinal cord compression, catalepsy/dopamine-system models, and nitric-oxide-system interactions; useful for neuroprotection claims but not human cognitive evidence.
    Used by: BPC-157
  77. Peptides and ageing
    pubmed_short_peptides_ageing_2002
    Broad Russian peptide-bioregulator review; useful background but low specificity for named peptide products.
    Used by: Cartalax, Thymalin
  78. Pharmacological effects of polydatin in the treatment of metabolic diseases: A review
    sciencedirect_polydatin_metabolic_review_2022
    Review of polydatin metabolic-disease pharmacology through obesity, diabetes, dyslipidemia, NAFLD, and related models.
    Used by: Polydatin
  79. Pharmacology of moclobemide
    pubmed_moclobemide_pharmacology_1993
    Mechanistic RIMA pharmacology review, including MAO-A preference and reversibility.
    Used by: No public entries linked.
  80. Positive and negative allosteric modulators of NMDA receptors
    pubmed_nmda_pam_review_2018
    NMDA PAM/NAM SAR and mechanism review.
    Used by: No public entries linked.
  81. Pursuing the Elixir of Life: In Vivo Antioxidative Effects of Manganosalen Complexes
    mdpi_manganosalen_in_vivo_review_2020
    Review of in vivo manganosalen SOD/catalase-mimetic literature including EUK compounds and dose/context caveats.
    Used by: EUK-134
  82. Racemic amphetamine sulfate (Evekeo) for ADHD
    pubmed_racemic_amphetamine_medletter_2015
    Medical Letter review context for racemic amphetamine sulfate as an ADHD drug.
    Used by: Racemic Amphetamine Sulfate
  83. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing
    pubmed_bpc157_review_2025
    Recent review noting preclinical base and safety/regulatory uncertainty.
    Used by: BPC-157
  84. Regenerative wound healing strategies activating Wnt/beta-catenin
    pubmed_cxxc5_wound_2021
    Includes PTD-DBM and CXXC5-DVL interaction.
    Used by: No public entries linked.
  85. Retatrutide-A Game Changer in Obesity Pharmacotherapy
    pubmed_retatrutide_review_2025
    Review synthesizing retatrutide mechanisms, clinical efficacy, metabolic outcomes, and safety; secondary support only.
    Used by: Retatrutide
  86. Salen Mn complexes mitigate radiation injury in normal tissues
    pubmed_salen_mn_radiation_review_2011
    Review of salen-manganese complexes such as EUK-134, EUK-189, and EUK-207 in oxidative/radiation injury models.
    Used by: EUK-134
  87. Selective androgen receptor modulators in preclinical and clinical development
    pubmed_sarms_preclinical_clinical_2009
    SARM class review covering multiple preclinical and early clinical programs.
    Used by: AC-262536, ACP-105, BMS-564929, LGD-3303, S-23
  88. Senolytic drugs: from discovery to translation
    pmc_senolytics_translation_review_2020
    Translational senolytics review that contextualizes piperlongumine among senescent-cell targeting leads and caveats.
    Used by: Piperlongumine
  89. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency
    pubmed_sermorelin_gh_deficiency_review_1999
    Clinical review in pediatric GH deficiency; not adult wellness evidence.
    Used by: Sermorelin
  90. Serotonergic 5-HT7 receptors and cognition
    pubmed_5ht7_cognition_review_2014
    5-HT7 cognition review.
    Used by: No public entries linked.
  91. Serotonin-1A anxiolytics: an overview
    pubmed_5ht1a_anxiolytics_1989
    5-HT1A partial agonist anxiolytic class overview.
    Used by: No public entries linked.
  92. Shared mechanistic pathways of glucagon signalling: unlocking its potential for treating obesity and MASLD
    pubmed_glucagon_signalling_masld_review_2025
    Mechanism review for glucagon agonism as a component of dual/triple agonist metabolic and liver-fat programs.
    Used by: Mazdutide, Survodutide
  93. Stable Gastric Pentadecapeptide BPC 157 and Striated, Smooth, and Heart Muscle
    pubmed_bpc157_muscle_review_2022
    Muscle-axis review covering myotendinous junction, skeletal muscle disability models, smooth muscle, and cardiac-function models; mostly hypothesis-generating animal/preclinical synthesis.
    Used by: BPC-157
  94. Stable Gastric Pentadecapeptide BPC 157 and Wound Healing
    pubmed_bpc157_wound_healing_review_2021
    Wound-healing review spanning incisional/excisional wounds, burns, diabetic ulcers, fistula-like wounds, thrombosis/bleeding models, and ischemia-reperfusion framing, mostly from animal work.
    Used by: BPC-157
  95. Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials)
    pubmed_enobosarm_power_trials_design_2016
    Phase 3 program design/rationale source for enobosarm in cancer muscle wasting; useful for clinical endpoint framing.
    Used by: Enobosarm
  96. The Bioactivities of Phycocyanobilin from Spirulina
    pubmed_phycocyanobilin_bioactivities_2022
    Review of PCB antioxidant, NADPH oxidase, anti-inflammatory, and disease-model mechanisms.
    Used by: Phycocyanobilin / Spirulina
  97. The development of INT131 as a selective PPAR-gamma modulator
    pmc_int131_development
    Development rationale and Phase 2 status at publication.
    Used by: INT131
  98. The human cathelicidin LL-37: a multifunctional peptide involved in infection and inflammation
    pmc_ll37_immunomodulation_review_2005
    Mechanistic review for LL-37 antimicrobial and immunomodulatory biology.
    Used by: LL-37
  99. The physiology of bilirubin: health and disease equilibrium
    pubmed_bilirubin_physiology_2023
    Review of bilirubin physiology, signaling, metabolic/cardiovascular context, and toxicity boundary.
    Used by: Bilirubin / Biliverdin axis
  100. The role of HGF/c-Met signaling in cognitive enhancement by Dihexa
    pubmed_dihexa_hepatocyte_growth_factor_review_2015
    Mechanistic review of Dihexa and HGF/c-Met cognitive-enhancement rationale.
    Used by: Dihexa
  101. The safety and efficacy of growth hormone secretagogues
    pubmed_gh_secretagogues_safety_2018
    Clinical review covering GH secretagogues and risk context.
    Used by: Hexarelin
  102. The therapeutic potential of IGF-I in skeletal muscle repair
    pmc_igf1_skeletal_muscle_repair_review_2013
    Review of IGF-I, muscle repair, satellite cells, PI3K/Akt/mTOR, and myogenic signaling.
    Used by: IGF-1 LR3 / DES(1-3)IGF-1
  103. Therapeutic potential and limitation of serotonin type 7 receptor modulation
    pubmed_5ht7_modulation_review_2023
    Modern 5-HT7 modulation review.
    Used by: No public entries linked.
  104. Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence
    pubmed_nad_boosting_molecules_review_2018
    Broad NAD-boosting review covering NR, NMN, CD38, PARP, sirtuins, aging, metabolic disease, and translational caveats.
    Used by: NAD+ / Intravenous NAD, NADH, Nicotinamide Mononucleotide, Nicotinamide Riboside
  105. Therapeutic potential of the chemical composition of Dendrobium nobile Lindl
    pubmed_dendrobium_nobile_chemistry_review_2023
    Dendrobium chemistry and pharmacology review that lists Batatasin III among constituent bibenzyl/stilbenoid compounds.
    Used by: Batatasin III
  106. Thymosin beta4 and cardiac repair
    pubmed_tb4_cardiac_repair_2010
    Related Tbeta4 cardiac-repair biology; included as indirect repair-mechanism context, not as evidence for injectable TB-500 musculoskeletal use.
    Used by: TB-500 / thymosin beta-4-related products
  107. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues
    pubmed_tb4_repair_review_2005
    Mechanism review for actin sequestration, dermal/corneal wound healing, and broader injury-repair hypotheses; not direct TB-500 clinical evidence.
    Used by: TB-500 / thymosin beta-4-related products
  108. Traditional application and modern pharmacological research of Eucommia ulmoides Oliv.
    biomedcentral_eucommia_review_2021
    Broad Eucommia ulmoides pharmacology review that discusses erectile, metabolic, cardiovascular, and traditional-use claims.
    Used by: Eucommia ulmoides Leaf Extract
  109. Transdermal selegiline for the treatment of major depressive disorder
    pubmed_selegiline_transdermal_2009
    Selegiline transdermal system and MAOI dietary interaction context.
    Used by: Selegiline
  110. Tyrosinase activated melanoma prodrugs
    pubmed_tyrosinase_prodrugs_2009
    General tyrosinase-activated prodrug strategy.
    Used by: Keraxidil
  111. VMAT2 and Parkinson's disease: harnessing the dopamine vesicle
    pmc_vmat2_parkinsons_review_2014
    VMAT2 neuroprotection and dopamine-vesicle biology review.
    Used by: No public entries linked.

safety review

  1. A Systematic Risk Assessment and Meta-Analysis on the Use of Oral Beta-Alanine Supplementation
    pubmed_beta_alanine_safety_meta_2019
    Human safety/risk-assessment meta-analysis; important for paresthesia, tolerability, and blood-marker context.
    Used by: Carnosine / Beta-Alanine
  2. Anabolic androgenic steroid-induced liver injury: an update
    pubmed_aas_liver_effects_2018
    Class hepatic-risk review, especially relevant for 17-alpha-alkylated oral AAS such as oxymetholone, methandienone, stanozolol, and oxandrolone.
    Used by: Methandienone, Oxandrolone, Oxymetholone, Stanozolol
  3. Anabolic-androgenic steroids among recreational athletes and cardiovascular risk
    pubmed_aas_recreational_athletes_cv_review_2025
    Recent cardiovascular-risk review focused on recreational athlete AAS use; class-level safety source for nonmedical androgen entries.
    Used by: Methandienone, Nandrolone Decanoate, Oxandrolone, Oxymetholone, Stanozolol, Testosterone, Trenbolone
  4. Association of anxiolytic drugs with Torsade de Pointes: a pharmacovigilance study of the FDA Adverse Event Reporting System
    pmc_anxiolytics_torsade_faers_2024
    FAERS pharmacovigilance analysis including hydroxyzine among anxiolytic drugs with TdP-related reports.
    Used by: Hydroxyzine
  5. LiverTox: Selective Androgen Receptor Modulators
    ncbi_livertox_sarms_2025
    NCBI LiverTox overview of SARM-associated liver injury and case literature.
    Used by: Ligandrol
  6. Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients
    pubmed_everolimus_stomatitis_review_2019
    Large safety review focused on stomatitis/mucocutaneous toxicity and broader mTOR-inhibitor adverse effects.
    Used by: Everolimus

structural

  1. Human carbonic anhydrase II inhibitor complexes reveal a second binding site for steroidal inhibitors
    pubmed_ca2_steroidal_inhibitors_2010
    CA II binding of steroidal sulfamate esters.
    Used by: No public entries linked.
  2. Structural basis of specific inhibition of extracellular activation of pro- or latent myostatin by the monoclonal antibody SRK-015
    pubmed_apitegromab_srk015_structure_2020
    Biochemical/structural mechanism source explaining how SRK-015/apitegromab binds pro- and latent myostatin and prevents activation rather than broadly blocking ActRII ligands.
    Used by: Apitegromab

systematic review

  1. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials
    pubmed_semaglutide_lean_mass_review_2024
    Lean-mass/body-composition context for interpreting GLP-1 weight loss rather than treating scale loss as pure fat loss.
    Used by: Semaglutide
  2. A Systematic Review of the Effects of Kefir on Metabolic Syndrome
    pubmed_kefir_metabolic_syndrome_systematic_review_2023
    Systematic review source for kefir and metabolic-syndrome endpoints; supports broad but heterogeneous human/preclinical context.
    Used by: Milk Kefir
  3. Adverse events of clenbuterol among athletes: a systematic review of case reports and case series
    pubmed_clenbuterol_athlete_adverse_events_2023
    Athlete adverse-event synthesis for clenbuterol misuse; central risk source for PED/fat-loss framing.
    Used by: Clenbuterol
  4. Alpha-2 agonists for sedation of mechanically ventilated adults
    pubmed_dexmedetomidine_systematic_review
    Includes dexmedetomidine efficacy and bradycardia signal.
    Used by: Dexmedetomidine
  5. Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults
    pmc_amphetamines_adult_adhd_cochrane_2018
    Cochrane review including dexamphetamine, lisdexamfetamine, and mixed amphetamine salts in adult ADHD.
    Used by: Dextroamphetamine, Lisdexamfetamine, Racemic Amphetamine Sulfate
  6. Anticholinergic burden for prediction of dementia or cognitive decline in older adults with no known cognitive syndrome
    cochrane_anticholinergic_burden_dementia_2021
    Cochrane prognostic-factor review on anticholinergic burden and future cognitive decline or dementia; useful for uncertainty and evidence-quality framing.
    Used by: Diphenhydramine
  7. Antioxidant Supplementation for Erectile Dysfunction: Systematic Review and Meta-Analysis of Double-Blind, Randomized, Placebo-Controlled Trials
    pmc_antioxidants_ed_meta_2024
    Human antioxidant-supplement ED context; includes astaxanthin-adjacent antioxidant rationale but is not a direct astaxanthin radiation-ED trial.
    Used by: Astaxanthin
  8. Association between nandrolone and behavioral alterations: A systematic review of preclinical studies
    pubmed_nandrolone_behavior_preclinical_review_2021
    Preclinical behavioral-risk synthesis for nandrolone; useful neuropsychiatric caution source.
    Used by: Nandrolone Decanoate
  9. Beta-hydroxy-beta-methylbutyrate and its impact on skeletal muscle mass and physical function in clinical practice
    pubmed_hmb_clinical_meta_2019
    Clinical-practice systematic review/meta-analysis for HMB, emphasizing context-specificity of muscle and function outcomes.
    Used by: HMB
  10. Cerebrolysin for acute ischaemic stroke
    pubmed_cerebrolysin_stroke_review_2020
    Cochrane systematic-review anchor; found no clear all-cause mortality benefit in acute ischemic stroke and a potential increase in non-fatal serious adverse events.
    Used by: Cerebrolysin
  11. Clinical Pharmacology of Citrus bergamia: A Systematic Review
    pubmed_citrus_bergamia_clinical_review_2017
    Broader clinical-pharmacology review for Citrus bergamia derivatives and formulation caveats.
    Used by: Bergamot Phytosome
  12. Cognitive benefits of Angiotensin IV and Angiotensin-(1-7): a systematic review of experimental studies
    pmc_angiotensin_iv_cognition_review_2022
    Experimental-study systematic review that discusses Dihexa as an AngIV-related procognitive compound.
    Used by: Dihexa
  13. Creatine supplementation research fails to support the theoretical basis for an effect on cognition: Evidence from a systematic review
    pubmed_creatine_cognition_negative_review_2024
    Skeptical cognition review; helps avoid overstating creatine as a general nootropic in unstressed healthy adults.
    Used by: Creatine
  14. Effect of acute and chronic oral L-carnitine supplementation on exercise performance based on exercise intensity
    pubmed_lcarnitine_performance_review_2021
    Exercise-performance review; useful for separating fatty-acid transport plausibility from mixed performance results.
    Used by: L-carnitine
  15. Effect of bergamot on lipid profile in humans: A systematic review
    pubmed_bergamot_lipid_systematic_2020
    Human lipid-profile review for bergamot products; not specific to the phytosome formulation.
    Used by: Bergamot Phytosome
  16. Evaluating the Leucine Trigger Hypothesis to Explain the Post-prandial Regulation of Muscle Protein Synthesis in Young and Older Adults: A Systematic Review
    pubmed_leucine_trigger_review_2021
    Systematic review of the leucine-trigger hypothesis for post-prandial muscle protein synthesis; important for mTORC1 activation claims.
    Used by: Leucine
  17. Everolimus therapy and side-effects: A systematic review and meta-analysis
    pubmed_everolimus_side_effects_meta_2021
    Systematic review/meta-analysis of everolimus adverse events; useful counterweight to longevity/immune-function extrapolations.
    Used by: Everolimus
  18. Extended-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults
    cochrane_methylphenidate_adult_adhd_2021
    Cochrane adult ADHD review for extended-release methylphenidate; useful comparator to amphetamine-class entries.
    Used by: Methylphenidate
  19. Gynecomastia: a systematic review of pharmacological treatments
    pubmed_gynecomastia_pharm_review_2022
    Reviews SERM, aromatase inhibitor, and androgen pharmacologic approaches for gynecomastia.
    Used by: Raloxifene, Tamoxifen
  20. Hydroxyzine for generalised anxiety disorder
    pubmed_hydroxyzine_gad_cochrane_2010
    Cochrane review summarizing hydroxyzine evidence for GAD and limitations of the trial base.
    Used by: Hydroxyzine
  21. Mechanism of Action and the Effect of Beta-Hydroxy-Beta-Methylbutyrate (HMB) Supplementation on Different Types of Physical Performance - A Systematic Review
    pubmed_hmb_performance_mechanism_review_2019
    Systematic review discussing HMB mechanisms including proteolysis inhibition, mTOR/protein synthesis, sarcolemma integrity, apoptosis, and exercise-performance contexts.
    Used by: HMB
  22. Over-the-Counter Agents for the Treatment of Occasional Disturbed Sleep or Transient Insomnia
    pubmed_otc_sleep_aids_review_2016
    Systematic review of OTC sleep-aid efficacy and safety; diphenhydramine evidence was limited and not robust.
    Used by: Diphenhydramine
  23. Oxandrolone Efficacy in Wound Healing in Burned and Decubitus Ulcer Patients: A Systematic Review
    pubmed_oxandrolone_wound_healing_review_2022
    Wound-healing/catabolic-care synthesis for oxandrolone; route and clinical context differ from PED use.
    Used by: Oxandrolone
  24. Pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder
    pubmed_adhd_sleep_pharmacology_review_2013
    Systematic review of sleep medications in ADHD youth; useful for off-label clonidine sleep-signal context with evidence limitations.
    Used by: Clonidine
  25. Safety, Tolerability and Efficacy of Drugs for Treating Behavioural Insomnia in Children with ADHD
    pubmed_child_adhd_insomnia_drug_review_2017
    Systematic review and methodological quality assessment for drugs used in behavioral insomnia in children with ADHD.
    Used by: Clonidine
  26. Selective Androgen Receptor Modulators effects on physical performance: a systematic review of randomized control trials
    pubmed_sarms_rct_systematic_review_2024
    Systematic review of randomized SARM trials and physical-performance endpoints.
    Used by: Enobosarm, GSK2881078
  27. Sildenafil does not reliably improve exercise performance in hypoxia: a systematic review
    pubmed_sildenafil_hypoxia_review_2019
    Systematic review showing the hypoxia-performance signal is inconsistent; useful against gym-performance overclaiming.
    Used by: PDE5 inhibitors / Cialis / Viagra, Sildenafil / Viagra
  28. Systemic glutathione as a skin-whitening agent in adult
    pubmed_glutathione_skin_systemic_2020
    Systemic glutathione dermatology evidence synthesis with safety caveats.
    Used by: Glutathione
  29. The clinical effect of glutathione on skin color and other related skin conditions: a systematic review
    pubmed_glutathione_skin_systematic_review_2019
    Human skin-lightening/skin endpoints; not a global detox or anti-aging proof.
    Used by: Glutathione
  30. Tirzepatide: A Systematic Update
    pubmed_tirzepatide_systematic_update_2022
    Systematic update across SURPASS trials and metabolic endpoints; useful for glycemic, lipid, blood-pressure, and safety context.
    Used by: Tirzepatide
  31. Trazodone for insomnia: a systematic review
    pubmed_trazodone_insomnia_review_2018
    Systematic review of trazodone insomnia studies; complements AASM guidance and sleep-architecture meta-analysis.
    Used by: Trazodone
  32. Vitamin C for preventing and treating the common cold
    pubmed_vitamin_c_common_cold_cochrane_2007
    Cochrane review PubMed record; useful for the distinction between routine cold prevention and the more plausible severe physical stress/cold-exposure subgroup.
    Used by: Vitamin C / Ascorbic Acid

umbrella review

  1. Berberine and health outcomes: An umbrella review
    pubmed_berberine_health_outcomes_umbrella_2023
    Umbrella review grading meta-analytic evidence across berberine health outcomes; useful for separating promising signals from uneven study quality.
    Used by: Berberine